A

Abbott, Frank S. *See* Acheampong, Andrew A., **73:** 489

Abe, Hidetsugu *See* Takahashi, Yoshimasa, **73:** 737

Abernethy, Darrell R. *See* Greenblatt, David J., **73:** 399

Abou El-Dahab, I. *See* El-Kerdawy, M., **73:** 1652

Abou-Gharbia, Magid; Cheeseman, Elaine N.; Pashko, Laura; Schwartz, Arthur; Swern, Daniel: Epiandrosterone- and dehydroepiandrosterone-3β-alkanesulfonates as inhibitors of mouse glucose-6-phosphate dehydrogenase activity, **73:** 1643

Aboulwafa, Omaima M. *See* Omar, A.-Mohsen M. E., **73:** 1871

Abou-Ouf, A. *See* El-Kerdawy, M., **73:** 1652

Abra, R. M.; Hunt, C. Anthony; Lau, D. T.: Liposome disposition *in vivo* VI: delivery to the lung, **73:** 203

Abraham, Isaac; Ueda, Clarence T.: Comparative disposition kinetics of two diastereomeric pairs of cinchona alkaloids in the dog, **73:** 452

Abrishami, Mohammad M. *See* Sajadi, Ziaodin, **73:** 266

Absil, A. C. *See* Buxeraud, J., **73:** 1687

Aceto, Mario D. *See* Awaya, Hiroyoshi, **73:** 1867

—; May, Everette L.; Harris, Louis S.; Jacobson, Arthur E.; Awaya, Hiroyoshi: Agonist–antagonist actions and stereoselectivity of optical pairs of some *N*-substituted α-*N*-normetazocines, **73:** 1864

Achari, Raja G.; Ederma, Heinz M.; Chin, David; Oles, Stanley R.: Determination of dextromethorphan in biological fluids by liquid chromatography by using semi-microbore columns, **73:** 1821

Achari, Ramanuj; Mayersohn, Michael: Analysis of 4-methylpyrazole in plasma and urine by gas chromatography with nitrogen-selective detection, **73:** 690

Acheampong, Andrew A.; Abbott, Frank S.; Orr, James M.; Ferguson, Sheila M.; Burton, Roland W.: Use of hexadeuterated valproic acid and gas chromatography–mass spectrometry to determine the pharmacokinetics of valproic acid, **73:** 489

Adair, Dennis *See* Soltero, Richard, **73:** 799

Adams, Mark E. *See* Bertermann, Ralph E., **73:** 1324

Adams, William E.; Heindel, Ned D.; Tutwiler, Gene; Fawthrop, Henry: Alloxan analogues as potential pancreatic-imaging radiopharmaceuticals, **73:** 394

Adams, William M. *See* Wainer, Irving W., **73:** 1162

Adjei, A.; Newburger, J.; Stavchansky, S.; Martin, A.: Membrane solubility parameter and *in situ* release of theophylline, **73:** 742

Advenier, C. *See* Leroyer, R., **73:** 844

Agyilirah, George A. *See* Nixon, Joseph R., **73:** 52

Ahmed, Mohamed S. *See* Marcelle, Guido B., **73:** 396

Ahokas, J. T. *See* Norris, R. L. G., **73:** 824

Ahumada, Amelia A. *See* Manzo, Ruben H., **73:** 1094, 1869

Aikawa, Renji *See* Morimoto, Kazuhiro, **73:** 1366

Akatsuchi, Hiroaki *See* Morimoto, Kazuhiro, **73:** 1366

Akers, Michael J.; Boand, Arthur V.; Binkley, Doris A.: Preformulation method for parenteral preservative efficacy evaluation, **73:** 903

Alam, Abu S. *See* Lee, Ying-Chi, **73:** 1660

Albert, Kenneth S. *See* Ayres, James W., **73:** 1629

—; Gillespie, W. R.; Raabe, A.; Garry, M.: Determination of flurbiprofen in human serum by reverse-phase high-performance liquid chromatography with fluorescence detection, **73:** 1823

—; Raabe, A.; Garry, M.; Antal, E. J.; Gillespie, W. R.: Determination of ibuprofen in capillary and venous plasma by high-performance liquid chromatography with ultraviolet detection, **73:** 1487

Aldred, J. P. *See* Garnick, R. L., **73:** 75

Ali, Farouk M.; Sarper, Rauf; Malveaux, Eugene J.; Faraj, Bahjat A.: Preparation and biodistribution of ^{99m}Tc-labeled tyramine iminodiacetic acid, **73:** 1363

Alich, A. A.; Wittmers, L. E., Jr.: Response to: "the ulcerogenic potential of copper aspirinate seems to be more imaginary than real", **73:** 1876

Allen, Rebecca J. *See* Hudson, Thomas J., **73:** 113

Alsina, A. *See* Valls, O., **73:** 1694

Al-Sowaygh, I. *See* Shibl, A. M., **73:** 841

Alt, Calvin J. *See* Scott, K. R., **73:** 1531

Althaus, James R. *See* Kasuya, Yasuji, **73:** 446

Alvarez, M. *See* Valls, O., **73:** 1694

Amato, Robert J. *See* Jones, Gary L., **73:** 310

Amidon, G. L. *See* Dressman, J. B., **73:** 935, 1274; Williams, N. A., **73:** 9, 14, 18

Ammann, Birgit *See* Scheurlen, M., **73:** 561

An, Seung Ho *See* Foye, William O., **73:** 1168

Andersen, Lars; Sundman, Lars-Olav; Lindén, Inge-Britt; Kontro, Pirjo; Oja, Simo S.: Synthesis and anticonvulsant properties of some 2-aminoethanesulfonic acid (taurine) derivatives, **73:** 106

Anderson, Bradley D. *See* Rowe, Englebert L., **73:** 1673

—; Conradi, R. A.; Lambert, W. J.: Carboxyl group catalysis of acyl transfer reactions in corticosteroid 17- and 21-monoesters, **73:** 604

Anderson, Gail D.; Elvin, Alfred T.; Lalka, David: Estimation of tris(2-butoxyethyl) phosphate in biological fluids: novel intersubject variability in recovery from human serum, **73:** 1791

Anderson, Wayne K.; Mulumba, Bipi: Synthesis of methyl 2,3-*bis*(hydroxymethyl)-5-phenyl-7-oxabicyclo[2.2.1]hepta-2,5-diene-6-carboxylate *bis*(*N*-methylcarbamate) derivatives as potential antitumor agents, **73:** 1182

Ando, H. Y.; Schultz, T. W.; Schnaare, R. L.; Sugita, E. T.: Percutaneous absorption: a new physicochemical predictive model for maximum human *in vivo* penetration rates, **73:** 461

Andreae, A. C. *See* Lerk, C. F., **73:** 856, 857

Andreani, Aldo; Bonazzi, Daniela; Rambaldi, Mirella; Galatulas, Iraklis; Bossa, Rosaria: Potential antitumor agents X: synthesis and antitumor activity of two nitrogen mustard derivatives related to ketocaine, **73:** 1175

Anik, Shabbir T.; McRae, Georgia I.; Nerenberg, Clinton; Worden, Ann; Foreman, Joann; Hwang, Jiin-Yu; Kushinsky, Stanley; Jones, Richard E.; Vickery, Brian: Nasal absorption of nafarelin acetate, the decapeptide [D-Nal(2)^6]LHRH, in rhesus monkeys I, **73:** 684

Antal, E. J. *See* Albert, Kenneth S., **73:** 1487

Antonini, Ippolito; Cristalli, Gloria; Franchetti, Palmarisa; Grifantini, Mario; Martelli, Sante; Petrelli, Franco: Deaza analogues of adenosine as inhibitors of blood platelet aggregation, **73:** 366

Aoki, S. *See* Kawashima, Y., **73:** 1407

Arai, Mikio *See* Nishimura, Kenji, **73:** 942

Aravagiri, M.; Hawes, Edward M.; Midha, Kamal K.: Radioimmunoassay for the sulfoxide metabolite of trifluoperazine and its application to a kinetic study in humans, **73:** 1383

Arcamone, Federico *See* Menozzi, Milena, **73:** 766

Arisawa, Munehisa; Pezzuto, John M.; Kinghorn, A. Douglas; Cordell, Geoffrey A.; Farnsworth, Norman R.: Plant anticancer agents XXX: cucurbitacins from *Ipomopsis aggregata* (Polemoniaceae), **73:** 411

Arison, B. H. *See* VandenHeuvel, W. J. A., **73:** 1731

Artursson, Per; Edman, Peter; Laakso, Timo; Sjöholm, Ingvar: Characterization of polyacryl starch microparticles as carriers for proteins and drugs, **73:** 1507

Asakawa, Y. *See* Shoji, N., **73:** 843

Asano, Tetsuo *See* Hamano, Shoichiro, **73:** 1422; Tsuji, Akira, **73:** 1418

Asmus, P. A.; Landis, J. B.; Grant, M. E.; Havel, H. A.: Determination of minoxidil in bulk drug and pharmaceutical formulations by ion-pairing high-performance liquid chromatography, **73:** 1290

Aszalos, Adorjan *See* Margosis, Michel, **73:** 835

Atkinson, W. Marc; Bowen, John M.; Purdie, Neil: Determination of "Brompton's cocktails" by circular dichroism, **73:** 1827

Au, D. S.-L.; Kuo, T. H.; Mederski-Samoraj, B.; Lee, Ching-San C.: Disposition of ibuprofen in nephrectomized dogs, **73:** 705

Autian, J. *See* Lawrence, W. H., **73:** 861

Awaya, Hiroyoshi *See* Aceto, Mario D., **73:** 1864

—; May, Everette L.; Jacobson, Arthur E.; Aceto, Mario D.: 9α- and 9β-hydroxyphenylmorphans, **73:** 1867

Axelson, James E. *See* Edwards, David J., **73:** 1264; Kapil, R. P., **73:** 215

Aylward, M. *See* Woodward, A. J., **73:** 1838

Ayres, James W. *See* Christensen, John M., **73:** 1245, 1529

—; Huang, Hua-Pin; Albert, Kenneth S.: Generic tolbutamide tablet dissolution: intralot and interlot variation, **73:** 1629

Azibi, M.; Draguet-Brughmans, M.; Bouche, R.: Polymorphism of butyrophenones related to haloperidol, **73:** 512

B

Baaske, David Michael *See* Lee, Ying-Chi, **73:** 1660

Baillet-Guffroy, A.; Baylocq, D.; Rabaron, A.; Pellerin, F.: Nuclear magnetic resonance spectrometry and liquid chromatography of two bile acid epimers: ursodeoxycholic and chenodeoxycholic acid, **73:** 847

Bajema, B. L. *See* Bult, A., **73:** 133

Baker, Glen B. *See* Coutts, Ronald T., **73:** 808

Baker, John K. *See* Clark, Alice M., **73:** 502

Baldwin, J. R.; Carrano, R. A.; Imondi, A. R.: Penetration of trolamine salicylate into the skeletal muscle of the pig, **73:** 1002

Ball, N. A.: Determination of ethylene oxide, ethylene chlorohydrin, and ethylene glycol in aqueous solutions and ethylene oxide residues in associated plastics, **73:** 1305

Ballard, Frances *See* Tse, Francis L. S., **73:** 1599
Ballesteros, Paloma *See* de la Cuesta, Elena, **73:** 1307
Bambury, Ronald E. *See* Marecki, Paul E., **73:** 1141
Banfield, Christopher; Rowland, Malcolm: Stereospecific fluorescence high-performance liquid chromatographic analysis of warfarin and its metabolites in plasma and urine, **73:** 1392
Banijamali, Ali R. *See* Shargel, Leon, **73:** 161
Banker, Gilbert S.: review of "Manufacturing Processes for New Pharmaceuticals", **73:** 572
Barbe, J. *See* Charlon, C., **73:** 1164
Barbhaiya, R. H.; Papp, E. A.; Van Harken, D. R.; Smyth, R. D.: Pharmacokinetics of mitomycin C in dogs: application of a high-performance liquid chromatographic assay, **73:** 1220
Barre, J. *See* Houin, G., **73:** 1450
—; Houin, G.; Tillement, J. P.: Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans, **73:** 1379
Basak, S. C.; Harriss, D. K.; Magnuson, V. R.: Comparative study of lipophilicity *versus* topological molecular descriptors in biological correlations, **73:** 429
Basmadjian, Garo P. *See* Sadek, Samy A., **73:** 416
Bast, Aalt; Savenije-Chapel, E. Maria; Noordhoek, Jan: Relationship between molecular structure and cytochrome P_{450}-metabolite intermediate complex formation, studied with orphenadrine analogues, **73:** 953
Bastian, J. W. *See* Garnick, R. L., **73:** 75
Bathala, M. S.; Weinstein, S. H.; Mecker, F. S., Jr.; Singhvi, S. M.; Migdalof, B. H.: Quantitative determination of captopril in blood and captopril and its disulfide metabolites in plasma by gas chromatography, **73:** 340
Baughman, Robert A. *See* Yacobi, Avraham, **73:** 1499
Baylocq, D. *See* Baillet-Guffroy, A., **73:** 847
Bayne, W. F. *See* Crisologo, N., **73:** 1313; Hwang, S. S., **73:** 708, 710; Pauliukonis, L. T., **73:** 99
Becker, Allyn R. *See* Magill, Adina, **73:** 1663
Becker, Charles H. *See* McMullen, Jean N., **73:** 1799
Beerbower, A. *See* Martin, A., **73:** 188
—; Wu, P. L.; Martin, A.: Expanded solubility parameter approach I: naphthalene and benzoic acid in individual solvents, **73:** 179
Behl, Charangit R.; Flynn, Gordon L.; Linn, Edwards E.; Smith, Ward M.: Percutaneous absorption of corticosteroids: age, site, and skin-sectioning influences on rates of permeation of hairless mouse skin by hydrocortisone, **73:** 1287
Belliveau, James F. *See* Griffiths, William C., **73:** 1836
Benedek, Irma H. *See* Duddy, John, **73:** 1525
Benet, Leslie Z. *See* Noonan, Patrick K., **73:** 923; Sörgel, Fritz, **73:** 831
Benfenati, E. *See* Bonati, M., **73:** 829
Benita, S.; Benoit, J. P.; Puisieux, Francis; Thies, C.: Characterization of drug-loaded poly(*d,l*-lactide) microspheres, **73:** 1721
—; Poly, P. A.; Puisieux, Francis; Delattre, J.: Radiopaque liposomes: effect of formulation conditions on encapsulation efficiency, **73:** 1751
Bennett, P. N.: Pharmaceutical company data on drugs in breast milk, **73:** 1877
Bennett, Robert M. *See* Spilman, Charles H., **73:** 282
Benoit, J. P. *See* Benita, S., **73:** 1721
Bensted, Charlene L. *See* Griffiths, William C., **73:** 1836
Benziger, David P. *See* Fritz, Alan K., **73:** 326
Bergan, Tom *See* Cocchetto, Joseph F., **73:** 58
Berge, G. *See* Fabre, H., **73:** 611
Bergquist, P. A. *See* Swanson, Brian N., **73:** 1655
Bergstrom, David H.; Fox, Jeffrey L.; Higuchi, William I.: Quantitative microradiographic study of simultaneous demineralization/remineralization of dental enamel in weak acid buffers, **73:** 653
—; Fox, Jeffrey L.; Higuchi, William I.: Quantitative microradiography for studying dental enamel demineralization and remineralization, **73:** 650
Berner, Bret; Cooper, Eugene R.: Application of diffusion theory to the relationship between partition coefficient and biological response, **73:** 102
Bernier, L. G.; Guadreault, R. C.; Page, M.; Joly, L. P.: Fluorescence determination of microconcentrations of chlorambucil after photoactivation, **73:** 1157
Bertermann, Ralph E.; Adams, Mark E.; Warner, John; Singleterry, Merril: Instrumentation of a tablet breaking-strength tester, **73:** 1324
Besner, J. G. *See* Clozel, J. P., **73:** 207
Beuving, Diane C. *See* Spilman, Charles H., **73:** 282
Bevill, R. F., Jr. *See* Ng, L. L., **73:** 293
Bhattacharjee, D. *See* Bhise, S. B., **73:** 1579
Bhise, S. B.; Bhattacharjee, D.; Srivastava, R. C.: Liquid membrane phenomenon in diuretics, **73:** 1579
Bialer, Meir; Friedman, Michael; Rubinstein, Abraham: Rapid gas chromatographic assay for monitoring valproic acid and valpromide in plasma, **73:** 991
Biddlecome, Charles E. *See* Stroshane, Ronald M., **73:** 1438
Bidlingmeyer, Brian A. *See* Richardson, Harold, **73:** 1480
Bikhazi, Anwar B.; Turyaki, Lutfiyyeh H.: Agglutination kinetics of enzymatically treated normal and diabetic rat hepatocytes, **73:** 628
Binkley, Doris A. *See* Akers, Michael J., **73:** 903
Binns, R. Bruce; Tsuji, Kiyoshi: High-performance liquid chromatographic analysis of neomycin in petrolatum-based ointments and in veterinary formulations, **73:** 69
Bird, C. C. *See* Panesar, N. S., **73:** 66
Biron, P. *See* Clozel, J. P., **73:** 207, 771
Bisaillon, Suzanne *See* Guay, France, **73:** 392
Bittiger, H. *See* Scheurlen, M., **73:** 561
Bjornsson, Thorir D. See Cocchetto, Joseph F., **73:** 58; Mahony, Cheryl, **73:** 838
Black, D. B. *See* Matsui, F., **73:** 1664
Blanchard, James See Perry, Dana F., **73:** 320
Blanchin, Marie Dominique *See* Bressolle, Françoise, **73:** 1128
Bloedow, Duane C. *See* Fritzberg, Alan R., **73:** 1861
Boand, Arthur V. *See* Akers, Michael J., **73:** 903
Bodor, Nicholas: review of "Techniques of Solubilization of Drugs. (Drugs and the Pharmaceutical Sciences Series, Vol 12.)", **73:** 288
—; Farag, Hassan H.: Improved delivery through biological membranes XIV: brain-specific, sustained delivery of testosterone using a redox chemical delivery system, **73:** 385
Boelema, G. J. *See* Bult, A., **73:** 133
Boer, Gerard J. *See* Kruisbrink, Jenneke, **73:** 1713
Bogardus, Joseph B.: Importance of viscosity in the dissolution rate of cholesterol in monooctanoin solutions, **73:** 906
Bolton, Barbara A.; Prasad, Paras N.: Laser Raman investigation of drug–polymer conjugates: sulfathiazole–povidone coprecipitates, **73:** 1849
Bolton, Sanford: Area under blood level *versus* time curves at steady state for daily dosing at unequal dosing intervals, **73:** 1501
Bonati, M.; Gaspari, F.; D'Aranno, V.; Benfenati, E.; Neyroz, P.; Galletti, F.; Tognoni, G.: Physicochemical and analytical characteristics of amiodarone, **73:** 829
Bonazzi, Daniela *See* Andreani, Aldo, **73:** 1175
Boots, Marvin R.: review of "Antibiotics: An Introduction", **73:** 572
Bopp, Barbara A. *See* Thomas, Elizabeth W., **73:** 1400
Borazan, Hanna N.: Binding parameters of interactions of monomer–polymer systems based on quenching of their completely overlapped fluorescence: a theory, **73:** 1815
Borne, Ronald F.: review of "A Guide to the Chemical Basis of Drug Design", **73:** 1502
Borsa, Massimiliano *See* Visconti, Marco, **73:** 1812
Bossa, Rosaria *See* Andreani, Aldo, **73:** 1175
Böttger, W. M.; Schoonen, A. J. M.; Visser, J.; Meijer, D. K. F.: Lumen perfusion of the human rectum *in situ*: a method to study mechanisms for rectal drug transport in humans, **73:** 95
Bouche, R. *See* Azibi, M., **73:** 512
Boudinot, F. Douglas; Jusko, William J.: Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis, **73:** 774
Bourne, David W. A. *See* Duddy, John, **73:** 1525
Bowen, John M. *See* Atkinson, W. Marc, **73:** 1827
Boxenbaum, Harold; Ciraulo, Domenic: Alcoholism and mortality kinetics, **73:** 1191
Boyd, James R.: The need for information on product formulations, **73:** 1335
Boynes, Dutton *See* Kowarski, Chana R., **73:** 1298
Breaux, Steven P. *See* Maderazo, Eufronio G., **73:** 1403
Bremecker, K.-D.; Strempel, H.; Klein, G.: Novel concept for a mucosal adhesive ointment, **73:** 548
Bres, Janine *See* Bressolle, Françoise, **73:** 1128
Bressolle, Françoise; Bres, Janine; Blanchin, Marie Dominique; Gomeni, Roberto: Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels, **73:** 1128
Briggs, C. J. *See* Hubbard, J. W., **73:** 1319
Brightwell, David *See* Shi, Yi-Fan, **73:** 819
Briley, Mary R. *See* Otani, Theodore T., **73:** 264
Brinkley, Floyd B. *See* Reifenrath, William G., **73:** 1388
Britt, Thomas E. *See* DePaolis, Anneli M., **73:** 1650
Broberg, F. *See* Brodin, A., **73:** 481
Brodin, A.; Nyqvist-Mayer, A.; Wadsten, T.; Forslund, B.; Broberg, F.: Phase diagram and aqueous solubility of the lidocaine–prilocaine binary system, **73:** 481
Brom, Jeffrey *See* Swarbrick, James, **73:** 1352
Bronaugh, Robert L.; Stewart, Raymond F.: Methods for *in vitro* percutaneous absorption studies III: hydrophobic compounds, **73:** 1255
Broomfield, Clarence A. *See* Reifenrath, William G., **73:** 1388
Brower, James F.; Toler, Duckhee Y.; Reepmeyer, John C.: Determination of sodium levothyroxine in bulk, tablet, and injection formulations by high-performance liquid chromatography, **73:** 1315
Brown, James E. *See* Mahony, Cheryl, **73:** 838
Brown, Larry R. See Sefton, Michael V., **73:** 1859
Brunk, Ulf *See* Edman, Peter, **73:** 153
Bryant, Shelley See Smith, Mary Faye, **73:** 1091
Buchheit, David J. *See* Hong, Chung Il, **73:** 278
Buchwald, W. F. *See* Cone, E. J., **73:** 243
Bujaczek, R. F. *See* Rummens, F. H. A., **73:** 231

Bult, A.; Bajema, B. L.; Boelema, G. J.; Saene, J. J. M. v.; Doornbos, D. A.: Remarks on the structure–activity relationship of silver sulfanilamides, **73:** 133

Burt, G. F. *See* Garnick, R. L., **73:** 75

Burton, Roland W. *See* Acheampong, Andrew A., **73:** 489

Bustrack, James A.; Katz, Jeffrey D.; Hull, J. Heyward; Foster, James R.; Hammond, John E.; Christenson, Robert H.: Bioavailability of digoxin capsules and tablets: effect of coadministered fluid volume, **73:** 1397

Butz, Robert F. *See* Findlay, John W. A., **73:** 1339

Buxeraud, J.; Absil, A. C.; Raby, C.: Secondary antithyroid action of drugs in relation to structure, **73:** 1687

Byrn, S. R. *See* Stewart, B. A., **73:** 1322

C

Caillé, G. *See* Clozel, J. P., **73:** 207, 771

Calabresi, Steven G. *See* Griffiths, William C., **73:** 1836

Caldwell, L. *See* Sloan, K. B., **73:** 1734

Campanale, Kristina M. *See* Su, Kenneth S. E., **73:** 1251, 1602

Campbell, J. B. *See* Maharaj, I., **73:** 39

Caramella, Carla *See* Colombo, Paolo, **73:** 701

Caritis, Steve N. *See* Lin, Li Shei, **73:** 131

Carli, F.; Motta, A.: Particle size and surface area distributions of pharmaceutical powders by microcomputerized mercury porosimetry, **73:** 197

Carlotti, M. E. *See* Gasco, M. R., **73:** 662

Carlson, G. L. *See* Johnson, J. D., **73:** 1469

Caron, J. C.; Shroot, B.: Determination of partition coefficients of glucocorticosteroids by high-performance liquid chromatography, **73:** 1703

Carrano, R. A. *See* Baldwin, J. R., **73:** 1002

Carson, Paul E. *See* Parkhurst, George W., **73:** 1329

Carstensen, J. T.: review of "Solid-State Chemistry of Drugs", **73:** 573

Casey, D. L. *See* Ross, A. J., **73:** 1211

Cates, L. A.; Li, V-S.; Hu, Z-S.; Lehmann, J.; Coyle, J. T.; Ferkany, J. W.: Excitatory amino acid receptor interactions of a novel α-phosphinic acid analogue of α-methyl-aspartic acid, **73:** 1550

Cesar, E. Y. *See* Higuchi, William I., **73:** 146

Chafetz, Lester; Hong, Wen-hai; Tsilifonis, Dimitri C.; Taylor, Anne K.; Philip, Jose: Decrease in the rate of capsule dissolution due to formaldehyde from polysorbate 80 autoxidation, **73:** 1186

Chambliss, Diana A. *See* Chambliss, Walter G., **73:** 1215

Chambliss, Walter G.; Chambliss, Diana A.; Cleary, Robert W.; Jones, Alan B.; Harland, Ernest C.; Kibbe, Arthur H.: Development and evaluation of enteric-coated penicillamine tablets, **73:** 1215

Champion, G. David *See* Lee, Edmund J. D., **73:** 1542

Chang, S. F. *See* Johnson, J. D., **73:** 1469

Chang, T. *See* Siegel, Marshal M., **73:** 498

Chang, Tsailing *See* Tse, Francis L. S., **73:** 1599

Chao, Ching-Chiu *See* Foye, William O., **73:** 1284

Chapman, James M., Jr. *See* Hall, Iris H., **73:** 956; Sajadi, Ziaodin, **73:** 266

—; Wyrick, Steven D.; Voorstad, P. Josée; Maguire, James H.; Cocolas, George H.; Hall, Iris H.: Hypolipidemic activity of phthalimide derivatives V: reduced and hydrolytic products of simple cyclic imides, **73:** 1482

Chapron, Dennis J.; White, Lorraine B.: Determination of acetazolamide in biological fluids by reverse-phase high-performance liquid chromatography, **73:** 985

Charlon, C.; Galy, A.-M.; Duc, C. Luu; Barbe, J.: Dipole moments and conformational equilibrium in some substituted 1-phenyl-1-fluoro-2-halogenoethanes, **73:** 1164

Chasseaud, L. F.; Darragh, A.; Doyle, E.; Lambe, R. F.; Taylor, T.: Isosorbide dinitrate plasma concentrations and bioavailability in human subjects after administration of standard oral and sublingual formulations, **73:** 699

Chatterji, Dulal C. *See* Shi, Yi-Fan, **73:** 819

Cheeseman, Elaine N. *See* Abou-Gharbia, Magid, **73:** 1643

Chelly, Jacques: review of "Calcium Antagonism in Heart and Smooth Muscle: Experimental Facts and Therapeutic Perspectives", **73:** 1016

Chen, Chester G. *See* Rice, Frederick A. H., **73:** 1846

Chen, M. M.; Lee, Ching-San C.; Perrin, J. H.: Absorption and disposition of ethambutol in rabbits, **73:** 1053

Chen, S. S. *See* Lulla, H., **73:** 1004

Cheng, C. C.: review of "Free Radicals and Cancer", **73:** 574

Chiba, Etsuko *See* Matsuda, Yoshihisa, **73:** 1453

Chiba, Kan *See* Ishizaki, Takashi, **73:** 494

Chien, Yie W. *See* Kabadi, Mohan B., **73:** 1461, 1464

Long-term controlled navel administration of testosterone, **73:** 1064

Navel absorption: transdermal bioavailability of testosterone, **73:** 283

Child, J. A. *See* Panesar, N. S., **73:** 66

Chin, David *See* Achari, Raja G., **73:** 1821

Ching, Michael S.; Mihaly, George W.; Jones, D. Brian; Smallwood, Richard A.: Liquid chromatographic analysis of cimetidine with procainamide as internal standard, **73:** 1015

Cho, P. W. *See* Higuchi, William I., **73:** 146

Cho, Young W. *See* Henderson, James D., **73:** 1748

Chopra, S. K.; Tawashi, R.: Tack behavior of coating solutions II, **73:** 477

Chou, Ruby C.; Levy, Gerhard: Comparative *in vivo* and *in vitro* studies of phenytoin protein binding and *in vitro* lipolysis in plasma of pregnant and nonpregnant rats, **73:** 1121

—; Levy, Gerhard: Effect of folic acid on the pharmacokinetics of acutely administered phenytoin in pregnant and nonpregnant rats, **73:** 1180

—; Levy, Gerhard: Kinetics of drug action in disease states III: effect of pregnancy on the relationship between phenytoin concentration and antiseizure activity in rats, **73:** 1348

Chow, D. S-L.; Kaka, I.; Wang, T. I.: Concentration-dependent enhancement of 1-dodecylazacycloheptan-2-one on the percutaneous penetration kinetics of triamcinolone acetonide, **73:** 1794

Christensen, John M.; Ghannam, Musa; Ayres, James W.: Effects of divalent amino acids on iron absorption, **73:** 1245

—; Ghannam, Musa; Ayres, James W.: Neutron activation of iron tablets to evaluate the effects of glycine on iron absorption, **73:** 1529

Christenson, Robert H. *See* Bustrack, James A., **73:** 1397

Chrzanowski, F. A.; Fegely, B. J.; Sisco, W. R.; Newton, M. P.: Analysis of *N*-(4-hydroxyphenyl)retinamide polymorphic forms by X-ray powder diffraction, **73:** 1448

Chung, Menger: Computation of model-independent pharmacokinetic parameters during multiple dosing, **73:** 570

Ciraulo, Domenic *See* Boxenbaum, Harold, **73:** 1191

Cirelli, Rosetta A. *See* Khan, Arshad R., **73:** 302

Citerio, Luisa *See* Visconti, Marco, **73:** 1812

Clark, Alice M.; Baker, John K.; McChesney, James D.: Excretion, distribution, and metabolism of primaquine in rats, **73:** 502

Clarke, Frank H.: Ionization constants by curve fitting: application to the determination of partition coefficients, **73:** 226

Cleary, Robert W. *See* Chambliss, Walter G., **73:** 1215

Clozel, J. P.; Caillé, G.; Taeymans, Y.; Théroux, P.; Biron, P.; Trudel, F.: High-performance liquid chromatographic determination of diltiazem and six of its metabolites in human urine, **73:** 771

—; Caillé, G.; Taeymans, Y.; Théroux, P.; Biron, P.; Besner, J. G.: Improved gas chromatographic determination of diltiazem and deacetyldiltiazem in human plasma, **73:** 207

Cobby, John *See* Grass, George M., **73:** 618

Coburn, W. C., Jr. *See* Shealy, Y. Fulmer, **73:** 745

Cocchetto, David M. *See* Cocchetto, Joseph F., **73:** 58

Cocchetto, Joseph F.; Cocchetto, David M.; Bjornsson, Thorir D.; Bergan, Tom: Initial slope technique for estimation of the apparent volume of distribution during constant-rate intravenous infusion, **73:** 58

Cocolas, George H. *See* Chapman, James M., Jr., **73:** 1482; Hall, Iris H., **73:** 812, 956, 1819

Cohen, Allen I. *See* Ivashkiv, Eugene, **73:** 1113

—; Devlin, Richard G.; Ivashkiv, Eugene; Funke, Phillip T.; McCormick, Terrence: Determination of orally coadministered nadolol and its deuterated analogue in human serum and urine by gas chromatography with selected-ion monitoring mass spectrometry, **73:** 1571

—; Ivashkiv, Eugene; McCormick, Terrence; McKinstry, Doris N.: Identification and determination of the *S*-methyl metabolite of captopril in human plasma by selected-ion monitoring gas chromatography–mass spectrometry, **73:** 1493

Cohen, Jonathan; Siegel, Ronald A.; Langer, Robert: Sintering technique for the preparation of polymer matrices for the controlled release of macromolecules, **73:** 1034

Cohen, Jordan L.: review of "Advances in Chromatography. Vol. 22", **73:** 1336

Cohen, Sasson *See* Liron, Zvi, **73:** 534, 538

Coker, Geoffrey G. *See* Findlay, John W. A., **73:** 1339

Colburn, Wayne A. *See* Cotler, S., **73:** 348; Holazo, A. A., **73:** 1108

Pharmacokinetic analysis of concentration–time data obtained following administration of drugs that are recycled in the bile, **73:** 313

—; Gibson, Donald M.: Composite pharmacokinetic profiling, **73:** 1667

Colombo, Paolo; Conte, Ubaldo; Caramella, Carla; Geddo, Mario; La Manna, Aldo: Disintegrating force as a new formulation parameter, **73:** 701

Conard, G. J. *See* Johnson, J. D., **73:** 1469

Cone, E. J.; Gorodetzky, C. W.; Darwin, W. D.; Buchwald, W. F.: Stability of the 6,14-*endo*-ethanotetrahydrooripavine analgesics: acid-catalyzed rearrangement of buprenorphine, **73:** 243

Conine, J. W. *See* Pikal, M. J., **73:** 1608

Conklin, J. *See* Eckelman, William C., **73:** 529

Connors, Kenneth A. *See* Pendergast, David D., **73:** 1779

Conradi, R. A. *See* Anderson, Bradley D., **73:** 604

Constanzer, M. L. *See* Musson, D. G., **73:** 1270

Conte, Ubaldo *See* Colombo, Paolo, **73:** 701

Cooper, Eugene R. *See* Berner, Bret, **73:** 102

Increased skin permeability for lipophilic molecules, **73:** 1153

Cooper, J. K. *See* Hawes, Edward M., **73:** 247; Midha, Kamal K., **73:** 261, 1144

Cooper, Thomas B. *See* Suckow, Raymond F., **73:** 1745
—; Suckow, Raymond F.; Glassman, Alexander: Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual-wavelength ultraviolet detection, **73:** 1104
Cordell, Geoffrey A. *See Arisawa, Munehisa,* **73:** 411; Marcelle, Guido B., **73:** 396
Cosulich, Donna B. *See* Siegel, Marshal M., **73:** *498; Yacobi, Avraham,* **73:** *1499*
Cotler, S.; Gustafson, J. H.; Colburn, Wayne A.: Pharmacokinetics of diazepam and *nordiazepam in the cat,* **73:** *348*
Courtney, M. L. *See* Escobar, A., **73:** 1640
Courtois, Philippe *See* Guillard, Olivier, **73:** *1642*
Coutts, Ronald T.; Prelusky, Daniel B.; Baker, Glen B.: Determination of amphetamine, norephedrine, and their phenolic metabolites in rat brain by gas chromatography, **73:** 808
Couvreur, P. *See* Lenaerts, V., **73:** 980
Covington, Tim R.: review of "Applied Therapeutics: *The Clinical Use of Drugs, 3rd* Ed.", **73:** 1335
Cox, Don C.; Furman, William B.: Collaborative *study of the USP dissolution test for* prednisone tablets with Apparatus 2, **73:** 670
—; Furman, William B.: Systematic error associated with Apparatus 2 of the USP dissolution test V: interaction of two tableted prednisone formulations with glass and plastic vessels, **73:** 1125
Coyle, J. T. *See* Cates, L. A., **73:** 1550
Cranford, H. Bruce *See* Reifenrath, William G., **73:** 1388
Crawford, Michael H. *See Mungall, Dennis,* **73:** 1000
Crider, A. Michael; Hemdi, Talal F.; Hassan, Mohamed N.; Fahn, Stanley: Synthesis and dopaminergic activity of 3-(3,4-dihydroxyphenyl)-1-*n*-propylpyrrolidine hydrobromide, **73:** 1585
—; Wood, J. D.; Tschappat, Kathryn D.; Hinko, Christine N.; Seibert, Karen: γ-Aminobutyric acid uptake inhibition and anticonvulsant activity of nipecotic acid esters, **73:** 1612
Crisologo, N.; Dye, D.; Bayne, W. F.: Electron-capture capillary gas chromatographic determination of phenylpropanolamine in human plasma following derivatization with trifluoroacetic anhydride, **73:** 1313
Cristalli, Gloria *See* Antonini, Ippolito, **73:** 366
Crommelin, Daan J. A. *See* Grijseels, H., **73:** 1771
Influence of lipid composition and ionic strength on the physical stability of liposomes, **73:** 1559
Crooks, Peter A. *See* Deeks, Trevor, **73:** 457
Cross, B. M. *See* Dimmock, J. R., **73:** 471
Cullen, Ernest: Novel anti-inflammatory agents, **73:** 579
Cybulski, Z. R.: Determination of benzalkonium chloride by gas chromatography, **73:** 1700
Czok, Rudolf *See* Nefzger, Marijke, **73:** 1309

D

Daisley, Roy W.; Shah, Vasanti K.: Synthesis and antibacterial activity of some 5-nitro-3-phenyliminoindol-2(3*H*)-ones and their *N*-Mannich bases, **73:** 407
Danzinger, R. G. *See* Su, C. C., **73:** 1160
D'Aranno, V. *See* Bonati, M., **73:** 829
Darragh, A. *See* Chasseaud, L. F., **73:** 699
Darwin, W. D. *See* Cone, E. J., **73:** 243
Davidson, A. G.: Assay of chlordiazepoxide and demoxepam in chlordiazepoxide formulations by difference spectrophotometry, **73:** 55
—; Hassan, S. M.: Assay of benzenoid drugs in tablet and capsule formulations by second-derivative ultraviolet spectrophotometry, **73:** 413
Davidson, Alexander G.: *Difference spectrophotometric assay of 1,2-diphenolic drugs in pharmaceutical formulations II: germanium dioxide reagent,* **73:** *1582*
Davies, Walter C. *See* DePaolis, Anneli M., **73:** 1650
Davis, Michael G.; Manners, Carol N.; Payling, David W.; Smith, Dennis A.; Wilson, Carol A.: Gastrointestinal absorption of the strongly acidic drug proxicromil, **73:** 949
Dawson, Marcia: review of "Natural Product Chemistry—A Mechanistic and Biosynthetic Approach to Secondary Metabolism", **73:** 287
Day, Richard O. *See* Lee, Edmund J. D., **73:** 1542
DeAngelis, Richard L. *See* Findlay, John W. A., **73:** 1339
De Blaey, C. J. *See* Grijseels, H., **73:** 1771
de Boer, A. H. *See Lerk, C. F.,* **73:** *856, 857*
Debono, Manuel: review of "Polyether Antibiotics, Volume 2: Naturally Occurring Acid Ionophores", **73:** 289
De Camp, Wilson H.: review of "X-ray Crystallography and Drug Action", **73:** 1878
Deeks, Trevor; Crooks, Peter A.; Waigh, Roger D.: Leucine enkephalin analogues containing *a conformationally restrained N-terminal* amino acid residue, **73:** 457
de Hoog, P. *See* Lerk, C. F., **73:** 856, 857
de la Cuesta, Elena; *Ballesteros, Paloma;* Trigo, Gregorio G.: Anti-influenza A activity of some *N*-substituted bicyclo[3.2.1]octane-3-spiro-3′-pyrrolidine hydrochlorides: synthesis and structure, **73:** 1307
Delattre, J. *See* Benita, S., **73:** 1751
Del Mauro, M. D. *See* Ross, A. J., **73:** 1211
DeLuca, Patrick P. *See* Leu, Daniel, **73:** 1433
DePaolis, Anneli M.; Britt, Thomas E.; Holman, Arlene J.; McGonigle, Eugene J.; Kaplan, Gerald; Davies, Walter C.: Determination of meclocycline, a tetracycline analogue, in cream formulations by liquid chromatography, **73:** 1650
De Reijke, A.; Van Bemmel, P.; Geluk, H. W.: Relationship between refractive index and dry-substance content for lactulose syrups, **73:** 1478
Derendorf, Hartmut; El-Koussi, Alaa El-Din A.; Garrett, Edward R.: Electrochemical chromatographic determinations of morphine antagonists in biological fluids, with applications, **73:** 621
Detty, T. E. *See* Musson, D. G., **73:** 1270
Devlin, Richard G. *See* Cohen, Allen I., **73:** 1571
Diamond, Israel *See* Griffiths, William C., **73:** 1836
Digenis, George A. *See* Smith, Mary Faye, **73:** 1091
DiGregorio, G. John *See* Fruncillo, Richard J., **73:** 1117
Dimmitt, Dan C. *See* Wiens, Robert E., **73:** 688
Dimmock, J. R. *See* Khachatourians, G. G., **73:** 803
—; Shyam, K.; Logan, B. M.; Smith, P. J.; Cross, B. M.: Syntheses and evaluation of some Mannich bases derived from acetophenones against P388 lymphocytic leukemia and toxicological assessment of 3-dimethylamino-2-dimethylaminomethyl-1-(4-methoxyphenyl)-1-propanone dihydrochloride in rats, **73:** 471
Divoll, Marcia *See* Greenblatt, David J., **73:** 399
Dixon, Ross; Hsiao, Jane; Taaffe, William; Hahn, Elliott; Tuttle, Ronald: Nalmefene: radioimmunoassay for a new opioid antagonist, **73:** 1645
Dobek, Arthur S. *See* Klayman, Daniel L., **73:** 1763
Doornbos, D. A. *See* Bult, A., **73:** 133
Down, G. R. B. *See* Vadas, E. B., **73:** 781
Doyle, E. *See Chasseaud, L. F.,* **73:** *699*
Doyle, Thomas D. *See* Wainer, Irving W., **73:** 1162
Drachenberg, M. *See* Kannan, R., **73:** 1208
Draguet-Brughmans, M. *See* Azibi, M., **73:** 512
Dressman, J. B.; Amidon, G. L.: Radiotelemetric method for evaluating enteric coatings *in vivo,* **73:** 935
—; Fleisher, D.; Amidon, G. L.: Physicochemical model for dose-dependent drug absorption, **73:** 1274
Dromgoole, Sydney H.; *Furst, Daniel E.;* Paulus, Harold E.: Metabolism of salsalate in normal subjects, **73:** 1657
Drummer, Olaf H. *See* Worland, Peter J., **73:** 1755
Dubey, Agnes *See* Hall, Iris H., **73:** 378; Wyrick, Steven D., **73:** 374
Duc, C. Luu *See* Charlon, C., **73:** 1164
Ducassou, Daniel *See* Guillard, Olivier, **73:** 1642
Duddy, John; Hayden, Thomas L.; Bourne, David W. A.; Fiske, William D.; Benedek, Irma H.; Stanley, Dorothy; Gonzalez, Alberto; Heierman, William: Physiological *model for distribution of sulfathiazole in* swine, **73:** 1525
Duffel, Michael W.: review of "Review of *Organic Functional Groups: Introduction to* Medicinal Organic Chemistry", **73:** 1188
Dye, D. *See* Crisologo, N., **73:** 1313
Dye, Daniel M. *See* Tao, Frank T., **73:** 1311

E

Ebert, Cynthia; Lassiani, Lucia; Linda, Paolo; Lovrecich, Mara; Nisi, Carlo; Rubessa, Fulvio: Kinetic study of the hydrolysis of 1-(4-nitrophenyl)-3-methyltriazene in aqueous solution and in the presence of surfactants, **73:** 1691
Ecanow, Bernard *See* Hughes, Christopher, **73:** 1729
Eckelman, William C.; Grissom, M.; Conklin, J.; Rzeszotarski, W. J.; Gibson, R. E.; Francis, B. E.; Jagoda, E. M.; Eng, R.; Reba, R. C.: *In vivo* competition studies with analogues of 3-quinuclidinyl benzilate, **73:** 529
Eddine, N. Hussam *See* Fabre, H., **73:** 611
Edelson, Jerome *See* Fritz, Alan K., **73:** 326; Stroshane, Ronald M., **73:** 1438
—; Shaw, David; Palace, Gerard: Pharmacokinetics of iohexol, a new nonionic radiocontrast agent, in humans, **73:** 993
Ederma, Heinz M. *See* Achari, Raja G., **73:** 1821
Edman, Peter *See* Artursson, Per, **73:** 1507
—; Sjöholm, Ingvar; Brunk, Ulf: Ultrastructural alterations in macrophages after phagocytosis of acrylic microspheres, **73:** 153
Edwards, David J.: Evidence favoring the venous equilibrium model for hepatic clearance of (*S*)-(−)-propranolol, **73:** 1498
—; Axelson, James E.; Slaughter, Richard L.; Elvin, Alfred T.; Lalka, David: Factors affecting quinidine protein binding in humans, **73:** 1264
El-Fishawy, A. M.; Slatkin, D. J.; Knapp, J. E.; Schiff, P. L., Jr.: Preparation of 7,8-dimethoxy-3,4-dihydroisoquinoline, facile route to 7,8-dioxygenated-3,4-dihydroisoquinolines, **73:** 1639
El-Hawash, Soad A. *See* Shafik, Ragab M., **73:** 1548
El-Kerdawy, M.; Abou-Ouf, A.; Tantawy, A.; Abou El-Dahab, I.: Preparation of alkoxyquinoline derivatives and their evaluation as potential central nervous system stimulants, **73:** 1652

El-Koussi, Alaa El-Din A. *See* Derendorf, Hartmut, **73:** 621
Eller, Mark G.; Schoenwald, R. D.: Determination of ethoxzolamide in the iris/ciliary body of the rabbit eye by high-performance liquid chromatography: comparison of tissue levels following intravenous and topical administrations, **73:** 1261
El Sadany, Samir K. *See* Soliman, Raafat, **73:** 403
Elvin, Alfred T. *See* Anderson, Gail D., **73:** 1791; Edwards, David J., **73:** 1264
El-Yazigi, Adnan: Analysis of oxprenolol in formulations by high-performance liquid chromatography, **73:** 751
Emori, Hisatoshi; Ishizaka, Takafumi; Koishi, Masumi: Effects of acrylic acid polymer and its arrangement on drug release from a wax matrix, **73:** 910
Eng, R. *See* Eckelman, William C., **73:** 529
Eppel, J. G.; Thiessen, J. J.: Liquid chromatographic analysis of sulfaquinoxaline and its application to pharmacokinetic studies in rabbits, **73:** 1635
Escobar, A.; Maher, R. T.; Courtney, M. L.; Valicenti, A. J.: Determination of heparin activity by a new laser nephelometric method and comparison to the USP method, **73:** 1640
Eshba, Nabil H. See Omar, A.-Mohsen M. E., **73:** 1166
Eshima, Dennis *See* Fritzberg, Alan R., **73:** 1861
Evans, William E. *See* Sinkule, Joseph A., **73:** 164
Ezzedeen, Fikrat W.; Stohs, Sidney J.; Kilzer, Karen L.; Makoid, Michael C.; Ezzedeen, Nihad W.: Percutaneous absorption and disposition of iodochlorhydroxyquin in dogs, **73:** 1369
Ezzedeen, Nihad W. See Ezzedeen, Fikrat W., **73:** 1369

F

Fabre, H.; Eddine, N. Hussam; Berge, G.: Degradation kinetics in aqueous solution of cefotaxime sodium, a third-generation cephalosporin, **73:** 611
—; Hussam-Eddine, N.; Lerner, D.; Mandrou, B.: Autoxidation and hydrolysis kinetics of the sodium salt of phenylbutazone in aqueous solution, **73:** 1709
—; Hussam-Eddine, N.; Mandrou, B.: Stability-indicating assay for phenylbutazone: high-performance liquid chromatographic determination of hydrazobenzene and azobenzene in degraded aqueous phenylbutazone solutions, **73:** 1706
Fahn, Stanley *See* Crider, A. Michael, **73:** 1585
Farag, Hassan H. *See* Bodor, Nicholas, **73:** 385
Faraj, Bahjat A. *See* Ali, Farouk M., **73:** 1363
Farnsworth, Norman R. *See* Arisawa, Munehisa, **73:** 411
Fauvel, A.; Labrude, P.; Vigneron, C.: Freeze-drying of oxyhemoglobin: protection against oxidation in the presence of EDTA salts, sulfonic acid buffers, and pantothenic acid derivatives, **73:** 784
Fawthrop, Henry *See* Adams, William E., **73:** 394
Fedder, Ira L.; Vlasses, Peter H.; Mojaverian, Parviz; Rocci, Mario L., Jr.; Rotmensch, Heschi H.; Swanson, Brian N.; Ferguson, Roger K.: Relationship of morphine-induced miosis to plasma concentration in normal subjects, **73:** 1496
Fegely, B. J. *See* Chrzanowski, F. A., **73:** 1448
Feldkamp, Joseph R. *See* Liu, Jue-Chen, **73:** 1355; Scholtz, Edward C., **73:** 209, 967, 1007; Sepelyak, Robert J., **73:** 1514, 1517; Zapata, Mary I., **73:** 3
Feldmann, Edward G.: Author's response to "safety and efficacy of dental sealants in the prevention of tooth decay", **73:** 1675
Author's response to "secret formulations from the industry's perspective", **73:** 1501
"Coming of age" for device technology, **73:** 713
A drug is a drug—or is it?, **73:** 1189
FDA commissioners—their function and operation, **73:** 1
Good public policy requires good science, **73:** 1019
Having a voice in APhA scientific policy, **73:** 291
The industry–university interface, **73:** 1677
Observations on the selection of our professional leaders, **73:** 427
Putting an end to secret formulations, **73:** 577
The sad state of current research instruments, **73:** 865
"Scientific proof"—an elusive goal, **73:** 1337
Sending unapproved drugs abroad, **73:** 1505
Universities for hire, **73:** 139
Ferguson, P. W.; Keller, W. J.; Risinger, F. O.: [^{14}C]Normacromerine fate in the rat, **73:** 692
Ferguson, Roger K. *See* Fedder, Ira L., **73:** 1496; Swanson, Brian N., **73:** 1655
Ferguson, Sheila M. *See* Acheampong, Andrew A., **73:** 489
Ferkany, J. W. *See* Cates, L. A., **73:** 1550
Findlay, John W. A.; Butz, Robert F.; Coker, Geoffrey G.; DeAngelis, Richard L.; Welch, Richard M.: Triprolidine radioimmunoassay: disposition in animals and humans, **73:** 1339
Finkelstein, Barbara *See* Tse, Francis L. S., **73:** 1599
Finlayson, J. S. *See* Yu, M. W., **73:** 82
Fisher, Joyce M. *See* Naujokaitis, Saulius A., **73:** 34
Fiske, William D. *See* Duddy, John, **73:** 1525
Fleisher, D. *See* Dressman, J. B., **73:** 1274
Florey, Klaus G.: review of "Instrumental Data for Drug Analysis. Vol. 2", **73:** 1335
Flynn, Gordon L. *See* Behl, Charangit R., **73:** 1287
Flynn, H. *See* VandenHeuvel, W. J. A., **73:** 1731
Fong, H. H. S. *See* Marcelle, Guido B., **73:** 396
Forbes, Adelbert D. *See* Spilman, Charles H., **73:** 282
Foreman, Joann *See* Anik, Shabbir T., **73:** 684
Forslund, B. *See* Brodin, A., **73:** 481
Foster, James R. *See* Bustrack, James A., **73:** 1397
Fox, J. M. *See* Johnson, J. D., **73:** 1469
Fox, Jeffrey L. *See* Bergstrom, David H., **73:** 650, 653; Higuchi, William I., **73:** 146; Patel, Dinesh C., **73:** 1028
Foye, William O.; An, Seung Ho; Maher, Timothy J.: Synthesis of *N,N'*-disubstituted *N''*-2-(2-quinolinylmethylthio)ethylguanidines as potential anticancer agents, **73:** 1168
—; Chao, Ching-Chiu: Antiradiation compounds XIX: metal-binding abilities of thioureas, **73:** 1284
—; Jan, Chaur-Ming: Synthesis and evaluation of *N*-alkanoyl-*S*-benzyl-L-cysteinylglutamic acid esters as glyoxalase I inhibitors and anticancer agents, **73:** 559
Franchetti, Palmarisa *See* Antonini, Ippolito, **73:** 366
Francis, B. E. *See* Eckelman, William C., **73:** 529
Francis, Marion D.; Slough, Candice L.: Acute intravenous infusion of disodium dihydrogen (1-hydroxyethylidene)diphosphonate: mechanism of toxicity, **73:** 1097
Freeman, James P. *See* Kasuya, Yasuji, **73:** 446
Friberg, Stig E. *See* Wahlgren, Sven, **73:** 1484
Friedman, Michael *See* Bialer, Meir, **73:** 991; Harary, D., **73:** 135
Frith, Evelyn M. *See* Simons, Keith J., **73:** 595
Fritz, Alan K.; Benziger, David P.; Peterson, James E.; Park, George B.; Edelson, Jerome: Relative bioavailability and pharmacokinetics: a combination of pentazocine and acetaminophen, **73:** 326
Fritzberg, Alan R.; Bloedow, Duane C.; Eshima, Dennis; Johnson, Dennis L.: Comparison of ^{99m}Tc-*N*-pyridoxyl-5-methyltryptophan and ^{99m}Tc-*N*-(3-bromo-2,4,6-trimethylacetanilide)iminodiacetate as hepatobiliary radiopharmaceuticals in rats, **73:** 1861
Truncillo, Richard J.; DiGregorio, G. John: Pharmacokinetics of pentobarbital, quinidine, lidocaine, and theophylline in the thermally injured rat, **73:** 1117
Fry, William C.; Stagner, William C.; Wichman, Kenneth C.: Computer-interfaced capacitive sensor for monitoring the granulation process, **73:** 420
Frye, Jerry L. *See* Shealy, Y. Fulmer, **73:** 745
Fujise, Akihiko *See* Uekama, Kaneto, **73:** 382
Fujita, Shoichi *See* Suzuki, Tokuji, **73:** 136
Fujita, Takeshi *See* Hasegawa, Jiro, **73:** 442
Fung, Ho-Leung *See* King, Shang-Ying P., **73:** 657
—; Ogata, H.; Kamiya, Akira; Maier, G. A.: Pharmacokinetics of nitroglycerin after parenteral and oral dosing in the rat, **73:** 873
Funke, Phillip T. *See* Cohen, Allen I., **73:** 1571
Furman, William B. *See* Cox, Don C., **73:** 670, 1125
Furst, Daniel E. *See* Dromgoole, Sydney H., **73:** 1657

G

Gabbay, Edmond J. *See* Yen, Shau-Fong, **73:** 1575
Gaffar, Abdul *See* Tavss, Edward A., **73:** 1148
Gal, Joseph; Sedman, Allen J.: Does cimetidine impair nitroreduction?, **73:** 1187
Galante, Robert N.; Visalli, Anthony J.; Grim, Wayne M.: Stabilized normal-phase high-performance liquid chromatographic analysis of aspirin and salicylic acid in solid pharmaceutical dosage forms, **73:** 195
Galatulas, Iraklis *See* Andreani, Aldo, **73:** 1175
Galeazzi, R. L. *See* Strachl, P., **73:** 1317
Galinsky, Raymond E. *See* Morris, Marilyn E., **73:** 853
Gallelli, Joseph F. *See* Shi, Yi-Fan, **73:** 819
Galletti, F. *See* Bonati, M., **73:** 829
Galy, A.-M. *See* Charlon, C., **73:** 1164
Garcia Fernandez, S. *See* Valls, O., **73:** 1694
Garnick, R. L.; Burt, G. F.; Long, D. A.; Bastian, J. W.; Aldred, J. P.: High-performance liquid chromatographic assay for sodium levothyroxine in tablet formulations: content uniformity applications, **73:** 75
Garrett, Edward R. *See* Derendorf, Hartmut, **73:** 621
Bioanalyses and pharmacokinetics of nafronyl in the dog, **73:** 635
Garry, M. *See* Albert, Kenneth S., **73:** 1487, 1823
Garst, John E.: Accurate, wide-range, automated, high-performance liquid chromatographic method for the estimation of octanol/water partition coefficients II: equilibrium in partition coefficient measurements, additivity of substituent constants, and correlation of biological data, **73:** 1623
review of "Nutrition and Drugs", **73:** 863
—; Wilson, W. C.: Accurate, wide-range, automated, high-performance liquid chromatographic method for the estimation of octanol/water partition coefficients I: effect of chromatographic conditions and procedure variables on accuracy and reproducibility of the method, **73:** 1616
Gasco, M. R.; Carlotti, M. E.; Trotta, M.: Behavior of ATP toward phenothiazine drugs, **73:** 662
Gaspari, F. *See* Bonati, M., **73:** 829

Gatto, G. J. *See* VandenHeuvel, W. J. A., **73:** 1731
Gautieri, Ronald F. *See* Mann, David E., Jr., **73:** 1491
Geddo, Mario *See* Colombo, Paolo, **73:** 701
Gehrlein, Lane *See* Siegel, Marshal M., **73:** 498
Geluk, H. W. *See* De Reijke, A., **73:** 1478
Gengo, Francis M.; Schentag, Jerome J.; Jusko, William J.: Pharmacokinetics of capacity-limited tissue distribution of methicillin in rabbits, **73:** 867
—; Ziemniak, M. A.; Kinkel, W. R.; McHugh, W. B.: High-performance liquid chromatographic determination of metoprolol and α-hydroxymetoprolol concentrations in human serum, urine, and cerebrospinal fluid, **73:** 961
Gensmantel, Nigel P. *See* Swarbrick, James, **73:** 1352
Geran, Ruth I. *See* Otani, Theodore T., **73:** 264
Gershon, Herman; Rowe, Gail E.; Santore, Robert C.; Gilbertson, John R.; Langkamp, Herman: Antifungal properties of 2-*n*-alkyn-1-ols, **73:** 1840
Ghannam, Musa *See* Christensen, John M., **73:** 1245, 1529
Ghebre-Sellassie, Isaac; Hem, Stanley L.; Knevel, Adelbert M.: Epimerization of benzylpenicilloic acid in alkaline media, **73:** 125
Gibbs, V.; Zaidi, Z.: Evaluation of high-performance liquid chromatography and gas chromatography for quantitation of dextromethorphan hydrobromide in cough–cold syrup preparations, **73:** 1248
Gibson, Donald M. *See* Colburn, Wayne A., **73:** 1667
Gibson, R. E. *See* Eckelman, William C., **73:** 529
Gigot, Daniel; Penninckx, Michel: New compounds: peptide derivatives of the antitumor agent *N*-phosphonoacetyl-L-aspartic acid, **73:** 275
Gilbert, Colleen J. *See* Hall, Iris H., **73:** 973
Gilbertson, John R. *See* Gershon, Herman, **73:** 1840
Gilbertson, Terry J. *See* Lakings, Duane B., **73:** 317
Gillespie, W. R. *See* Albert, Kenneth S., **73:** 1487, 1823
Gilmore, I. T. *See* Su, C. C., **73:** 1160
Glassman, Alexander *See* Cooper, Thomas B., **73:** 1104
Glenn, Thomas M. *See* Henderson, James D., **73:** 1748
Goehl, Thomas J. *See* Patel, Rajni B., **73:** 964
Gomeni, Roberto *See* Bressolle, Françoise, **73:** 1128
Gómez-Jeria, J. S.; Morales-Lagos, D. R.: Quantum chemical approach to the relationship between molecular structure and serotonin receptor binding affinity, **73:** 1725
Gonzalez, Alberto *See* Duddy, John, **73:** 1525
Gordon, W. Perry *See* Lin, Huey-shin, **73:** 285
Gore, William E. *See* Siegel, Marshal M., **73:** 498
Gorodetzky, C. W. *See* Cone, E. J., **73:** 243
Goundalkar, Ashok; Mezei, Michael: Chemical modification of triamcinolone acetonide to improve liposomal encapsulation, **73:** 834
Gowan, Walter, G. *See* Stavchansky, S., **73:** 733
Graham, Garry G. *See* Lee, Edmund J. D., **73:** 1542
Grant, David J. W. *See* Mehdizadeh, Mehdi, **73:** 1195
Grant, M. E. *See* Asmus, P. A., **73:** 1290
Grasela, Dennis M.; Rocci, Mario L., Jr.: Liquid chromatographic microassay for carbamazepine and its 10,11-epoxide in plasma, **73:** 1874
Grass, George M.; Cobby, John; Makoid, Michael C.: Ocular delivery of pilocarpine from erodible matrices, **73:** 618
—; Robinson, Joseph R.: Relationship of chemical structure to corneal penetration and influence of low-viscosity solution on ocular bioavailability, **73:** 1021
Green, R. D. *See* Rummens, F. H. A., **73:** 231
Greenblatt, David J.; Abernethy, Darrell R.; Divoll, Marcia; Locniskar, Ann; Harmatz, Jerold S.; Shader, Richard I.: Noninteraction of temazepam and cimetidine, **73:** 399
Gresser, Joseph D. *See* Phillips, Michael, **73:** 1718
Gries, Christian L. *See* Su, Kenneth S. E., **73:** 1251
Grifantini, Mario *See* Antonini, Ippolito, **73:** 366
Griffiths, William C.; Belliveau, James F.; Bensted, Charlene L.; Calabresi, Steven G.; Diamond, Israel: Chromatographic separation of the C(1), C(1a), and C(2) components of gentamicin and the assessment of their individual binding to serum proteins, **73:** 1836
Grijseels, H.; Crommelin, Daan J. A.; De Blaey, C. J.: Dissolution at porous interfaces VI: multiple-pore systems, **73:** 1771
Grim, Wayne M. *See* Galante, Robert N., **73:** 195
Grislain, L. *See* Lenaerts, V., **73:** 980
Grissom, M. *See* Eckelman, William C., **73:** 529
Guadreault, R. C. *See* Bernier, L. G., **73:** 1157
Guay, France; Bisaillon, Suzanne: Determination of the average molecular weight of nonionic emulsifiers by vapor-phase osmometry, **73:** 392
Guillard, Olivier; Courtois, Philippe; Murai, Patrick; Ducassou, Daniel; Reiss, Daniel: Comparative pharmacokinetics of [^{65}Zn]zinc sulfate and [^{65}Zn]zinc pantothenate injected intravenously in rabbits, **73:** 1642
Guo, Zong-Ru *See* Li, Wen-Yen, **73:** 553
Gupta, V. Das. Effect of ethanol, glycerol, and propylene glycol on the stability of phenobarbital sodium, **73:** 1661
Quantitation of metronidazole in pharmaceutical dosage forms using high-performance liquid chromatography, **73:** 1331
Quantitation of phenobarbital and phenobarbital sodium in pharmaceutical dosage forms, **73:** 1158
Stability of cefotaxime sodium as determined by high-performance liquid chromatography, **73:** 565
—; Heble, Arun R.: Quantitation of acetaminophen, chlorpheniramine maleate, dextromethorphan hydrobromide, and phenylpropanolamine hydrochloride in combination using high-performance liquid chromatography, **73:** 1553
Gustafson, J. H. *See* Cotler, S., **73:** 348; Holazo, A. A., **73:** 1108
Guy, Richard H.; Hadgraft, Jonathan: Prediction of drug disposition kinetics in skin and plasma following topical administration, **73:** 883

H

Habib, N. S.; Khalil, M. A.: Synthesis and antimicrobial activity of novel quinazolone derivatives, **73:** 982
Hacker, Bruce; Medon, Philip J.: Cytotoxic effects of *Eleutherococcus senticosus* aqueous extracts in combination with N^6-(Δ^2-isopentenyl)adenosine and 1-β-D-arabinofuranosylcytosine against L1210 leukemia cells, **73:** 270
Hadgraft, Jonathan *See* Guy, Richard H., **73:** 883
Hahn, Elliott *See* Dixon, Ross, **73:** 1645
Hajratwala, B. R.; Ho, D. S. S.: Effect of aging on hydrocortisone–polyethylene glycol 4000 and hydrocortisone–polyvinylpyrrolidone dispersions, **73:** 1539
Hall, Iris H. *See* Chapman, James M., Jr., **73:** 1482; Sajadi, Ziaodin, **73:** 266; Wyrick, Steven D., **73:** 374
—; Chapman, James M., Jr.; Voorstad, P. Josée; Cocolas, George H.: Hypolipidemic activity of 3-*N*-(1′,8′-naphthalimido)propionic acid in rodents, **73:** 956
—; Cocolas, George H.; Voorstad, P. Josée: Hypolipidemic activity of 4-phenyl-5,5-dicarbethoxy-2-pyrrolidinone in rodents, **73:** 812
—; Cocolas, George H.; Williams, W. L., Jr.: Hypolipidemic activity of 4-pyrimidinecarboxylic acids in CF_1 mice, **73:** 1819
—; Spielvogel, B. F.; McPhail, A. T.: Antineoplastic activity of tetrakis-μ-(trimethylamine-boranecarboxylato)-*bis*(trimethylamine-carboxyborane)dicopper(II) in Ehrlich ascites carcinoma, **73:** 222
—; Williams, W. L., Jr.; Gilbert, Colleen J.; McPhail, A. T.; Spielvogel, B. F.: Hypolipidemic activity of tetrakis-μ-(trimethylamineboranecarboxylato)-*bis*(trimethylamine-carboxyborane)dicopper(II) in rodents and its effect on lipid metabolism, **73:** 973
—; Williams, W. L., Jr; Wyrick, Steven D.; Voorstad, P. Josée: Biological activity of the hypolipidemic agent, N^2-*n*-butylindazolone, **73:** 1788
—; Wyrick, Steven D.; Voorstad, P. Josée; Dubey, Agnes: Antihyperlipidemic activity of *o*-chlorobenzylsulfonamide in rodents, **73:** 378
Hamada, Kozo *See* Yagi, Akira, **73:** 62
Hamano, Shoichiro *See* Tsuji, Akira, **73:** 1418
—; Tsuji, Akira; Asano, Tetsuo; Tamai, Ikumi; Nakashima, Emi; Yamana, Tsukinaka; Mitsuhashi, Susumu: Kinetic analysis and characterization of the bacterial regrowth after treatment of *Escherichia coli* with β-lactam antibiotics, **73:** 1422
Hammond, John E. *See* Bustrack, James A., **73:** 1397
Hammouda, Y. *See* Shibl, A. M., **73:** 841
Hanano, Manabu *See* Igari, Yasutaka, **73:** 826; Sato, Jun, **73:** 519; Sugita, Osamu, **73:** 631; Terasaki, Tetsuya, **73:** 524, 1359
Harada, Nobuo *See* Yagi, Akira, **73:** 62
Harary, D.; Friedman, Michael: Enhancement of fluoride concentration in saliva after topical application of fluoride sustained-release dosage form on orthodontic plates, **73:** 135
Harland, Ernest C. *See* Chambliss, Walter G., **73:** 1215
Harmatz, Jerold S. *See* Greenblatt, David J., **73:** 399
Harper, Alice: review of "Pattern Recognition Approaches To Data Interpretation", **73:** 1878
Harris, K. *See* Swanson, Brian N., **73:** 1655
Harris, Louis S. *See* Aceto, Mario D., **73:** 1864
Harriss, D. K. *See* Basak, S. C., **73:** 429
Haruno, Akihiro *See* Yamamoto, Jyunji, **73:** 212
Hase, Ayumi *See* Kobayashi, Kunio, **73:** 1684
Hasegawa, Jiro *See* Sörgel, Fritz, **73:** 831
—; Fujita, Takeshi; Hayashi, Yayoi; Iwamoto, Kikuo; Watanabe, Jun: pK_a determination of verapamil by liquid–liquid partition, **73:** 442
Hashimoto, Naofumi; Tasaki, Takenobu; Tanaka, Hiroyoshi: Degradation and epimerization kinetics of moxalactam in aqueous solution, **73:** 369
Haslam, J. *See* Sloan, K. B., **73:** 1734
Hassan, Mohamed N. *See* Crider, A. Michael, **73:** 1585
Hassan, S. M. *See* Davidson, A. G., **73:** 413
Havel, H. A. *See* Asmus, P. A., **73:** 1290
Hawes, Edward M. *See* Aravagiri, M., **73:** 1383; Midha, Kamal K., **73:** 261; Shetty, H. Umesha, **73:** 87
—; Shetty, H. U.; Cooper, J. K.; Rauw, G.; McKay, G.; Midha, K. K.: Radioimmunoassay for psychotropic drugs III: synthesis and properties of haptens for trifluoperazine and fluphenazine, **73:** 247

Hawkins, David W. *See* Mungall, Dennis, **73:** 1000
Hayasaka, Hiroshi *See* Takahashi, Yoshimasa, **73:** 737
Hayashi, Yayoi *See* Hasegawa, Jiro, **73:** 442
Hayden, Thomas L. *See* Duddy, John, **73:** 1525
Hayes, Elise *See* Scott, K. R., **73:** 1531
Hayes, Johnnie R.: review of "Host Factors in Human Carcinogenesis. (IARC Scientific Publications, No. 30.)", **73:** 288
Heble, Arun R. *See* Gupta, V. Das, **73:** 1553
Heeg, Joel F.; Hiser, Michael F.; Satonin, Darlene K.; Rose, James Q.: Pharmacokinetics of probucol in male rats, **73:** 1758
Heierman, William *See* Duddy, John, **73:** 1525
Heindel, Ned D. *See* Adams, William E., **73:** 394
Helms, Paul E. *See* Streng, William H., **73:** 1679
Hem, Stanley L. *See* Ghebre-Sellassie, Isaac, **73:** 125; Liu, Jue-Chen, **73:** 1355; Scholtz, Edward C., **73:** 209, 967, 1007; Sepelyak, Robert J., **73:** 1514, 1517; Zapata, Mary I., **73:** 3
Hemdi, Talal F. *See* Crider, A. Michael, **73:** 1585
Henderson, James D.; Mankad, Vipul N.; Glenn, Thomas M.; Cho, Young W.: Gas chromatographic analysis of cetiedil, a candidate antisickling agent, in human plasma with nitrogen-sensitive detection, **73:** 1748
Hendrick, Sheila A. *See* Winkel, Deborah R., **73:** 115
Henesian, Maida *See* Yu, Cheng Der, **73:** 344
Henry, M. *See* Norris, R. L. G., **73:** 824
Hermes, M.; Malbica, J. O.: High-performance liquid chromatographic determination of tracazolate and its major metabolite in plasma, **73:** 667
Hetyei, Nancy *See* Tischio, John, **73:** 546
Higgins, Edwin S.: review of "Nicotinic Acid: Nutrient–Cofactor–Drug (Clinical Pharmacology Series, Vol. 1)", **73:** 1016
Higuchi, Takeru *See* Nguyen, Tue Huu, **73:** 1563; Nishihata, Toshiaki, **73:** 109, 1326, 1523
Higuchi, William I. *See* Bergstrom, David H., **73:** 650, 653; Patel, Dinesh C., **73:** 1028; Su, C. C., **73:** 1160
—; Cesar, E. Y.; Cho, P. W.; Fox, Jeffrey L.: Powder suspension method for critically re-examining the two-site model for hydroxyapatite dissolution kinetics, **73:** 146
Hilbert, James M.; Ning, James M.; Murphy, Gregory; Jimenez, Angel; Zampaglione, Nicola: Gas chromatographic determination of quazepam and two major metabolites in human plasma, **73:** 516
Himmelstein, Kenneth J. *See* Nguyen, Tue Huu, **73:** 1563; Thombre, Avinash G., **73:** 219
review of "Compartmental Models and Their Application", **73:** 1018
Hinderling, Peter H.: Kinetics of partitioning and binding of digoxin and its analogues in the subcompartments of blood, **73:** 1042
—; Roos, André: Pharmacokinetics of the antirheumatic proquazone in healthy humans, **73:** 332
Hinko, Christine N. *See* Crider, A. Michael, **73:** 1612
Hinsvark, Orville N. *See* Park, Young Han, **73:** 24
Hirayama, Fumitoshi *See* Uekama, Kaneto, **73:** 382
Hiser, Michael F. *See* Heeg, Joel F., **73:** 1758
Ho, D. S. S. *See* Hajratwala, B. R., **73:** 1539
Ho, N. F. H. *See* Park, J. Y., **73:** 1588; Rogers, J. D., **73:** 1594
Physical model approach to taste studies of drugs and pharmaceutical formulations, **73:** 600
Hoch, James M. *See* Klayman, Daniel L., **73:** 1763
Hoener, Betty-ann; Krueger, Terry Ray: Disposition of nitrofurantoin and nitrofurazone in the isolated perfused rat kidney, **73:** 1669
Hofmann, A. F. *See* Su, C. C., **73:** 1160
Holazo, A. A.; Colburn, Wayne A.; Gustafson, J. H.; Young, R. L.; Parsonnet, M.: Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects, **73:** 1108
Hollister, Leo E.: review of "Drugs and Therapy: A Handbook of Psychotropic Drugs, 2nd Ed.", **73:** 1016
Holman, Arlene J. *See* DePaolis, Anneli M., **73:** 1650
Holmlund, P. K. *See* Khachatourians, G. G., **73:** 803
Hong, Chung Il; Kirisits, Alan J.; Nechaev, Alexander; Buchheit, David J.; West, Charles R.: Nucleoside conjugates V: synthesis and biological activity of 9-(β-D-arabinofuranosyl)adenine conjugates of corticosteroids, **73:** 278
Hong, Wen-hai *See* Chafetz, Lester, **73:** 1186
Hoogmartens, J. *See* Thomis, R., **73:** 1830
Hori, Ryohei *See* Kamiya, Akira, **73:** 892
Hottendorf, G. H. *See* Stavchansky, S., **73:** 169
Houin, G. *See* Barre, J., **73:** 1379
—; Barre, J.; Tillement, J. P.: Absolute intramuscular, oral, and rectal bioavailability of alizapride, **73:** 1450
Hoyt, A. M., Jr. *See* Whitaker, J. E., **73:** 1184
Hsi, Swee K. *See* Streng, William H., **73:** 1679
Hsiao, Jane *See* Dixon, Ross, **73:** 1645
Hu, Z-S. *See* Cates, L. A., **73:** 1550
Huang, Chong Heng *See* Hussain, Anwar A., **73:** 1300
Huang, Hua-Pin *See* Ayres, James W., **73:** 1629
Hubbard, J. W.; Briggs, C. J.; Savage, C.; Smith, D.: Binding of sulfadimethoxine to isolated human blood protein fractions, **73:** 1319
Hudson, Thomas J.; Allen, Rebecca J.: Determination of pantothenic acid in multivitamin pharmaceutical preparations by reverse-phase high-performance liquid chromatography, **73:** 113
Hufford, Charles D. *See* McChesney, James D., **73:** 1854
Hughes, Christopher; Ecanow, Bernard: Electrical conductivity of a docusate sodium coacervate system, **73:** 1729
Huitfeldt, Bernhard *See* Sjövall, Jan, **73:** 141
Hull, J. Heyward *See* Bustrack, James A., **73:** 1397
Hunt, C. Anthony *See* Abra, R. M., **73:** 203
Hussain, Anwar A.; Kimura, Ryohei; Huang, Chong Heng: Nasal absorption of testosterone in rats, **73:** 1300
Hussam-Eddine, N. *See* Fabre, H., **73:** 1706, 1709
Hwang, Jiin-Yu *See* Anik, Shabbir T., **73:** 684
Hwang, S. S.; Bayne, W. F.: Dynamic method for estimating the extent of plasma protein binding in a dialysis experiment, **73:** 708
—; Bayne, W. F.: Influence of protein binding on the accumulation and depletion of drug from the skin, **73:** 710
Hyman, Clifton *See* Lever, O. William, Jr., **73:** 1241

I

Iga, Tatsuji *See* Igari, Yasutaka, **73:** 826; Sugita, Osamu, **73:** 631; Terasaki, Tetsuya, **73:** 524, 1359
Igari, Yasutaka; Sugiyama, Yuichi; Sawada, Yasufumi; Iga, Tatsuji; Hanano, Manabu: *In vitro* and *in vivo* assessment of hepatic and extrahepatic metabolism of diazepam in the rat, **73:** 826
Ikeda, N. *See* Kannan, R., **73:** 1208
Ikegami, Yoshihiko *See* Nishimura, Kenji, **73:** 942
Imai, H. *See* Tamai, G., **73:** 1825
Imai, Yutaka *See* Shimada, Kazutake, **73:** 119
Imondi, A. R. *See* Baldwin, J. R., **73:** 1002
Inaba, Kohji *See* Uekama, Kaneto, **73:** 382
Ings, R. M. J. *See* Martin, B. K., **73:** 437
Iranloye, T. A.; Pilpel, N.: Simple, rapid method for comparing the self-emulsifiability of hydrocarbon oils, **73:** 1267
Irvin, J. D. *See* Swanson, Brian N., **73:** 1655
Ishii, Fumiyoshi *See* Takamura, Akira, **73:** 91, 676
Ishizaka, Takafumi *See* Emori, Hisatoshi, **73:** 910
Ishizaki, Takashi; Chiba, Kan; Suganuma, Toshiyuki; Sasaki, Tomio; Kamiyama, Hiroshi; Nakano, Hideki: Pharmacokinetics of nicorandil, a new coronary vasodilator, in dogs, **73:** 494
Ivashkiv, Eugene *See* Cohen, Allen I., **73:** 1493, 1571
Spectrofluorometric determination of captopril plus captopril disulfide metabolites in plasma, **73:** 1427
—; McKinstry, Doris N.; Cohen, Allen I.: Determination of total captopril in human plasma by gas chromatography–mass spectrometry with selected-ion monitoring after reduction of disulfides, **73:** 1113
Iwamoto, Kikuo *See* Hasegawa, Jiro, **73:** 442
Iyer, Balasubramanian V. *See* Khan, Arshad R., **73:** 302

J

Jackson, Andre J.; Sutherland, John C.: Novel device for quantitatively collecting small volumes of urine from laboratory rats, **73:** 816
Jacobson, Arthur E. *See* Aceto, Mario D., **73:** 1864; Awaya, Hiroyoshi, **73:** 1867
Jaffe, James M. *See* Tse, Francis L. S., **73:** 1599
Jagoda, E. M. *See* Eckelman, William C., **73:** 529
Jain, N. K.; Naik, S. U.: Design of a slow-release capsule using laser drilling, **73:** 1806
Jakobs, Uwe *See* Krause, Werner, **73:** 563
Jan, Chaur-Ming *See* Foye, William O., **73:** 559
Jarowski, C. I. *See* Liao, Chi-Chow, **73:** 401
Jarreau, C. *See* Leroyer, R., **73:** 844
Jarrott, Bevyn *See* Worland, Peter J., **73:** 1755
Jensen, B. *See* Reed, K., **73:** 237
Jimenez, Angel *See* Hilbert, James M., **73:** 516
Jizomoto, Hiroaki: Phase separation induced in gelatin–base coacervation systems by addition of water-soluble nonionic polymers I: microencapsulation, **73:** 879
Johnson, David M.; Taylor, William F.: Degradation of fenprostalene in polyethylene glycol 400 solution, **73:** 1414
Johnson, Dennis L. *See* Fritzberg, Alan R., **73:** 1861
Johnson, E. L.; Pachla, Lawrence A.: Improved liquid chromatographic assay for the analysis of pirmenol in plasma and urine, **73:** 754
Johnson, J. D.; Carlson, G. L.; Fox, J. M.; Miller, A. M.; Chang, S. F.; Conard, G. J.: Quantitation of flecainide acetate, a new antiarrhythmic agent, in biological fluids by gas chromatography with electron-capture detection, **73:** 1469
Johnson, Mark A.: review of "Applied Statistics: A Handbook of Techniques, 5th Ed.", **73:** 289
Johnson, Scott M.; Nygard, Gloria; Khalil, S. K. Wahba: Isocratic liquid chromatographic method for the determination of amoxapine and its metabolites, **73:** 696
Joly, L. P. *See* Bernier, L. G., **73:** 1157
Jones, Alan B. *See* Chambliss, Walter G., **73:** 1215
Jones, D. Brian *See* Ching, Michael S., **73:** 1015

Jones, Gary L.; Amato, Robert J.; Jones, Mary F.: α,α-Diphenylsuccinimide: evaluation of anticonvulsant and hydrophobic properties, **73:** 310
Jones, Mary F. *See* Jones, Gary L., **73:** 310
Jones, Richard E. *See* Anik, Shabbir T., **73:** 684; Yu, Cheng Der, **73:** 344
Jusko, William J. *See* Boudinot, F. Douglas, **73:** 774; Gengo, Francis M., **73:** 867; Khalafallah, Nawal, **73:** 362

K

Kabadi, Mohan B.; Chien, Yie W.: Intravaginal controlled administration of flurogestone acetate II: development of an *in vitro* system for studying the intravaginal release and permeation of flurogestone acetate, **73:** 1464
—; Valia, Kirti H.; Chien, Yie W.: Intravaginal controlled administration of flurogestone acetate I: development of a stability-indicating liquid chromatographic method and stability kinetics of flurogestone acetate, **73:** 1461
Kadaba, Pankaja K.: Triazolines XIII: Δ^2-1,2,3-triazolines, a new class of anticonvulsants, **73:** 850
Kaka, I. *See* Chow, D. S-L., **73:** 1794
Kallmerten, James: review of "The Total Synthesis of Natural Products, Vol. 5", **73:** 426
Kaminski, James J.: Aspirin prodrug studies: lack of proper literature citation, **73:** 425
Kamiya, Akira *See* Fung, Ho-Leung, **73:** 873
—; Okumura, Katsuhiko; Hori, Ryohei: Quantitative investigation of renal handling of drugs in dogs with renal insufficiency, **73:** 892
Kamiyama, Hiroshi *See* Ishizaki, Takashi, **73:** 494
Kampa, Ingo S. *See* Rosenberg, Jack M., **73:** 1833
Kampa, Lidija *See* Rosenberg, Jack M., **73:** 1833
Kaneko, Shigeo *See* Kobayashi, Kunio, **73:** 1684
Kanfer, Isadore *See* Noonan, Patrick K., **73:** 923
Kann, Jules *See* Levitt, Monte J., **73:** 977
Kannan, R.; Ikeda, N.; Wagner, R.; Drachenberg, M.; Singh, B. N.: Serum and myocardial kinetics of amiodarone and its deethyl metabolite after intravenous administration in rabbits, **73:** 1208
Kannisto, Hannu; Neuvonen, Pertti J.: Adsorption of sulfonylureas onto activated charcoal *in vitro*, **73:** 253
Kapil, R. P.; Axelson, James E.; Ongley, R.; Price, J. D. E.: Nonlinear bioavailability of metoclopramide in the rat: evidence for saturable first-pass metabolism, **73:** 215
Kaplan, Gerald *See* DePaolis, Anneli M., **73:** 1650
Kasuya, Yasuji; Althaus, James R.; Freeman, James P.; Mitchum, Ronald K.; Skelly, Jerome P.: Quantitative determination of dexamethasone in human plasma by stable-isotope dilution mass spectrometry, **73:** 446
Katz, Jeffrey D. *See* Bustrack, James A., **73:** 1397
Kawaguchi, Sachiyo *See* Matsuda, Yoshihisa, **73:** 173
Kawai, Ryosei *See* Suzuki, Tokuji, **73:** 136
Kawashima, Y.; Aoki, S.; Takenaka, H.; Miyake, Y.: Preparation of spherically agglomerated crystals of aminophylline, **73:** 1407
—; Okumura, M.; Takenaka, H.; Kojima, A.: Direct preparation of spherically agglomerated salicylic acid crystals during crystallization, **73:** 1535
Keller, W. J. *See* Ferguson, P. W., **73:** 692
Kemp, Murray *See* Scott, K. R., **73:** 1531
Kent, J. S. *See* Sanders, L. M., **73:** 1294
Khachatourians, G. G.; Holmlund, P. K.; Dimmock, J. R.: Some effects of 1-(2,4-dichlorophenyl)-4-dimethylaminomethyl-1-nonen-3-one hydrochloride on *Escherichia coli* GK-19, **73:** 803
Khalafallah, Nawal; Jusko, William J.: Determination and prediction of tissue binding of prednisolone in the rabbit, **73:** 362
Khalil, M. A. *See* Habib, N. S., **73:** 982
Khalil, S. K. Wahba *See* Johnson, Scott M., **73:** 696
Khan, Arshad R.; Iyer, Balasubramanian V.; Cirelli, Rosetta A.; Vasavada, Ravindra C.: *In vitro* release of salicylic acid from lanolin alcohols–ethylcellulose films, **73:** 302
Khan, M. Niyaz: Kinetics and mechanism of the alkaline hydrolysis of maleimide, **73:** 1767
Kibbe, Arthur H. *See* Chambliss, Walter G., **73:** 1215
Kier, Lemont B.: review of "Information Theoretic Indices for Characterization of Chemical Structures", **73:** 1336
Kilzer, Karen L. *See* Ezzedeen, Fikrat W., **73:** 1369
Kimura, Masako *See* Kobayashi, Kunio, **73:** 1684
Kimura, Ryohei *See* Hussain, Anwar A., **73:** 1300
Kimura, Toshikiro *See* Yamamoto, Akira, **73:** 48
King, Shang-Ying P.; Kung, Min-Shya; Fung, Ho-Leung: Statistical prediction of drug stability based on nonlinear parameter estimation, **73:** 657
King, William J. *See* Tavss, Edward A., **73:** 1148
Kinghorn, A. Douglas *See* Arisawa, Munehisa, **73:** 411
Kinkel, W. R. *See* Gengo, Francis M., **73:** 961
Kirisits, Alan J. *See* Hong, Chung Il, **73:** 278
Kirk, Marion C. *See* Shealy, Y. Fulmer, **73:** 745
Kirsch, Lee E.; Notari, Robert E.: Aqueous conversion kinetics and mechanisms of ancitabine, a prodrug of the antileukemic agent cytarabine, **73:** 896
—; Notari, Robert E.: Pharmacokinetic prodrug modeling: *in vitro* and *in vivo* kinetics and mechanisms of ancitabine bioconversion to cytarabine, **73:** 728
—; Notari, Robert E.: Theoretical basis for the detection of general-base catalysis in the presence of predominating hydroxide catalysis, **73:** 724
Kirschbaum, Joel J. *See* Perlman, Solomon, **73:** 259
—; Perlman, Solomon: Analysis of captopril and hydrochlorothiazide combination tablet formulations by liquid chromatography, **73:** 686
Kissinger, Peter T.: review of "A Textbook of Pharmaceutical Analysis, 3rd Ed.", **73:** 1015
Kitagawa, Isao *See* Miyamoto, Etsuko, **73:** 409
Klayman, Daniel L.; Lin, Ai J.; Hoch, James M.; Scovill, John P.; Lambros, Chris; Dobek, Arthur S.: 2-Acetylpyridine thiosemicarbazones XI: 2-(α-hydroxyacetyl)pyridine thiosemicarbazones as antimalarial and antibacterial agents, **73:** 1763
Klein, G. *See* Bremecker, K.-D., **73:** 548
Klotz, Irving M. *See* Massil, Solomon E., **73:** 418, 1013, 1851
Knapp, J. E. *See* El-Fishawy, A. M., **73:** 1639
Knapp, Steven *See* Zatz, Joel L., **73:** 468
Knevel, Adelbert M. *See* Ghebre-Sellassie, Isaac, **73:** 125
Kobayashi, Hitomi *See* Matsuda, Yoshihisa, **73:** 173
Kobayashi, Kunio; Kimura, Masako; Sakoguchi, Takafumi; Hase, Ayumi; Matsuoka, Akira; Kaneko, Shigeo: Pharmacokinetics of gliclazide in healthy and diabetic subjects, **73:** 1684
Koike, Masahiro; Norikura, Ryo; Mizorjiri, Kenji; Sugeno, Koichi: Time-dependent elimination of cinoxacin in rats, **73:** 1697
Koishi, Masumi *See* Emori, Hisatoshi, **73:** 910; Takamura, Akira, **73:** 676
Kojima, A. *See* Kawashima, Y., **73:** 1535
Kolb, Vera M.: New insights in the clastic binding hypothesis for opiate–receptor interactions I: electron-transfer mechanism, **73:** 715
—; Scheiner, Steve: Angular dependence of the interaction energy between the N lone pair of amines and a proton: relevance to drug–receptor systems, **73:** 389
—; Scheiner, Steve: New insights in the clastic binding hypothesis for opiate–receptor interactions II: proton-transfer mechanism, **73:** 719
Kontro, Pirjo *See* Andersen, Lars, **73:** 106
Koplove, H. Michael: review of "Methods in Industrial Microbiology", **73:** 1018
Korchinski, E. D. *See* Midha, Kamal K., **73:** 261
Korduba, Chryzanta A.; Petruzzi, Ralph F.: High-performance liquid chromatographic method for the determination of trace amounts of acetaminophen in plasma, **73:** 117
Kornet, Milton J.: Synthesis and anticonvulsant evaluation of *N*-aminosuccinimides, **73:** 405
Koss, Raymond F. *See* Stroshane, Ronald M., **73:** 1438
Kowaluk, Elizabeth A.; Roberts, Michael S.; Polack, Alan E.: Dynamics of clomethiazole edisylate interaction with plastic infusion systems, **73:** 43
Kowarski, A. Avinoam *See* Kowarski, Chana R., **73:** 1298
Kowarski, Chana R.; Liaou, Ming Yu; Kowarski, David; Weizer, Jeffrey; Boynes, Dutton; Kowarski, A. Avinoam: Improved bioassay for glucagon by continuous glucose monitoring, **73:** 1298
Kowarski, David *See* Kowarski, Chana R., **73:** 1298
Krause, Werner; Jakobs, Uwe: Determination of 17β-hydroxy-1α-methyl-17α-propyl-5-α-androstan-3-one in plasma by gas chromatography–mass spectrometry with single-ion detection, **73:** 563
Krejci, Carolyn *See* Kupchik, Eugene J., **73:** 1012
Kreuter, Jorg *See* Leu, Daniel, **73:** 1433; Nefzger, Marijke, **73:** 1309
Krikorian, S. Edward *See* Tangtatsawasdi, Paktiya, **73:** 1238
Krueger, Terry Ray *See* Hoener, Betty-ann, **73:** 1669
Kruisbrink, Jenneke; Boer, Gerard J.: Controlled long-term release of small peptide hormones using a new microporous polypropylene polymer: its application for vasopressin in the Brattleboro rat and potential perinatal use, **73:** 1713
Kuang-Paio, Chen: Determination of calcium gluconate by selective oxidation with periodate, **73:** 681
Kullberg, M. Peter *See* Park, Young Han, **73:** 24
Kung, Min-Shya *See* King, Shang-Ying P., **73:** 657
Kunimune, Yoshio *See* Yamamoto, Jyunji, **73:** 212
Kuo, T. H. *See* Au, D. S.-L., **73:** 705
Kupchik, Eugene J.; Pisano, Michael A.; Parikh, Dilipkumar K.; Krejci, Carolyn; Taylor, Jonathan: Antimicrobial activity of triethylammonium chloride–*N*-substituted *N'*-cyano-*O*-(triphenylstannyl)isourea complexes, **73:** 1012
Kushinsky, Stanley *See* Anik, Shabbir T., **73:** 684; Wu, Anne T., **73:** 1444
Kussendrager, K. *See* Lerk, C. F., **73:** 856, 857
Kuttab, Simon H. *See* Shargel, Leon, **73:** 161

Küttel, S. *See* Mezei, J., **73:** 1489
Kwan, Lilian Chong; Schott, Hans: Colorimetric prednisolone assay and its application to dissolution studies, **73:** 157

L

Laakso, Timo *See* Artursson, Per, **73:** 1507
Labrude, P. *See* Fauvel, A., **73:** 784
Lacz, Joseph P. *See* Wiens, Robert E., **73:** 688
Lakings, Duane B.; Stryd, Ronald P.; Gilbertson, Terry J.: Quantitative determination of *N*-(*trans*-2-dimethylaminocyclopentyl)-*N*-(3′,4′-dichlorophenyl)propanamide and its *N*-demethyl metabolite in dog serum by gas chromatography, **73:** 317
Lalka, David *See* Anderson, Gail D., **73:** 1791; Edwards, David J., **73:** 1264
La Manna, Aldo *See* Colombo, Paolo, **73:** 701
Lambe, R. F. *See* Chasseaud, L. F., **73:** 699
Lambert, Howard J. *See* Lee, Hyuk-Koo, **73:** 306
Lambert, W. J. *See* Anderson, Bradley D., **73:** 604
Lambros, Chris *See* Klayman, Daniel L., **73:** 1763
Landis, J. B. *See* Asmus, P. A., **73:** 1290
Lane, Elizabeth A. *See* Lin, Huey-shin, **73:** 285
Langer, Robert *See* Cohen, Jonathan, **73:** 1034; Sefton, Michael V., **73:** 1859
Langkamp, Herman *See* Gershon, Herman, **73:** 1840
Lassiani, Lucia *See* Ebert, Cynthia, **73:** 1691
Lasswell, William L., Jr.; Weber, Stanley S.; Wilkins, John M.: *In vitro* interaction of neuroleptics and tricylic antidepressants with coffee, tea, and gallotannic acid, **73:** 1056
Lau, D. T. *See* Abra, R. M., **73:** 203
Lawrence, W. H.; Autian, J.: Problems involved with developing a suitable model for evaluating exposure to bis(2-ethylhexyl) phthalate from medical devices, **73:** 861
Leclercq, G. *See* Omar, A.-Mohsen M. E., **73:** 1871
Lee, Chia-Shun *See* Nishihata, Toshiaki, **73:** 1326, 1523
Lee, Ching-San C. *See* Au, D. S.-L., **73:** 705; Chen, M. M., **73:** 1053
—; Varughese, Abraham: Disposition kinetics of ethambutol in nephrectomized dogs, **73:** 787
Lee, Choon S. *See* Nam, Doo H., **73:** 1843
Lee, Edmund J. D.; Williams, Kenneth M.; Graham, Garry G.; Day, Richard O.; Champion, G. David: Liquid chromatographic determination and plasma concentration profile of optical isomers of ibuprofen in humans, **73:** 1542
Lee, Geoffrey *See* Swarbrick, James, **73:** 1352
Lee, Hyuk-Koo; Lambert, Howard J.; Schowen, Richard L.: On the mechanism of dehydration of a β-hydroxycyclopentanone analogue of prostaglandin E_1, **73:** 306
Lee, Ping I.: Novel approach to zero-order drug delivery *via* immobilized nonuniform drug distribution in glassy hydrogels, **73:** 1344
Lee, Ying-Chi; Baaske, David Michael; Alam, Abu S.: High-performance liquid chromatographic method for the determination of esmolol hydrochloride, **73:** 1660
Lehmann, J. *See* Cates, L. A., **73:** 1550
Lenaerts, V.; Nagelkerke, J. F.; Van Berkel, T. J. C.; Couvreur, P.; Grislain, L.; Roland, M.; Speiser, P.: *In vivo* uptake of polyisobutyl cyanoacrylate nanoparticles by rat liver Kupffer, endothelial, and parenchymal cells, **73:** 980
Lensmeyer, Gary L.: review of "Deposition of Toxic Drugs and Chemicals in Man, 2nd Ed.", **73:** 426
Lerk, C. F.; Andreae, A. C.; de Boer, A. H.; de Hoog, P.; Kussendrager, K.; van Leverink, J.: Alterations of α-lactose during differential scanning calorimetry, **73:** 856
—; Andreae, A. C.; de Boer, A. H.; de Hoog, P.; Kussendrager, K.; van Leverink, J.: Transitions of lactoses by mechanical and thermal treatment, **73:** 857
Lerner, D. *See* Fabre, H., **73:** 1709
Leroyer, R.; Jarreau, C.; Pays, M.; Varoquaux, O.; Advenier, C.: Reverse-phase liquid chromatography and pharmacokinetic study of two hydroxylated analogues of quinidine in dogs, **73:** 844
Leu, Daniel; Manthey, Barbara; Kreuter, Jorg; Speiser, Peter; DeLuca, Patrick P.: Distribution and elimination of coated polymethyl [2-^{14}C]methacrylate nanoparticles after intravenous injection in rats, **73:** 1433
Lever, O. William, Jr.; Hyman, Clifton; White, Helen L.: Synthesis of bridged catechol–homocysteine derivatives as potential inhibitors of catechol *O*-methyltransferase, **73:** 1241
Levitt, Monte J.; Kann, Jules: Choline magnesium trisalicylate: comparative pharmacokinetic study of once-daily and twice-daily dosages, **73:** 977
Levy, Gerhard *See* Chou, Ruby C., **73:** 1121, 1180, 1348; Morris, Marilyn E., **73:** 853, 1038; Whitfield, Lloyd R., **73:** 72
Levy, René H. *See* Lin, Huey-shin, **73:** 285
Lewis, D. H. *See* Sanders, L. M., **73:** 1294
Lewis, P. A. *See* Woodward, A. J., **73:** 1838
—; Woodward, A. J.; Maddock, J.: High-performance liquid chromatographic assay for *N*-acetylcysteine in plasma and urine, **73:** 996
Li, V-S. *See* Cates, L. A., **73:** 1550
Li, Wen-Yen; Guo, Zong-Ru; Lien, Eric J.: Examination of the interrelationship between aliphatic group dipole moment and polar substituent constants, **73:** 553
Liao, Chi-Chow; Jarowski, C. I.: Dissolution rates of corticoid solutions dispersed on silicas, **73:** 401
Liaou, Ming Yu *See* Kowarski, Chana R., **73:** 1298
Lichtenberg, D.; Markello, T.: Structural characteristics of phospholipid multilamellar liposomes, **73:** 122
Liehl, Ekke *See* Nefzger, Marijke, **73:** 1309
Lien, Eric J. *See* Li, Wen-Yen, **73:** 553
Lin, Ai J. *See* Klayman, Daniel L., **73:** 1763
Lin, Emil T. *See* Sörgel, Fritz, **73:** 831
Lin, Huey-shin; Levy, René H.; Lane, Elizabeth A.; Gordon, W. Perry: Variability in the determination of fraction metabolized in a triangular metabolic problem and its resolution with stable isotope methodology, **73:** 285
Lin, Li Shei; Caritis, Steve N.; Wong, Lan K.: Analysis of ritodrine in serum by high-performance liquid chromatography with electrochemical detection, **73:** 831
Lin, Tai-Shun: Synthesis and *in vitro* antiviral activity of 3′-*O*-acyl derivatives of 5′-amino-5′-deoxythymidine: potential prodrugs for topical application, **73:** 1568
Linda, Paolo *See* Ebert, Cynthia, **73:** 1691
Lindén, Inge-Britt *See* Andersen, Lars, **73:** 106
Lindstrom, Anna L. *See* Wahlgren, Sven, **73:** 1484
Linn, Edwards E. *See* Behl, Charangit R., **73:** 1287
Liron, Zvi; Cohen, Sasson: Percutaneous absorption of alkanoic acids I: a study of operational conditions, **73:** 534
—; Cohen, Sasson: Percutaneous absorption of alkanoic acids II: application of regular solution theory, **73:** 538
Liu, Jue-Chen; Feldkamp, Joseph R.; White, Joe L.; Hem, Stanley L.: Adsorption of phosphate by aluminum hydroxycarbonate, **73:** 1355
Locniskar, Ann *See* Greenblatt, David J., **73:** 399
Logan, B. M. *See* Dimmock, J. R., **73:** 471
Long, D. A. *See* Garnick, R. L., **73:** 75
Lovering, E. G. *See* Matsui, F., **73:** 1664
Lovrecich, Mara *See* Ebert, Cynthia, **73:** 1691
Lowe, John A., III: review of "Current Trends in Organic Synthesis. Proceedings of the Fourth International Conference on Organic Synthesis", **73:** 574
Lubey, Gwen S. *See* Schieffer, Gary W., **73:** 1856
Luciuk, George H. *See* Simons, Keith J., **73:** 595
Luczkowec, Carol *See* Stroshane, Ronald M., **73:** 1438
Ludden, Thomas M. *See* Mungall, Dennis, **73:** 1000
Lukes, A. L. *See* Pikal, M. J., **73:** 1608
Lulla, H.; Chen, S. S.; Sena, F. J.: Simultaneous determination of nitrate and nitrite in toothpastes by high-performance liquid chromatography, **73:** 1004
Luna, Ernestina *See* Manzo, Ruben H., **73:** 1094, 1869

M

Maddock, J. *See* Lewis, P. A., **73:** 996; Woodward, A. J., **73:** 1838
Maderazo, Eufronio G.; Breaux, Steven P.; Woronick, Charles L.: Inhibition of human polymorphonuclear leukocyte cell responses by ibuprofen, **73:** 1403
Magill, Adina; Becker, Allyn R.: Spectrophotometric method for quantitation of peroxides in sorbitan monooleate and monostearate, **73:** 1663
Magnuson, V. R. *See* Basak, S. C., **73:** 429
Maguire, James H. *See* Chapman, James M., Jr., **73:** 1482
Maharaj, I.; Nairn, J. G.; Campbell, J. B.: Simple rapid method for the preparation of enteric-coated microspheres, **73:** 39
Maher, R. T. *See* Escobar, A., **73:** 1640
Maher, Timothy J. *See* Foye, William O., **73:** 1168
Mahony, Cheryl; Brown, James E.; Stargel, W. Wayne; Verghese, Chacko P.; Bjornsson, Thorir D.: *In vitro* stability of sodium nitroprusside solutions for intravenous administration, **73:** 838
Maibach, Howard: review of "Dermatological Formulations: Percutaneous Absorption", **73:** 573
Maier, G. A. *See* Fung, Ho-Leung, **73:** 873
Maincent, Philippe *See* McGinity, James W., **73:** 1441
Makoid, Michael C. *See* Ezzedeen, Fikrat W., **73:** 1369; Grass, George M., **73:** 618
Malbica, J. O. *See* Hermes, M., **73:** 667
Malveaux, Eugene J. *See* Ali, Farouk M., **73:** 1363
Mandrou, B. *See* Fabre, H., **73:** 1706, 1709
Mankad, Vipul N. *See* Henderson, James D., **73:** 1748
Mann, David E., Jr.; Gautieri, Ronald F.: Influence of α- and β-adrenergic antagonists on dopamine-induced responses in the isolated heart of *Mercenaria mercenaria*, **73:** 1491
Manners, Carol N. *See* Davis, Michael G., **73:** 949
Mansour, Nabil A. *See* Shafik, Ragab M., **73:** 1548
Manthey, Barbara *See* Leu, Daniel, **73:** 1433
Manzo, Ruben H.; Ahumada, Amelia A.; Luna, Ernestina: Effects of solvent medium on solubility III: hydrophilic–lipophilic character exhibited by some functional groups having oxygen or nitrogen in ethanol–water, **73:** 1094
—; Ahumada, Amelia A.; Luna, Ernestina: Effects of solvent medium on solubility IV: comparison of the hydrophilic–lipophilic character exhibited by functional groups in ethanol–water and ethanol–cyclohexane mixtures, **73:** 1869
Marcelle, Guido B.; Ahmed, Mohamed S.; Pez-

zuto, John M.; Cordell, Geoffrey A.; Waller, Donald P.; Soejarto, D. D.; Fong, H. H. S.: Analysis of gossypol and gossypol-acetic acid by high-performance liquid chromatography, **73:** 396

Marecki, Paul E.; Bambury, Ronald E.: Synthesis of 4-substituted aminoquinoline-3-carboxylates as potential antimicrobial agents, **73:** 1141

Margosis, Michel; Aszalos, Adorjan: Quantitation of amphotericins by reverse-phase high-performance liquid chromatography, **73:** 835

Markello, T. *See* Lichtenberg, D., **73:** 122

Marshall, James *See* Mungall, Dennis, **73:** 1000

Martelli, Sante *See* Antonini, Ippolito, **73:** 366

Martin, A. *See* Adjei, A., **73:** 742; Beerbower, A., **73:** 179; Stavchansky, S., **73:** 169

—; Wu, P. L.; Beerbower, A.: Expanded solubility parameter approach II: *p*-hydroxybenzoic acid and methyl *p*-hydroxybenzoate in individual solvents, **73:** 188

Martin, B. K.; Uihlein, M.; Ings, R. M. J.; Stevens, L. A.; McEwen, J.: Comparative bioavailability of two furosemide formulations in humans, **73:** 437

Marton, S. *See* Mezei, J., **73:** 1489

Mascher, H. *See* Nitsche, V., **73:** 1556

Mason, William D.: Comparative aspirin absorption kinetics after administration of sodium- and potassium-containing buffered solutions, **73:** 998

Kinetics of aspirin absorption following oral administration of six aqueous solutions with different buffer capacities, **73:** 1258

Massey, Ian J. *See* Wu, Anne T., **73:** 1444

Massil, Solomon E.; Shi, Guey-Yueh; Klotz, Irving M.: Acylation of hemoglobin by aspirin-like diacyl esters, **73:** 1013

—; Shi, Guey-Yueh; Klotz, Irving M.: Diaspirins of methylenecitric acid, **73:** 418

—; Shi, Guey-Yueh; Klotz, Irving M.: Electrostatic effects in acylation of hemoglobin by aspirins, **73:** 1851

Mastalerz, Przemslaw *See* Nelson, Victor, **73:** 1844

Masujima, T. *See* Tamai, G., **73:** 1825

Matsuda, Yoshihisa; Kawaguchi, Sachiyo; Kobayashi, Hitomi; Nishijo, Jujiro: Physicochemical characterization of spray-dried phenylbutazone polymorphs, **73:** 173

—; Tatsumi, Etsuko; Chiba, Etsuko; Miwa, Yukie: Kinetic study of the polymorphic transformations of phenylbutazone, **73:** 1453

Matsui, F.; Lovering, E. G.; Watson, J. R.; Black, D. B.; Sears, R. W.: Gas chromatographic method for solvent residues in drug raw materials, **73:** 1664

Matsuoka, Akira *See* Kobayashi, Kunio, **73:** 1684

May, Everette L. *See* Aceto, Mario D., **73:** 1864; Awaya, Hiroyoshi, **73:** 1867

Mayer, Joachim *See* Toon, Stephen, **73:** 625

Mayersohn, Michael *See* Achari, Ramanuj, **73:** 690

review of "Drug Fate and Metabolism: Methods and Techniques, Vol. 4", **73:** 862

McChesney, James D. *See* Clark, Alice M., **73:** 502

—; Sarangan, S.; Hufford, Charles D.: Bromo-6-methoxy-8-aminoquinolines: preparation and ^{13}C-NMR assignments, **73:** 1854

McCormick, Terrence *See* Cohen, Allen I., **73:** 1493, 1571

McEwen, J. *See* Martin, B. K., **73:** 437

McGinity, James W.; Maincent, Philippe; Steinfink, Hugo: Crystallinity and dissolution rate of tolbutamide solid dispersions prepared by the melt method, **73:** 1441

McGonigle, Eugene J. *See* DePaolis, Anneli M., **73:** 1650

McGuire, Howard *See* Rosenberg, Jack M., **73:** 1833

McHugh, W. B. *See* Gengo, Francis M., **73:** 961

McKay, G. *See* Hawes, Edward M., **73:** 247; Midha, Kamal K., **73:** 261, 1144

McKinstry, Doris N. *See* Cohen, Allen I., **73:** 1493; Ivashkiv, Eugene, **73:** 1113

McMullen, Jean N.; Newton, David W.; Becker, Charles H.: Pectin–gelatin complex coacervates II: effect of microencapsulated sulfamerazine on size, morphology, recovery, and extraction of water-dispersible microglobules, **73:** 1799

McPhail, A. T. *See* Hall, Iris H., **73:** 222, 973

McRae, Georgia I. *See* Anik, Shabbir T., **73:** 684; Sanders, L. M., **73:** 1294

McVittie, J. *See* Midha, Kamal K., **73:** 1144

Mederski-Samoraj, B. *See* Au, D. S.-L., **73:** 705

Medon, Philip J. *See* Hacker, Bruce, **73:** 270

Medwid, Jeffrey *See* Siegel, Marshal M., **73:** 498

Meeker, F. S., Jr. *See* Bathala, M. S., **73:** 340

Mehdizadeh, Mehdi; Grant, David J. W.: Solubility and complexation behavior of griseofulvin in fatty acid–isooctane mixtures, **73:** 1195

Meijer, D. K. F. *See* Böttger, W. M., **73:** 95

Mendenhall, Douglas W.: Secret formulations from the industry's perspective, **73:** 1501

Menon, G.; Norris, B.; Webster, J.: Simultaneous determination of chloroprocaine hydrochloride and its degradation product 4-amino-2-chlorobenzoic acid in bulk drug and injection solutions by high-performance liquid chromatography, **73:** 251

Menozzi, Milena; Valentini, Luigi; Vannini, Elisabetta; Arcamone, Federico: Self-association of doxorubicin and related compounds in aqueous solution, **73:** 766

Mereish, K. *See* Reed, K., **73:** 237

Mershon, Millard M. *See* Reifenrath, William G., **73:** 1388

Mertel, H. E. *See* VandenHeuvel, W. J. A., **73:** 1731

Meyer, Edgar F., Jr. *See* Vedani, Angelo, **73:** 352

Meyer, Marvin C.; Straughn, Arthur B.; Raghow, Gursharan; Schary, William L.; Rotenberg, Keith S.: Absorption of phenobarbital from tablets and elixir, **73:** 485

Mezei, J.; Küttel, S.; Szentmiklósi, P.; Marton, S.; Rácz, I.: A new method for high-performance liquid chromatographic determination of drotaverine in plasma, **73:** 1489

Mezei, Michael *See* Goundalkar, Ashok, **73:** 834

Michael, J. P.: review of "Total Synthesis of Natural Products: The 'Chiron' Approach", **73:** 1502

Michaels, Michael K. *See* Shah, Kirit A., **73:** 822

Midha, Kamal K. *See* Aravagiri, M., **73:** 1383; Hawes, Edward M., **73:** 247; Shetty, H. Umesha, **73:** 87

—; Korchinski, E. D.; Roscoe, R. M. H.; Hawes, E. M.; Cooper, J. K.; McKay, G.: Relative bioavailability of a commercial trifluoperazine tablet formulation using a radioimmunoassay technique, **73:** 261

—; Rauw, G.; McKay, G.; Cooper, J. K.; McVittie, J.: Subnanogram quantitation of chlorpheniramine in plasma by a new radioimmunoassay and comparison with a liquid chromatographic method, **73:** 1144

Midland, S. L. *See* Stewart, B. A., **73:** 1322

Migdalof, B. H. *See* Bathala, M. S., **73:** 340

Mihaly, George W. *See* Ching, Michael S., **73:** 1015

Mihashi, Kunihide *See* Yagi, Akira, **73:** 62

Miles, D. Howard *See* Parish, Edward J., **73:** 694

Miller, A. M. *See* Johnson, J. D., **73:** 1469

Miller, Duane D.: review of "Annual Review of Pharmacology and Toxicology, Volume 23", **73:** 573

Miller, R. A. *See* Vadas, E. B., **73:** 781

Miller, Raymond: Pharmacokinetics and bioavailability of ranitidine in humans, **73:** 1376

Mills, Richard *See* Siegel, Marshal M., **73:** 498

Mima, Hiroyuki *See* Okada, Hiroaki, **73:** 298

Mirando, P. *See* Siegel, Marshal M., **73:** 498

Mitchell, A. G. *See* Suryanarayanan, R., **73:** 78

Mitchum, Ronald K. *See* Kasuya, Yasuji, **73:** 446

Mitsuhashi, Susumu *See* Hamano, Shoichiro, **73:** 1422; Tsuji, Akira, **73:** 1418

Miura, George A. *See* Reifenrath, William G., **73:** 1388

Miwa, Yukie *See* Matsuda, Yoshihisa, **73:** 1453

Miyake, Y. *See* Kawashima, Y., **73:** 1407

Miyamoto, Etsuko; Odashima, Shizuo; Kitagawa, Isao; Tsuji, Akira: Stability kinetics of ginsenosides in aqueous solution, **73:** 409

Miyashita, Yoshikatsu *See* Takahashi, Yoshimasa, **73:** 737

Mizorjiri, Kenji *See* Koike, Masahiro, **73:** 1697

Mojaverian, Parviz *See* Fedder, Ira L., **73:** 1496

Mokhtar, Hassan M. *See* Soliman, Raafat, **73:** 403

Moody, Timothy E. *See* Sepelyak, Robert J., **73:** 1514

Mooney, K. G. *See* Stella, V. J., **73:** 946

Morales-Lagos, D. R. *See* Gómez-Jeria, J. S., **73:** 1725

Morimoto, Kazuhiro; Akatsuchi, Hiroaki; Aikawa, Renji; Morishita, Masataka; Morisaka, Katsuaki: Enhanced rectal absorption of [$Asu^{1,7}$]-eel calcitonin in rats using polyacrylic acid aqueous gel base, **73:** 1366

Morioka, Tadashi *See* Nishimura, Kenji, **73:** 942

Morisaka, Katsuaki *See* Morimoto, Kazuhiro, **73:** 1366

Morishita, Masataka *See* Morimoto, Kazuhiro, **73:** 1366

Morita, I. *See* Tamai, G., **73:** 1825

Morita, Ken'ichi *See* Yamamoto, Jyunji, **73:** 212

Morozowich, W. *See* Park, J. Y., **73:** 1588; Rogers, J. D., **73:** 1594

Morris, Marilyn E.; Galinsky, Raymond E.; Levy, Gerhard: Depletion of endogenous inorganic sulfate in the mammalian central nervous system by acetaminophen, **73:** 853

—; Levy, Gerhard: Renal clearance and serum protein binding of acetaminophen and its major conjugates in humans, **73:** 1038

Morshedy, Mahmoud *See* Shafik, Ragab M., **73:** 1548

Morton, George *See* Siegel, Marshal M., **73:** 498

Motta, A. *See* Carli, F., **73:** 197

Müller, B. W.; Müller, R. H.: Particle size analysis of latex suspensions and microemulsions by photon correlation spectroscopy, **73:** 915

—; Müller, R. H.: Particle size distributions and particle size alterations in microemulsions, **73:** 919

Müller, R. H. *See* Müller, B. W., **73:** 915, 919

Mulley, B. A. *See* Wou, Lyndon L-S., **73:** 1738

Mulumba, Bipi *See* Anderson, Wayne K., **73:** 1182

Mungall, Dennis; Wong, Yan Yan; Talbert, Robert L.; Crawford, Michael H.; Marshall, James; Hawkins, David W.; Ludden, Thomas M.: Plasma protein binding of warfarin: methodological considerations, **73:** 1000

Murai, Patrick *See* Guillard, Olivier, **73:** 1642

Murphy, Gregory *See* Hilbert, James M., **73:** 516

Musson, D. G. *See* Pauliukonis, L. T., **73:** 99

—; Vincek, W. C.; Constanzer, M. L.; Detty, T. E.: Analytical methods for the determination of sulindac and metabolites in plasma, urine, bile, and gastric fluid by liquid chromatography using ultraviolet detection, **73:** 1270

N

Nagelkerke, J. F. *See* Lenaerts, V., **73:** 980
Naik, S. U. *See* Jain, N. K., **73:** 1806
Nairn, J. G. *See* Maharaj, I., **73:** 39
Nakajima, Eiichi *See* Nishimura, Kenji, **73:** 942
Nakajima, Shinobu *See* Takamura, Akira, **73:** 91
Nakamura, Junzo *See* Yamamoto, Akira, **73:** 48
Nakano, Hideki *See* Ishizaki, Takashi, **73:** 494
Nakashima, Emi *See* Hamano, Shoichiro, **73:** 1422; Tsuji, Akira, **73:** 1418
Nam, Doo H.; Lee, Choon S.; Ryu, Dewey D. Y.: An improved synthesis of captopril, **73:** 1843
Nambara, Toshio *See* Shimada, Kazutake, **73:** 119
Naujokaitis, Saulius A.; Fisher, Joyce M.; Rabinovitz, Marco: Protection of murine L1210 leukemia and bone marrow progenitor cells against mechlorethamine and inhibition of choline uptake as a structure–activity relationship of 2-dimethylaminoethanol and its analogues, **73:** 34
Naviasky, Helen: Quantitative analysis of trimethobenzamide hydrochloride by ion-pair column chromatography and semiquantitative analysis of 3,4,5-trimethoxybenzoic acid by thin-layer chromatography, **73:** 542
Nechaev, Alexander *See* Hong, Chung Il, **73:** 278
Nefzger, Marijke; Kreuter, Jörg; Voges, Rolf; Liehl, Ekke; Czok, Rudolf: Distribution and elimination of polymethyl methacrylate nanoparticles after peroral administration to rats, **73:** 1309
Nelson, Victor; Mastalerz, Przemslaw: Phosphorous-containing analogues of aspartame, **73:** 1844
Nerenberg, Clinton *See* Anik, Shabbir T., **73:** 684
Nester, Thomas J.: review of "Applied Clinical Pharmacokinetics", **73:** 1188
Neuvonen, Pertti J. *See* Kannisto, Hannu, **73:** 253
Newburger, J. *See* Adjei, A., **73:** 742; Stavchansky, S., **73:** 169
Newby, Daniel G. *See* Schieffer, Gary W., **73:** 1856
Newton, David W. *See* McMullen, Jean N., **73:** 1799
Newton, M. P. *See* Chrzanowski, F. A., **73:** 1448
Neyroz, P. *See* Bonati, M., **73:** 829
Ng, L. L.; Bevill, R. F., Jr.; Perkins, E. G.: *In vivo* and *in vitro* pharmacokinetics and fate of furaltadone in meat- and milk-producing animals, **73:** 293
Nghiem, Ba Thu *See* Nishihata, Toshiaki, **73:** 1523
Nguyen, Tue Huu; Shih, Chung; Himmelstein, Kenneth J.; Higuchi, Takeru: Hydrolysis of some poly(*ortho*-ester)s in homogeneous solutions, **73:** 1563
Nicolau, Gabriela *See* Yacobi, Avraham, **73:** 1499
Ning, James M. *See* Hilbert, James M., **73:** 516
Nishihata, Toshiaki; Lee, Chia-Shun; Nghiem, Ba Thu; Higuchi, Takeru: Possible mechanism behind the adjuvant action of phosphate derivatives on rectal absorption of cefoxitin in rats and dogs, **73:** 1523
—; Lee, Chia-Shun; Yamamoto, Midori; Rytting, J. Howard; Higuchi, Takeru: The effects of salicylate on the rectal absorption of phenylalanine and some peptides, and the effects of these peptides on the rectal absorption of cefoxitin and cefmetazole, **73:** 1326
—; Takahagi, Hidekuni; Yamamoto, Midori; Tomida, Hisao; Rytting, J. Howard; Higuchi, Takeru: Enhanced rectal absorption of cefmetazole and cefoxitin in the presence of epinephrine metabolites in rats and a high-performance liquid chromatographic assay for cephamycin antibiotics, **73:** 109
Nishijo, Jujiro *See* Matsuda, Yoshihisa, **73:** 173
Nishimura, Kenji; Sasahara, Kunihiro; Arai, Mikio; Nitanai, Takashi; Ikegami, Yoshihiko; Morioka, Tadashi; Nakajima, Eiichi: Dosage form design for improvement of bioavailability of levodopa VI: formulation of effervescent enteric-coated tablets, **73:** 942
Nishioka, Itsuo *See* Yagi, Akira, **73:** 62
Nisi, Carlo *See* Ebert, Cynthia, **73:** 1691
Nitanai, Takashi *See* Nishimura, Kenji, **73:** 942
Nitsche, V.; Mascher, H.: Determination of codeine in human plasma by reverse-phase high-performance liquid chromatography, **73:** 1556
Nixon, Joseph R.; Agyilirah, George A.: Effect of microcapsule core–wall ratio and aggregate size on the properties of tableted microcapsules, **73:** 52
Nomoto, K. *See* Shoji, N., **73:** 843
Noonan, Patrick K.; Kanfer, Isadore; Riegelman, Sidney; Benet, Leslie Z.: Determination of picogram nitroglycerin plasma concentrations using capillary gas chromatography with on-column injection, **73:** 923
Noordhoek, Jan *See* Bast, Aalt, **73:** 953
Nora, Maris V. *See* Parkhurst, George W., **73:** 1329
Norikura, Ryo *See* Koike, Masahiro, **73:** 1697
Noro, Shun'ichi *See* Takamura, Akira, **73:** 91, 676
Norris, B. *See* Menon, G., **73:** 251
Norris, R. L. G.; Ahokas, J. T.; Ravenscroft, P. J.; Henry, M.: Binding of disopyramide to α_1-acid glycoprotein in plasma measured by competitive equilibrium dialysis, **73:** 824
Notari, Robert E. *See* Kirsch, Lee E., **73:** 724, 728, 896
Nygard, Gloria *See* Johnson, Scott M., **73:** 696
Nyqvist, Håkan *See* Sjövall, Jan, **73:** 141
Nyqvist-Mayer, A. *See* Brodin, A., **73:** 481

O

O'Connell, S. E.; Zurzola, F. J.: Rapid quantitative liquid chromatographic determination of caffeine levels in plasma after oral dosing, **73:** 1009
Odashima, Shizuo *See* Miyamoto, Etsuko, **73:** 409
O'Dell, C. Allen *See* Shealy, Y. Fulmer, **73:** 745
Ogata, H. *See* Fung, Ho-Leung, **73:** 873
Ohizumi, Y. *See* Shoji, N., **73:** 568, 843
Oja, Simo S. *See* Andersen, Lars, **73:** 106
Okada, Hiroaki; Yamazaki, Iwao; Yashiki, Takatsuka; Shimamoto, Tsugio; Mima, Hiroyuki: Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats IV: evaluation of the vaginal absorption and gonadotropin responses by radioimmunoassay, **73:** 298
Okumura, Katsuhiko *See* Kamiya, Akira, **73:** 892
Okumura, M. *See* Kawashima, Y., **73:** 1535
Oles, Stanley R. *See* Achari, Raja G., **73:** 1821
Olsen, Carolyn S.; Scroggins, Henry S.: High-performance liquid chromatographic determination of the nitrate esters isosorbide dinitrate, pentaerythritol tetranitrate, and erythrityl tetranitrate in various tablet forms, **73:** 1303
Omar, A.-Mohsen M. E.; Aboulwafa, Omaima M.; Leclercq, G.: Synthesis and evaluation of novel *N*-substituted *N'*-(3-hydroxy-17-oxoestra-1,3,5(10)-trien-2-yl- and -4-yl)-thiourea derivatives for binding to the estrogen receptor and cytotoxic activity on MCF-7 cells, **73:** 1871
—; Eshba, Nabil H.: Synthesis and biological evaluation of new 2,3-dihydrothiazole derivatives for antimicrobial, antihypertensive, and anticonvulsant activities, **73:** 1166
O'Neill, John J.: Effect of film irregularities on sunscreen efficacy, **73:** 888
Ongley, R. *See* Kapil, R. P., **73:** 215
Orr, James M. *See* Acheampong, Andrew A., **73:** 489
Otagiri, Masaki *See* Uekama, Kaneto, **73:** 382
Otani, Theodore T.; Briley, Mary R.; Geran, Ruth I.: Use of a *Lactobacillus casei* assay as a prescreen for potential anticancer agents: an update study, **73:** 264
Otterness, Ivan: review of "Cologne Atherosclerosis Conference No. I: Inflammatory Aspects", **73:** 862

P

Pachla, Lawrence A. *See* Johnson, E. L., **73:** 754
review of "Progress in Drug Metabolism, Vol. 7", **73:** 863
Page, M. *See* Bernier, L. G., **73:** 1157
Palace, Gerard *See* Edelson, Jerome, **73:** 993
Palermo, Philip J. *See* Schieffer, Gary W., **73:** 128
Panesar, N. S.; Bird, C. C.; Roberts, B. E.; Child, J. A.: Prednisolone levels in plasma and leukemia cells during therapy of chronic lymphocytic leukemia, **73:** 66
Pankaskie, Marvin C.: review of "Nucleosides, Nucleotides, and Their Biological Applications", **73:** 1676
Papp, E. A. *See* Barbhaiya, R. H., **73:** 1220
Paricher-Mohseni *See* Sajadi, Ziaodin, **73:** 266
Parikh, Dilipkumar K. *See* Kupchik, Eugene J., **73:** 1012
Parish, Edward J.; Miles, D. Howard: Investigation of the antitumor activity of podocarpic acid derivatives, **73:** 694
Park, George B. *See* Fritz, Alan K., **73:** 326
Park, J. Y.; Ho, N. F. H.; Morozowich, W.: Physical model approach to gastrointestinal absorption of prostaglandins II: *in situ* rat intestinal absorption of dinoprost, **73:** 1588
Park, Young Han; Kullberg, M. Peter; Hinsvark, Orville N.: Quantitative determination of dextromethorphan and three metabolites in urine by reverse-phase high-performance liquid chromatography, **73:** 24
Parkhurst, George W.; Nora, Maris V.; Thomas, Russel W.; Carson, Paul E.: High-performance liquid chromatographic–ultraviolet determination of primaquine and its metabolites in human plasma and urine, **73:** 1329
Parrott, Eugene L. *See* Weng, Ho-Lun, **73:** 1059
review of "Handbook of Powder Science and Technology", **73:** 1676
Parsonnet, M. *See* Holazo, A. A., **73:** 1108
Pashko, Laura *See* Abou-Gharbia, Magid, **73:** 1643
Pasteelnick, L.: review of "Pharmaceutical Quality Control", **73:** 864
Patel, Dinesh C.; Fox, Jeffrey L.; Higuchi, William I.: Physical model approach in the study of the transport of alkyl amines across a silicone rubber membrane in a two-chamber diffusion cell, **73:** 1028
Patel, Indravadan H.: Concentration ratio method to determine the rate constant for the special case when $k_a = k_e$, **73:** 859
Patel, Rajni B.; Patel, Usha R.; Rogge, Mark C.; Shah, Vinod P.; Prasad, Vadlamani K.; Selen, Arzu; Welling, Peter G.: Bioavailability of hydrochlorothiazide from tablets and suspensions, **73:** 359
—; Rogge, Mark C.; Selen, Arzu; Goehl, Thomas J.; Shah, Vinod P.; Prasad, Vadlamani K.; Welling, Peter G.: Bioavailability

of hydrocortisone from commercial 20-mg tablets, **73:** 964
Patel, Usha R. *See* Patel, Rajni B., **73:** 359
Patrick, Graham A.: review of "Pain, Analgesia, and Addiction: The Pharmacologic Treatment of Pain", **73:** 1017
Patrick, James *See* Tischio, John, **73:** 546
Pauliukonis, L. T.; Musson, D. G.; Bayne, W. F.: Quantitation of norfloxacin, a new antibacterial agent in human plasma and urine by ion-pair reverse-phase chromatography, **73:** 99
Paulus, Harold E. *See* Dromgoole, Sydney H., **73:** 1657
Payling, David W. *See* Davis, Michael G., **73:** 949
Pays, M. *See* Leroyer, R., **73:** 844
Pearce, Stevens W. *See* Yen, Shau-Fong, **73:** 1575
Pearlman, Robert S. *See* Stavchansky, S., **73:** 169; Wills, Robert J., **73:** 928
—; Yakatan, Gerald J.; Wills, Robert J.: Effect of nonuniform bile flow rate on the rate of biliary excretion of bromophenol blue in the beagle, **73:** 932
Peck, Garnet E. *See* Zapata, Mary I., **73:** 3
Pellerin, F. *See* Baillet-Guffroy, A., **73:** 847
Pendergast, David D.; Connors, Kenneth A.: Improved competitive indicator methods for the study of α-cyclodextrin complexes, **73:** 1779
Peng, Geoffrey W.: Assay of adinazolam in plasma by liquid chromatography, **73:** 1173
Penninckx, Michel *See* Gigot, Daniel, **73:** 275
Pento, J. Thomas *See* Sadek, Samy A., **73:** 416
Perkins, E. G. *See* Ng, L. L., **73:** 293
Perlman, Solomon *See* Kirschbaum, Joel J., **73:** 686; Sieh, David H., **73:** 1545
—; Szyper, Mira; Kirschbaum, Joel J.: High-performance liquid chromatographic analysis of nadolol and bendroflumethiazide combination tablet formulations, **73:** 259
Perrin, J. H. *See* Chen, M. M., **73:** 1053
Perry, Dana F.; Walson, Philip D.; Blanchard, James: Effect of pH on theophylline transfer across the everted rat jejunum, **73:** *320*
Peters, M. *See* Rummens, F. H. A., **73:** 231
Peterson, James E. *See* Fritz, Alan K., **73:** 326
Petrelli, Franco *See* Antonini, Ippolito, **73:** 366
Petruzzi, Ralph F. *See* Korduba, Chryzanta A., **73:** 117
Pezzuto, John M. *See* Arisawa, Munehisa, **73:** 411; Marcelle, Guido B., **73:** 396
Pfeffer, M.: *Estimation of mean residence time* from data obtained when multiple-dosing steady state has been reached, **73:** 854
Philip, Jose *See* Chafetz, Lester, **73:** *1186*
Phillips, Michael; Gresser, Joseph D.: Sustained-release characteristics of a new implantable formulation of disulfiram, **73:** 1718
Pifferi, Giorgio *See* Visconti, Marco, **73:** 1812
Pikal, M. J.; Lukes, A. L.; Conine, J. W.: Effect of nitroglycerin-soluble additives on the stability of molded nitroglycerin tablets, **73:** 1608
—; Roy, M. L.; Shah, Saroj: Mass and heat transfer in vial freeze-drying of pharmaceuticals: role of the vial, **73:** 1224
Pilpel, N. See Iranloye, T. A., **73:** 1267
Pipkin, J. D. *See* Stella, V. J., **73:** 946
Pisano, Michael A. *See* Kupchik, Eugene J., **73:** 1012
Pitha, Josef; *Szente, Lajos: Digitonin derivatives* of low toxicity: potential solubilizers for lipophilic compounds, **73:** 240
Plaizier-Vercammen, J. A.: *Interaction of povidone* with aromatic compounds V: relationship of binding tendency in a macromolecular solution treated as a pseudo two phase and a monophase, **73:** 1774
Plett, Kim D. *See* Simons, Keith J., **73:** 939
Polack, Alan E. *See* Kowaluk, Elizabeth A., **73:** 43
Pollack, Gary M. *See* Shen, Danny D., **73:** 1334
—; Shen, Danny D.: Effect of renal failure and bis(2-ethylhexyl) phthalate pretreatment on the disposition and metabolism of antipyrine in the rat, **73:** 29
Pollard-Walker, Susan *See* Schieffer, Gary W., **73:** 128
Poly, P. A. *See* Benita, S., **73:** 1751
Porter, William B.: review of "Structure–Activity Correlation as a Predictive Tool in Toxicology: Fundamentals, Methods, and Applications", **73:** 289
Prasad, Paras N. *See* Bolton, Barbara A., **73:** 1849
Prasad, Vadlamani K. *See* Patel, Rajni B., **73:** 359, 964
Prelusky, Daniel B. *See* Coutts, Ronald T., **73:** 808
Price, J. D. E. *See* Kapil, R. P., **73:** 215
Puisieux, Francis *See* Benita, S., **73:** 1721, 1751; Treiner, Claude, **73:** 256
Purdie, Neil *See* Atkinson, W. Marc, **73:** 1827

Q

Quay, John F. *See* Su, Kenneth S. E., **73:** 1602

R

Raabe, A. *See* Albert, Kenneth S., **73:** 1487, 1823
Rabaron, A. *See* Baillet-Guffroy, A., **73:** 847
Rabinovitz, Marco *See* Naujokaitis, Saulius A., **73:** 34
Raby, C. *See* Buxeraud, J., **73:** 1687
Rácz, I. *See* Mezei, J., **73:** 1489
Radebaugh, Galen W.; Simonelli, Anthony P.: Application of dynamic mechanical testing to characterize the viscoelastic properties of powder-filled semisolids, **73:** 590
Raghow, Gursharan *See* Meyer, Marvin C., **73:** 485
Rahwan, Ralf G.: review of "New Calcium Antagonists: Recent Developments and Prospects", **73:** 290
Rakestraw, Dariel C.; *Whitney, Charles C., Jr.:* High-performance liquid chromatographic method for the determination of tiflamizole in plasma, **73:** *1829*
Rambaldi, Mirella *See* Andreani, Aldo, **73:** 1175
Ramzan, Iqbal: review of "Drug Dosage and Administration—Modern Theory and Practice", **73:** 1336
Rao, G. Subba: Safety and efficacy of dental sealants in the prevention of tooth decay, **73:** *1675*
Rauw, G. *See* Hawes, Edward M., **73:** 247; Midha, Kamal K., **73:** 1144
Ravenscroft, P. J. *See* Norris, R. L. G., **73:** *824*
Reader, M. J.: Influence of isotonic agents on the stability of thimerosal in ophthalmic formulations, **73:** *840*
Reba, R. C. *See* Eckelman, William C., **73:** 529
Reed, K.; Mereish, K.; Jensen, B.: Quantitative relationships between structure and pharmacokinetic parameters using molecular connectivity Chi indices I: substituted 2-sulfapyridines, **73:** 237
Reepmeyer, John C. See Brower, James F., **73:** 1315
Regnier, Fred E. *See* Sepelyak, Robert J., **73:** 1517
Reich, Jack W.: *review of "The Clinical Research* Process in the Pharmaceutical Industry", **73:** 1336
Reifenrath, William G.; *Mershon, Millard M.;* Brinkley, Floyd B.; Miura, George A.; Broomfield, Clarence A.; Cranford, H. *Bruce: Evaluation of diethyl malonate as a* simulant for 1,2,2-trimethylpropyl methylphosphonofluoridate (soman) in shower decontamination of the skin, **73:** *1388*
Reiss, Daniel *See* Guillard, Olivier, **73:** 1642
Rice, Frederick A. H.; Chen, Chester G.: Induction of hyperpyrexia by dihydrocurvularin, a metabolic product of *Penicillium gilmanii*, **73:** 1846
Richardson, Harold; Bidlingmeyer, Brian A.: Bare silica as a reverse-phase stationary phase: liquid chromatographic separation of antihistamines with buffered aqueous organic mobile phases, **73:** 1480
Riegelman, Sidney *See* Noonan, Patrick K., **73:** 923
Risinger, F. O. *See* Ferguson, P. W., **73:** 692
Roberts, B. E. *See* Panesar, N. S., **73:** 66
Roberts, Michael S. *See* Kowaluk, Elizabeth A., **73:** 43
Robinson, John *See* Soltero, Richard, **73:** 799
Robinson, Joseph R. *See* Grass, George M., **73:** 1021
Rocci, Mario L., Jr. *See* Fedder, Ira L., **73:** 1496; Grasela, Dennis M., **73:** 1874
Roets, E. *See* Thomis, R., **73:** 1830
Rogers, J. A. *See* Venkataram, S., **73:** 757
Rogers, J. D.; Ho, N. F. H.; Morozowich, W.: Physical model approach to gastrointestinal absorption of prostaglandins III: *in situ* rat intestinal absorption of dinoprostone, **73:** 1594
Rogge, Mark C. *See* Patel, Rajni B., **73:** 359, 964
Roland, M. *See* Lenaerts, V., **73:** 980
Roos, André *See* Hinderling, Peter H., **73:** 332
Rosazza, John P.: review of "Fungal Metabolites. Vol. II", **73:** 1878
Roscoe, R. M. H. *See* Midha, Kamal K., **73:** 261
Rose, James Q. *See* Heeg, Joel F., **73:** 1758
Roseman, Theodore J. *See* Spilman, Charles H., **73:** 282
Rosenberg, Jack M.; Sideman, Martin; Kampa, Ingo S.; McGuire, Howard; Kampa, Lidija: Effects of benztropine mesylate on haloperidol-induced prolactin secretion and serum haloperidol levels in rats, **73:** 1833
Rosenberg, Leonard S. *See* Vincent, William R., **73:** 1279
Rosoff, Morton *See* Serajuddin, Abu T. M., **73:** 1203
Ross, A. J.; Del Mauro, M. D.; Sokoloff, H. K.; Casey, D. L.: Analysis of carprofen dosage forms and drug substance by high-performance liquid chromatography, **73:** 1211
Rotenberg, Keith S. *See* Meyer, Marvin C., **73:** 485
Rotmensch, Heschi H. *See* Fedder, Ira L., **73:** 1496
Rowe, Englebert L.; Anderson, Bradley D.: Thermodynamic studies of tolbutamide polymorphs, **73:** 1673
Rowe, Gail E. *See* Gershon, Herman, **73:** 1840
Rowland, Malcolm *See* Banfield, Christopher, **73:** 1392; Toon, Stephen, **73:** 625
Roy, M. L. *See* Pikal, M. J., **73:** 1224
Royce, Alan E. *See* Schott, Hans, **73:** *793*
Rubessa, Fulvio *See* Ebert, Cynthia, **73:** 1691
Rubinstein, Abraham *See* Bialer, Meir, **73:** 991
Rudman, R. *See* Woodward, A. J., **73:** 1838
Rummens, F. H. A.; Bujaczek, R. F.; Peters, M.; Green, R. D.: Improved techniques for the photometric determination of partition coefficients, with particular reference to the chloroform–ammonia solvent system, **73:** 231
Runser, Dennis J. See Wiens, Robert E., **73:** *688*
Ryan, James A.: Colorimetric determination of gentamicin, kanamycin, tobramycin, and amikacin aminoglycosides with 2,4-dinitrofluorobenzene, **73:** 1301
Rytting, J. Howard *See* Nishihata, Toshiaki, **73:** *109, 1326*
Ryu, Dewey D. Y. *See* Nam, Doo H., **73:** 1843
Rzeszotarski, W. J. *See* Eckelman, William C., **73:** 529

S

Sadek, Samy A.; Pento, J. Thomas; Basmadjian, Garo P.: Estrogenic and antiestrogenic activity of novel selenosteroids, **73:** 416

Saene, J. J. M. v. *See* Bult, A., **73:** 133

Saitô, Hazime *See* Uekama, Kaneto, **73:** 382

Sajadi, Ziaodin; Abrishami, Mohammad M.; Paricher-Mohseni; Chapman, James M., Jr.; Hall, Iris H.: Synthesis and evaluation of the antitumor properties of esters of 2-furoic acid and 2-furylacrylic acid, **73:** 266

Sakoguchi, Takafumi *See* Kobayashi, Kunio, **73:** 1684

Sakurai, Tamiko; Tsuchiya, Seishi: Characterization of microenvironments of 2-(4′-hydroxyphenylazo)benzoic acid bound to bovine serum albumin by studying the solvent effects, **73:** 507

Samuels, Susan A. *See* Shah, Kirit A., **73:** 822

Sanders, L. M.; Kent, J. S.; McRae, Georgia I.; Vickery, B. H.; Tice, T. R.; Lewis, D. H.: Controlled release of a luteinizing hormone-releasing hormone analogue from poly(*d*,*l*-lactide-co-glycolide) microspheres, **73:** 1294

Santore, Robert C. *See* Gershon, Herman, **73:** 1840

Sarangan, S. *See* McChesney, James D., **73:** 1854

Sarper, Rauf *See* Ali, Farouk M., **73:** 1363

Sasahara, Kunihiro *See* Nishimura, Kenji, **73:** 942

Sasaki, Shin-Ichi *See* Takahashi, Yoshimasa, **73:** 737

Sasaki, Tomio *See* Ishizaki, Takashi, **73:** 494

Sato, Jun; Sugiyama, Yuichi; Hanano, Manabu: Use of the fluorescence probe 1-anilino-8-naphthalenesulfonate in predicting interindividual differences in the plasma protein binding of acidic drugs in rats, **73:** 519

Satonin, Darlene K. *See* Heeg, Joel F., **73:** 1758

Savage, C. *See* Hubbard, J. W., **73:** 1319

Savenije-Chapel, E. Maria *See* Bast, Aalt, **73:** 953

Sawada, Yasufumi *See* Igari, Yasutaka, **73:** 826; Sugita, Osamu, **73:** 631

Scerbo, Charles *See* Simons, Keith J., **73:** 939

Schary, William L. *See* Meyer, Marvin C., **73:** 485

Scheiner, Steve *See* Kolb, Vera M., **73:** 389, 719

Schentag, Jerome J. *See* Gengo, Francis M., **73:** 867; Smith, Ian L., **73:** 281

Scheurlen, M.; Bittiger, H.; Ammann, Birgit: Simple radioligand binding assay for the determination of urinary scopolamine, **73:** 561

Schieffer, Gary W.; Palermo, Philip J.; Pollard-Walker, Susan: Simultaneous determination of methyl, ethyl, propyl, and butyl 4-hydroxybenzoates and 4-hydroxybenzoic acid in liquid antacid formulations by gas chromatography, **73:** 128

—; Smith, Warren O.; Lubey, Gwen S.; Newby, Daniel G.: Determination of the structure of a synthetic impurity in guaifenesin: modification of a high-performance liquid chromatographic method for phenylephrine hydrochloride, phenylpropanolamine hydrochloride, guaifenesin, and sodium benzoate in dosage forms, **73:** 1856

Schiff, P. L., Jr. *See* El-Fishawy, A. M., **73:** 1639

Schnaare, R. L. *See* Ando, H. Y., **73:** 461

Schneider, L. W. *See* Stavchansky, S., **73:** 169

Schoenwald, R. D. *See* Eller, Mark G., **73:** 1261

Scholtz, Edward C.; Feldkamp, Joseph R.; White, Joe L.; Hem, Stanley L.: Desorption of carbonate from aluminum hydroxycarbonate gel by nitrogen purging, **73:** 209

—; Feldkamp, Joseph R.; White, Joe L.; Hem, Stanley L.: Exchange of sodium by magnesium in aluminum hydroxycarbonate gel, **73:** 1007

—; Feldkamp, Joseph R.; White, Joe L.; Hem, Stanley L.: Properties of carbonate-containing aluminum hydroxide produced by precipitation at constant pH, **73:** 967

Schoonen, A. J. M. *See* Böttger, W. M., **73:** 95

Schott, Hans *See* Kwan, Lilian Chong, **73:** 157

Solubility parameter and hydrophilic–lipophilic balance of nonionic surfactants, **73:** 790

—; Royce, Alan E.: Effect of inorganic additives on solutions of nonionic surfactants VI: further cloud point relations, **73:** 793

Schowen, Richard L. *See* Lee, Hyuk-Koo, **73:** 306

Schug, John C.; Viers, Jimmy W.; Seeman, Jeffrey I.: Kinetic steric factors and connectivity indices, **73:** 1472

Schuller, S. *See* Varia, S. A., **73:** 1068, 1074

Schulman, Stephen G. *See* Vincent, William R., **73:** 1279

Schultz, T. W. *See* Ando, H. Y., **73:** 461

Schwartz, Arthur *See* Abou-Gharbia, Magid, **73:** 1643

Scott, K. R.; Alt, Calvin J.; Kemp, Murray; Hayes, Elise; Telang, Vasant G.: Potential inhibitors of tyrosine hydroxylase and dopamine-β-hydroxylase, **73:** 1531

Scott, M. T.; Sinsheimer, Joseph E.: Direct chloride measurement of [4-^{36}Cl]chlorobiphenyl and [4,4′-^{36}Cl]dichlorobiphenyl dechlorination in the rat, **73:** 1171

—; Sinsheimer, Joseph E.: *In vitro* dehalogenation of *para*-substituted aromatic halides in rat liver preparations, **73:** 1101

Scovill, John P. *See* Klayman, Daniel L., **73:** 1763

Scroggins, Henry S. *See* Olsen, Carolyn S., **73:** 1303

Sears, R. W. *See* Matsui, F., **73:** 1664

Sedman, Allen J. *See* Gal, Joseph, **73:** 1187

Seeman, Jeffrey I. *See* Schug, John C., **73:** 1472

Sefton, Michael V.; Brown, Larry R.; Langer, Robert: Ethylene–vinyl acetate copolymer microspheres for controlled release of macromolecules, **73:** 1859

Seibert, Karen *See* Crider, A. Michael, **73:** 1612

Selen, Arzu *See* Patel, Rajni B., **73:** 359, 964

Selk, S. *See* Sloan, K. B., **73:** 1734

Sena, F. J. *See* Lulla, H., **73:** 1004

Sepelyak, Robert J.; Feldkamp, Joseph R.; Moody, Timothy E.; White, Joe L.; Hem, Stanley L.: Adsorption of pepsin by aluminum hydroxide I: adsorption mechanism, **73:** 1514

—; Feldkamp, Joseph R.; Regnier, Fred E.; White, Joe L.; Hem, Stanley L.: Adsorption of pepsin by aluminum hydroxide II: pepsin inactivation, **73:** 1517

Serajuddin, Abu T. M.; Rosoff, Morton: pH–Solubility profile of papaverine hydrochloride and its relationship to the dissolution rate of sustained-release pellets, **73:** 1203

Sezaki, Hitoshi *See* Yamamoto, Akira, **73:** 48

Shader, Richard I. *See* Greenblatt, David J., **73:** 399

Shaffer, R. *See* Sloan, K. B., **73:** 1734

Shafik, Ragab M.; Soliman, Raafat; El-Hawash, Soad A.; Morshedy, Mahmoud; Mansour, Nabil A.: α-Phenyl-β-(3,4-dimethoxy)phenethylamines: novel inhibitors of choline acetyltransferase from *Torpedo* electric organ, **73:** 1548

Shah, Kirit A.; Samuels, Susan A.; Michaels, Michael K.; Warren, James W.: Liquid chromatographic analysis of dichlorophen and its major impurity, **73:** 822

Shah, Mumtaz H.; Stewart, James T.: Amperometric determination of hydralazine hydrochloride in a flowing stream at the glassy carbon electrode, **73:** 989

Shah, Saroj *See* Pikal, M. J., **73:** 1224

Shah, Vasanti K. *See* Daisley, Roy W., **73:** 407

Shah, Vinod P. *See* Patel, Rajni B., **73:** 359, 964

Shamma, Maurice: review of "The Alkaloids: Chemistry and Pharmacology. Vol. 21", **73:** 1017

Shargel, Leon; Banijamali, Ali R.; Kuttab, Simon H.: Relationship between azo dye structure and rat hepatic azoreductase activity, **73:** 161

Shaw, David *See* Edelson, Jerome, **73:** 993

Shaw, M. C.; Vanderwielen, A. J.: Liquid chromatographic assay for diflorasone diacetate in cream and ointment formulations, **73:** 1606

Shealy, Y. Fulmer; Frye, Jerry L.; O'Dell, C. Allen; Thorpe, Martha C.; Kirk, Marion C.; Coburn, W. C., Jr.; Sporn, Michael B.: Synthesis and properties of some 13-*cis*- and all-*trans*-retinamides, **73:** 745

Shen, Danny D. *See* Pollack, Gary M., **73:** 29

—; Pollack, Gary M.: A reply to "problems involved with developing a suitable model for evaluating exposure to bis(2-ethylhexyl) phthalate from medical devices, **73:** 1334

Sherins, Richard J. *See* Shi, Yi-Fan, **73:** 819

Shetty, H. U. *See* Hawes, Edward M., **73:** 247

Shetty, H. Umesha; Hawes, Edward M.; Midha, Kamal K.: Synthesis of deuterium-labeled fluphenazine, **73:** 87

Shi, Guey-Yueh *See* Massil, Solomon E., **73:** 418, 1013, 1851

Shi, Yi-Fan; Sherins, Richard J.; Brightwell, David; Gallelli, Joseph F.; Chatterji, Dulal C.: Long-term stability of aqueous solutions of luteinizing hormone-releasing hormone assessed by an *in vitro* bioassay and liquid chromatography, **73:** 819

Shibl, A. M.; Hammouda, Y.; Al-Sowaygh, I.: Comparative effects of selected phenothiazine tranquilizers and antihistaminics on bacterial cells and possible interactions with antibiotics, **73:** 841

Shih, Chung *See* Nguyen, Tue Huu, **73:** 1563

Shimada, Kazutake; Tanaka, Makoto; Nambara, Toshio; Imai, Yutaka: Determination of a new antihypertensive agent (2*R*,4*R*)-2-(2-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinecarboxylic acid in blood by high-performance liquid chromatography with electrochemical detection, **73:** 119

Shimamoto, Tsugio *See* Okada, Hiroaki, **73:** 298

Shimizu, Yuzuru: review of "Alkaloids, Voiume 1: Chemical and Biological Perspectives", **73:** 573

Shoji, N.; Umeyama, A.; Asakawa, Y.; Takemoto, T.; Nomoto, K.; Ohizumi, Y.: Structural determination of nootkatol, a new sesquiterpene isolated from *Alpinia oxyphylla* Miquel possessing calcium-antagonistic activity, **73:** 843

—; Umeyama, A.; Takemoto, T.; Ohizumi, Y.: Serotonergic receptor antagonist from *Nandina domestica* Thunberg, **73:** 568

Shroot, B. *See* Caron, J. C., **73:** 1703

Shutske, Gregory M.: review of "Diuretics: Chemistry, Pharmacology, and Medicine", **73:** 288

Shyam, K. *See* Dimmock, J. R., **73:** 471

Sideman, Martin *See* Rosenberg, Jack M., **73:** 1833

Siegel, Marshal M.; Mills, Richard; Gehrlein, Lane; Gore, William E.; Morton, George; Chang, T.; Cosulich, Donna B.; Medwid, Jeffrey; Mirando, P.: Isolation and identification of piperacillin amide as an impurity in piperacillin, **73:** 498

Siegel, Ronald A. *See* Cohen, Jonathan, **73:** 1034

Sieh, David H.; Perlman, Solomon: Mechanism for the high bias in the USP colorimetric assay for diazotizable substances in hydrochlorothiazide, **73:** 1545

Simonelli, Anthony P. *See* Radebaugh, Galen W., **73:** 590

Simons, F. Estelle R. *See* Simons, Keith J., **73:** 595, 939

Simons, Keith J.; Simons, F. Estelle R.; Luciuk, George H.; Frith, Evelyn M.: Urinary excretion of chlorpheniramine and its metabolites *in children*, **73:** 595
—; Simons, F. Estelle R.; Plett, Kim D.; Scerbo, Charles: Dissolution studies of some *sustained-release theophylline dosage* forms, **73:** 939
Singh, B. N. *See* Kannan, R., **73:** 1208
Singhvi, S. M. *See Bathala, M. S.*, **73:** *340*
Singleterry, Merril *See* Bertermann, Ralph E., **73:** 1324
Sinkule, Joseph A.; Evans, William E.: High-performance liquid chromatographic analysis of the semisynthetic epipodophyllotoxins teniposide and etoposide using electrochemical detection, **73:** 164
Sinsheimer, Joseph E. *See* Scott, M. T., **73:** 1101, 1171
review of "Formaldehyde: Toxicology—Epi*demiology—Mechanisms*", **73:** *1018*
Sisco, W. R. *See* Chrzanowski, F. A., **73:** 1448
Sjöholm, Ingvar *See* Artursson, Per, **73:** 1507; Edman, Peter, **73:** *153*
Sjöqvist, Rolf *See* Sjövall, Jan, **73:** 141
Sjövall, Jan; Sjöqvist, Rolf; Huitfeldt, Bernhard; Nyqvist, Håkan: Correlation between the bioavailability of microencapsulated *bacampicillin hydrochloride in suspension* and *in vitro* microcapsule dissolution, **73:** 141
Skelly, Jerome P. *See Kasuya, Yasuji*, **73:** *446*
Slatkin, D. J. *See* El-Fishawy, A. M., **73:** 1639
Slaughter, Richard L. *See* Edwards, David J., **73:** 1264
Sloan, K. B. *See* Varia, S. A., **73:** 1068
—; Selk, S.; Haslam, J.; Caldwell, L.; Shaffer, R.: Acyloxyamines as prodrugs of anti-inflammatory carboxylic acids for improved *delivery through skin*, **73:** 1734
Slough, Candice L. *See* Francis, Marion D., **73:** 1097
Smallwood, Richard A. *See* Ching, Michael S., **73:** 1015
Smith, D. *See* Hubbard, J. W., **73:** 1319
Smith, Dennis A. *See* Davis, Michael G., **73:** 949
Smith, Ian L.; Schentag, Jerome J.: Noncompartmental determination of the steady-state volume of distribution during multiple dosing, **73:** 281
Smith, Mary Faye; Bryant, Shelley; Welch, Simon; Digenis, George A.: Labeling suspended aerosol particles with short-lived radionuclides for determination of particle deposition, **73:** 1091
Smith, P. J. *See* Dimmock, J. R., **73:** 471
Smith, Ward M. *See* Behl, Charangit R., **73:** 1287
Smith, Warren O. *See* Schieffer, Gary W., **73:** 1856
Smyth, R. D. *See* Barbhaiya, R. H., **73:** 1220; Stavchansky, S., **73:** 169
Soejarto, D. D. *See* Marcelle, Guido B., **73:** 396
Sokoloff, H. K. *See* Ross, A. J., **73:** 1211
Soliman, Raafat *See* Shafik, Ragab M., **73:** 1548
—; Mokhtar, Hassan M.; El Sadany, Samir K.: Synthesis of new 8-(5-substituted amino-1,3,4-oxadiazol-2-yl) and 8-(5-substituted amino-1,3,4-thiadiazol-2-yl) methoxyquinolines with antibilharzial activity, **73:** 403
Soltero, Richard; Robinson, John; Adair, Dennis: Dissolution profile determination of a multicomponent product using a rapid, liquid chromatographic analysis, **73:** 799
Sorenson, John R. J.: The ulcerogenic potential of copper aspirinate seems to be more imaginary than real, **73:** 1875
Sörgel, Fritz; Lin, Emil T.; Hasegawa, Jiro; Benet, Leslie Z.: Liquid chromatographic analysis of triamterene and its major metabolite, hydroxytriamterene sulfate, in blood, plasma, and urine, **73:** 831
Speiser, P. *See* Lenaerts, V., **73:** 980
Speiser, Peter *See* Leu, Daniel, **73:** 1433
Spielvogel, B. F. *See* Hall, Iris H., **73:** 222, 973
Spilman, Charles H.; Beuving, Diane C.; *Forbes, Adelbert D.; Roseman, Theodore* J.; Bennett, Robert M.: Transdermal administration of (15*S*)-15-methyl prostaglandin $F_{2\alpha}$ *methyl ester to rhesus monkeys*, **73:** 282
Sporn, Michael B. *See* Shealy, Y. Fulmer, **73:** *745*
Srivastava, R. C. *See* Bhise, S. B., **73:** 1579
Stagner, William C. *See* Fry, William C., **73:** 420
Stanley, Dorothy *See* Duddy, John, **73:** 1525
Stargel, W. Wayne *See* Mahony, Cheryl, **73:** 838
Stavchansky, S. *See* Adjei, A., **73:** 742
—; *Gowan, Walter, G.: Evaluation of the bioavailability of a solid dispersion of phenytoin in polyethylene glycol 6000 and a commercial phenytoin sodium capsule in* the dog, **73:** 733
—; Pearlman, Robert S.; Van Harken, D. R.; Smyth, R. D.; Hottendorf, G. H.; Martin, A.; Newburger, J.; Schneider, L. W.: Evaluation of the bioavailability of sarpicillin, the methoxymethyl ester of hetacillin, in humans, **73:** 169
Steinfink, Hugo *See* McGinity, James W., **73:** 1441
Stella, V. J. *See* Varia, S. A., **73:** 1068, 1074, *1080, 1087*
—; Mooney, K. G.; Pipkin, J. D.: Dissolution and ionization of warfarin, **73:** 946
Stevens, L. A. *See* Martin, B. K., **73:** 437
Stewart, B. A.; Midland, S. L.; Byrn, S. R.: Degradation of crystalline ergocalciferol [vitamin D_2, (3β,5*Z*,22*E*)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol], **73:** 1322
Stewart, James T. *See* Shah, Mumtaz H., **73:** 989
Stewart, Raymond F. *See* Bronaugh, Robert L., **73:** 1255
Stimmel, Glen L.: review of "Recent Advances in Clinical Therapeutics, Vol. II: Psychopharmacology, Neuropharmacology, and Gastrointestinal Therapeutics", **73:** 426
Stohs, Sidney J. *See* Ezzedeen, Fikrat W., **73:** 1369
Straehl, P.; Galeazzi, R. L.: Determination of isosorbide 5-mononitrate in human plasma by capillary column gas chromatography, **73:** 1317
Straughn, Arthur B. *See* Meyer, Marvin C., **73:** 485
Strempel, H. *See* Bremecker, K.-D., **73:** 548
Streng, William H.; Hsi, Swee K.; Helms, Paul E.; Tan, Hetty G. H.: General treatment of pH–solubility profiles of weak acids and bases and the effects of different acids on the solubility of a weak base, **73:** 1679
—; Zoglio, M. A.: Determination of the ionization constants of compounds which precipitate during potentiometric titration using extrapolation techniques, **73:** 1410
Stromberg, Rona: Determination of phenylbutazone in tablets by nuclear magnetic resonance spectrometry, **73:** 1653
Stroshane, Ronald M.; Koss, Raymond F.; Biddlecome, Charles E.; Luczkowec, Carol; Edelson, Jerome: Oral and intravenous pharmacokinetics of milrinone in human volunteers, **73:** 1438
Stryd, Ronald P. *See* Lakings, Duane B., **73:** 317
Stucky, John F. *See* Su, Kenneth S. E., **73:** 1602
Stul, M. S.; Vliers, D. P.; Uytterhoven, J. B.: *In vitro* adsorption–desorption of phenethylamines and phenylimidazoles by a bentonite and a resin, **73:** 1372
Su, C. C.; Higuchi, William I.; Gilmore, I. T.; Danzinger, R. G.; Hofmann, A. F.: Mesophase formation during cholesterol gallstone dissolution in human bile: effect of bile acid composition, **73:** 1160
Su, Kenneth S. E.; Campanale, Kristina M.; Gries, Christian L.: Nasal drug delivery system of a quaternary ammonium compound: clofilium tosylate, **73:** 1251
—; Quay, John F.; Campanale, Kristina M.; Stucky, John F.: Nonaqueous cephalosporin *in suspension for parenteral administration*: cefazolin sodium, **73:** 1602
Suckow, Raymond F. *See* Cooper, Thomas B., **73:** *1104*
—; Cooper, Thomas B.: Determination of trimipramine and metabolites in plasma by *liquid chromatography with electrochemical detection*, **73:** 1745
Suganuma, Toshiyuki *See* Ishizaki, Takashi, **73:** 494
Sugeno, Koichi *See* Koike, Masahiro, **73:** 1697
Sugita, E. T. *See* Ando, H. Y., **73:** 461
Sugita, Osamu; Sawada, Yasufumi; Sugiyama, Yuichi; Iga, Tatsuji; Hanano, Manabu: Effect *of sulfaphenazole on tolbutamide* distribution in rabbits: analysis of interspecies differences in tissue distribution of tolbutamide, **73:** *631*
Sugiyama, Yuichi *See* Igari, Yasutaka, **73:** 826; Sato, Jun, **73:** 519; Sugita, Osamu, **73:** 631; Terasaki, Tetsuya, **73:** 524, 1359
Sum, Check Y.; Yacobi, Avraham: Gas chromatographic–mass spectrometric assay for the ultra-short-acting β-blocker esmolol, **73:** 1177
Sundman, Lars-Olav *See* Andersen, Lars, **73:** 106
Suryanarayanan, R.; Mitchell, A. G.: Precipitation of calcium gluceptate from aqueous solutions, **73:** 78
Sutherland, John C. *See* Jackson, Andre J., **73:** 816
Suzuki, Tokuji; Fujita, Shoichi; Kawai, Ryosei: Precursor–metabolite interaction in the metabolism of lidocaine, **73:** 136
Swanson, Brian N. *See* Fedder, Ira L., **73:** 1496
—; Vlasses, P. H.; Ferguson, Roger K.; Bergquist, P. A.; Till, A. E.; Irvin, J. D.; Harris, K.: Influence of food on the bioavailability of enalapril, **73:** 1655
Swarbrick, James; Lee, Geoffrey; Brom, Jeffrey; Gensmantel, Nigel P.: Drug permeation through human skin II: permeability of ionizable compounds, **73:** 1352
Swern, Daniel *See* Abou-Gharbia, Magid, **73:** 1643
Szente, Lajos *See* Pitha, Josef, **73:** 240
Szentmiklósi, P. *See* Mezei, J., **73:** 1489
Szyper, Mira *See* Perlman, Solomon, **73:** 259

T

Taaffe, William *See* Dixon, Ross, **73:** 1645
Taeymans, Y. *See* Clozel, J. P., **73:** 207, 771
Takada, Shigeyuki *See* Yamamoto, Akira, **73:** 48
Takahagi, Hidekuni *See* Nishihata, Toshiaki, **73:** 109
Takahashi, Yoshimasa; Miyashita, Yoshikatsu; Tanaka, Yuichiro; Hayasaka, Hiroshi; Abe, Hidetsugu; Sasaki, Shin-Ichi: Discriminative structural analysis using pattern recognition techniques in the structure–taste problem of perillartines, **73:** 737
Takamura, Akira; Ishii, Fumiyoshi; Noro, Shun'ichi; Koishi, Masumi: Physicopharmaceutical characteristics of an oil-in-water emulsion-type ointment containing diclofenac sodium, **73:** 676
—; Ishii, Fumiyoshi; Noro, Shun'ichi; Tanifuji, Masaaki; Nakajima, Shinobu: Study of intravenous hyperalimentation: effect of selected amino acids on the stability of intravenous fat emulsions, **73:** 91
Takemoto, T. *See* Shoji, N., **73:** 568, 843
Takenaka, H. *See* Kawashima, Y., **73:** 1407, 1535
Talbert, Robert L. *See* Mungall, Dennis, **73:** 1000

Tamai, G.; Morita, I.; Masujima, T.; Yoshida, H.; Imai, H.: Direct, simultaneous determination of propranolol and its 4-hydroxy metabolite by liquid chromatography, **73:** 1825
Tamai, Ikumi *See* Hamano, Shoichiro, **73:** 1422
Tamura, Zenzo *See* Tanaka, Hiroshi, **73:** 1647
Tan, Hetty G. H. *See* **Streng, William H., 73:** 1679
Tanaka, Hiroshi; Tamura, Zenzo: Determination of the partition coefficient and acid dissociation constants of iodochlorhydroxyquin by an improved partition method, **73:** 1647
Tanaka, Hiroyoshi *See* Hashimoto, Naofumi, **73:** 369
Tanaka, Makoto *See* Shimada, Kazutake, **73:** 119
Tanaka, Yuichiro *See* **Takahashi, Yoshimasa, 73:** 737
Tangtatsawasdi, Paktiya; Krikorian, S. Edward: Determination of the chemical constituents and spectral properties of commerical and NF references standard potassium guaiacolsulfonate: implications of the findings on compendial analytical methodology, **73:** 1238
Tanifuji, Masaaki *See* Takamura, Akira, **73:** 91
Tantawy, A. *See* El-Kerdawy, M., **73:** 1652
Tao, Frank T.; Thurber, Joan S.; Dye, Daniel M.: High-performance liquid chromatographic determination of acetylcholine in a pharmaceutical preparation, **73:** 1311
Tasaki, Takenobu *See* Hashimoto, Naofumi, **73:** 369
Tatsumi, Etsuko *See* Matsuda, Yoshihisa, **73:** 1453
Tavss, Edward A.; Gaffar, Abdul; King, William J.: Studies on the formation of electrostatic complexes between benzethonium chloride and anionic polymers, **73:** 1148
Tawashi, R. *See* Chopra, S. K., **73:** 477
Taylor, Anne K. *See* Chafetz, Lester, **73:** 1186
Taylor, David C.: review of "Animal Models for Oral Drug Delivery in Man: In Situ and In Vivo Approaches", **73:** 1676
Taylor, Jonathan *See* Kupchik, Eugene J., **73:** 1012
Taylor, T. *See* Chasseaud, L. F., **73:** 699
Taylor, William F. *See* Johnson, David M., **73:** 1414
Telang, Vasant G. *See* Scott, K. R., **73:** 1531
Terasaki, Tetsuya; Iga, Tatsuji; Sugiyama, Yuichi; Hanano, Manabu: Interaction of doxorubicin with nuclei isolated from rat liver and kidney, **73:** 524
—; Iga, Tatsuji; Sugiyama, Yuichi; Hanano, Manabu: Pharmacokinetic study on the mechanism of tissue distribution of doxorubicin: interorgan and interspecies variation of tissue-to-plasma partition coefficients in rats, rabbits, and guinea pigs, **73:** 1359
Théroux, P. *See* Clozel, J. P., **73:** 207, 771
Thies, C. *See* Benita, S., **73:** 1721
Thiessen, J. J. *See* Eppel, J. G., **73:** 1635
Thomas, Elizabeth W.; Bopp, Barbara A.: Pharmacokinetics of fostedil, a new calcium antagonist, in beagle dogs following oral and intravenous administration, **73:** 1400
Thomas, Russel W. *See* Parkhurst, George W., **73:** 1329
Thombre, Avinash G.; Himmelstein, Kenneth J.: Quantitative evaluation of topically applied pilocarpine in the precorneal area, **73:** 219
Thomis, R.; Roets, E.; Hoogmartens, J.: Analysis of tablets containing aspirin, acetaminophen, and ascorbic acid by high-performance liquid chromatography, **73:** 1830
Thorpe, Martha C. *See* Shealy, Y. Fulmer, **73:** 745
Thurber, Joan S. *See* Tao, Frank T., **73:** 1311
Tice, T. R. *See* Sanders, L. M., **73:** 1294
Till, A. E. *See* Swanson, Brian N., **73:** 1655
Tillement, J. P. *See* Barre, J., **73:** 1379; Houin, G., **73:** 1450
Timmer, Cornelis J.; Wijnand, Herman P.: Organ perfusion studies: a rebuttal, **73:** 854
Tischio, John; Hetyei, Nancy; Patrick, James: Bromperidol radioimmunoassay: human plasma levels, **73:** 546
Tognoni, G. *See* Bonati, M., **73:** 829
Toler, Duckhee Y. *See* Brower, James F., **73:** 1315
Tomás-Vert, F. *See* Vicente-Pedrós, F., **73:** 1804
Tomida, Hisao *See* Nishihata, Toshiaki, **73:** 109
Toon, Stephen; Mayer, Joachim; Rowland, Malcolm: Liquid chromatographic determination of lipophilicity with application to a homologous series of barbiturates, **73:** 625
—; Trager, William F.: Pharmacokinetic implications of stereoselective changes in plasma-protein binding: warfarin/sulfinpyrazone, **73:** 1671
Trager, William F. *See* Toon, Stephen, **73:** 1671
Treiner, Claude; Vaution, Catherine; Puisieux, Francis: Equilibrium dialysis of barbituric acids up to high concentrations of aqueous sodium alkylsulfonate solutions, **73:** 256
Triggle, David J.: review of "Cell Surface Receptors", **73:** 572
Trigo, Gregorio G. *See* de la Cuesta, Elena, **73:** 1307
Trotta, M. *See* Gasco, M. R., **73:** 662
Trudel, F. *See* Clozel, J. P., **73:** 771
Tschappat, Kathryn D. *See* Crider, A. Michael, **73:** 1612
Tse, Francis L. S.; Chang, Tsailing; Finkelstein, Barbara; Ballard, Frances; Jaffe, James M.: Influence of mode of intravenous administration and blood sample collection on rat pharmacokinetic data, **73:** 1599
Tsilifonis, Dimitri C. *See* Chafetz, Lester, **73:** 1186
Tsuchiya, Seishi *See* Sakurai, Tamiko, **73:** 507
Tsuji, Akira *See* Hamano, Shoichiro, **73:** 1422; Miyamoto, Etsuko, **73:** 409
—; Hamano, Shoichiro; Asano, Tetsuo; Nakashima, Emi; Yamana, Tsukinaka; Mitsuhashi, Susumu: Microbial kinetics of β-lactam antibiotics against *Escherichia coli*, **73:** 1418
Tsuji, Kiyoshi *See* Binns, R. Bruce, **73:** 69
Tuckerman, Murray M.: review of "Analytical Profiles of Drug Substances, Vol. 12", **73:** 572
Turyaki, Lutfiyyeh H. *See* Bikhazi, Anwar B., **73:** 628
Tuttle, Ronald *See* Dixon, Ross, **73:** 1645
Tutwiler, Gene *See* Adams, William E., **73:** 394

U

Ueda, Clarence T. *See* Abraham, Isaac, **73:** 452
Uekama, Kaneto; Hirayama, Fumitoshi; Fujise, Akihiko; Otagiri, Masaki; Inaba, Kohji; Saitô, Hazime: Inclusion complexation of prostaglandin $F_{2\alpha}$ with γ-cyclodextrin in solution and solid phases, **73:** 382
Uihlein, M. *See* Martin, B. K., **73:** 437
Umeyama, A. *See* Shoji, N., **73:** 568, 843
Unemi, Norio *See* Yamamoto, Jyunji, **73:** 212
Uytterhoven, J. B. *See* Stul, M. S., **73:** 1372

V

Vadas, E. B.; Down, G. R. B.; Miller, R. A.: Effect of compressional force on tablets containing cellulosic disintegrators I: dimensionless disintegration values, **73:** 781
Valentini, Luigi *See* Menozzi, Milena, **73:** 766
Valia, Kirti H. *See* Kabadi, Mohan B., **73:** 1461
Valicenti, A. J. *See* Escobar, A., **73:** 1640
Valls, O.; Alvarez, M.; Alsina, A.; García Fernandez, S.: Kinetics and mechanism of enzymatic hydrolysis of pivampicillin monolayers, **73:** 1694
Van Bemmel, P. *See* De Reijke, A., **73:** 1478
Van Berkel, T. J. C. *See* Lenaerts, V., **73:** 980
VandenHeuvel, W. J. A.; Arison, B. H.; Flynn, H.; Gatto, G. J.; Mertel, H. E.; Wislocki, P. G.: Urinary metabolites of the antiprotozoal agent *cis*-3a,4,5,6,7,7a-hexahydro-3-(1-methyl-5-nitro-1*H*-imidazol-2-yl)-1,2-benzisoxazole in the rat, **73:** 1731
Vanderwielen, A. J. *See* Shaw, M. C., **73:** 1606
Van Harken, D. R. *See* Barbhaiya, R. H., **73:** 1220; Stavchansky, S., **73:** 169
van Leverink, J. *See* Lerk, C. F., **73:** 856, 857
Vannini, Elisabetta *See* Menozzi, Milena, **73:** 766
Varia, S. A.; Schuller, S.; Sloan, K. B.; Stella, V. J.: Phenytoin prodrugs III: water-soluble prodrugs for oral and/or parenteral use, **73:** 1068
—; Schuller, S.; Stella, V. J.: Phenytoin prodrugs IV: hydrolysis of various 3-(hydroxymethyl)phenytoin esters, **73:** 1074
—; Stella, V. J.: Phenytoin prodrugs VI: *in vivo* evaluation of a phosphate ester prodrug of phenytoin after parenteral administration to rats, **73:** 1087
—; Stella, V. J.: Phenytoin prodrugs V: *in vivo evaluation of some water-soluble phenytoin* prodrugs in dogs, **73:** 1080
Varoquaux, O. *See* Leroyer, R., **73:** 844
Varughese, Abraham *See* Lee, Ching-San C., **73:** 787
Vasavada, Ravindra C. *See* Khan, Arshad R., **73:** 302
Vaughan, D. P.: Theorem on the apparent volume of distribution and the amount of drug in the body at steady state, **73:** 273
Vaution, Catherine *See* Treiner, Claude, **73:** 256
Vedani, Angelo; Meyer, Edgar F., Jr.: Structure–activity relationships of sulfonamide drugs and human carbonic anhydrase C: modeling of inhibitor molecules into the receptor site of the enzyme with an interactive computer graphics display, **73:** 352
Veng-Pedersen, Peter: Model-independent steady-state plasma level predictions in autonomic nonlinear pharmacokinetics I: derivation and theoretical analysis, **73:** 761
Pulmonary absorption and excretion of compounds in the gas phase: theoretical pharmacokinetic and toxicokinetic analysis, **73:** 1136
Venkataram, S.; Rogers, J. A.: Characteristics of drug–phospholipid coprecipitates I: physical properties and dissolution behavior of griseofulvin–dimyristoylphosphatidylcholine systems, **73:** 757
Vera-Sánchez, J. *See* Vicente-Pedrós, F., **73:** 1804
Verghese, Chacko P. *See* Mahony, Cheryl, **73:** 838
Vicente-Pedrós, F.; Tomás-Vert, F.; Vera-Sánchez, J.: DC polarographic reduction of chloroguanide hydrochloride, **73:** 1804
Vickery, B. H. *See* Sanders, L. M., **73:** 1294
Vickery, Brian *See* Anik, Shabbir T., **73:** 684
Viers, Jimmy W. *See* Schug, John C., **73:** 1472
Vigneron, C. *See* Fauvel, A., **73:** 784
Vincek, W. C. *See* Musson, D. G., **73:** 1270
Vincent, William R.; Rosenberg, Leonard S.; Schulman, Stephen G.: Microcalorimetric investigation of the binding of some chemotherapeutic agents and related molecules to calf thymus DNA, **73:** 1279
Visalli, Anthony J. *See* Galante, Robert N., **73:** 195
Visconti, Marco; Citerio, Luisa; Borsa, Massimiliano; Pifferi, Giorgio: Degradative behavior of cadralazine in aqueous solution, **73:** 1812
Visser, J. *See* Böttger, W. M., **73:** 95
Vlasses, P. H. *See* Swanson, Brian N., **73:** 1655

Vlasses, Peter H. *See* Fedder, Ira L., **73:** 1496
Vliers, D. P. *See* Stul, M. S., **73:** 1372
Voges, Rolf *See* Nefzger, Marijke, **73:** 1309
Voorstad, P. Josée *See* Chapman, James M., Jr., **73:** 1482; Hall, Iris H., **73:** 378, 812, 956, 1788

W

Wadsten, T. *See* Brodin, A., **73:** 481
Wagner, R. *See* Kannan, R., **73:** 1208
Wahlgren, Sven; Lindstrom, Anna L.; Friberg, Stig E.: Liquid crystals as a potential ointment vehicle, **73:** 1484
Waigh, Roger D. *See* Deeks, Trevor, **73:** 457
Wainer, Irving W.; Doyle, Thomas D.; Adams, William M.: Liquid chromatographic chiral stationary phases in pharmaceutical analysis: determination of trace amounts of the (−)-enantiomer in (+)-amphetamine, **73:** 1162
Wall, Monroe E.: review of "Molecular Aspects of Anti-Cancer Drug Action", **73:** 1502
Waller, Donald P. *See* Marcelle, Guido B., **73:** 396
Walson, Philip D. *See* Perry, Dana F., **73:** 320
Wang, T. I. *See* Chow, D. S-L., **73:** 1794
Warner, John *See* Bertermann, Ralph E., **73:** 1324
Warren, James W. *See* Shah, Kirit A., **73:** 822
Watanabe, Jun *See* Hasegawa, Jiro, **73:** 442
Watson, J. R. *See* Matsui, F., **73:** 1664
Weber, Stanley S. *See* Lasswell, William L., Jr., **73:** 1056
Webster, J. *See* Menon, G., **73:** 251
Wedlund, P. J.; Wilkinson, G. R.: Hepatic tissue binding and the oral first-pass effect, **73:** 422
Weidner, Linda L.; Zacchei, Anthony G.: Gas chromatographic determination of a diuretic–antihypertensive agent, (±)-[[6,7-dichloro-2-(4-fluorophenyl)-2-methyl-1-oxo-5-indanyl]oxy]acetic acid, in biological fluids, **73:** 268
Weinstein, S. H. *See* Bathala, M. S., **73:** 340
Weizer, Jeffrey *See* Kowarski, Chana R., **73:** 1298
Welch, Richard M. *See* Findlay, John W. A., **73:** 1339
Welch, Simon *See* Smith, Mary Faye, **73:** 1091
Welling, Peter G. *See* Patel, Rajni B., **73:** 359, 964
Weng, Ho-Lun; Parrott, Eugene L.: Solid–solid reaction between sulfacetamide and phthalic anhydride, **73:** 1059
West, Charles R. *See* Hong, Chung Il, **73:** 278
Whitaker, J. E.; Hoyt, A. M., Jr.: Colorimetric determination of procainamide in injectable preparations, **73:** 1184
White, Helen L. *See* Lever, O. William, Jr., **73:** 1241
White, Joe L. *See* Liu, Jue-Chen, **73:** 1355; Scholtz, Edward C., **73:** 209, 967, 1007; Sepelyak, Robert J., **73:** 1514, 1517; Zapata, Mary I., **73:** 3
White, Lorraine B. *See* Chapron, Dennis J., **73:** 985
Whitfield, Lloyd R.; Wilkenfeld, Craig; Levy, Gerhard: Pharmacokinetics of heparin VII: effect of pregnancy on the relationship between concentration and anticoagulant action of heparin in rats, **73:** 72
Whitney, Charles C., Jr. *See* Rakestraw, Dariel C., **73:** 1829
Wichman, Kenneth C. *See* Fry, William C., **73:** 420
Wiens, Robert E.; Runser, Dennis J.; Lacz, Joseph P.; Dimmitt, Dan C.: Quantitation of diltiazem and desacetyldiltiazem in dog plasma by high-performance liquid chromatography, **73:** 688
Wijnand, Herman P. *See* Timmer, Cornelis J., **73:** 854
Wilkenfeld, Craig *See* Whitfield, Lloyd R., **73:** 72
Wilkins, John M. *See* Lasswell, William L., Jr., **73:** 1056
Wilkinson, G. R. *See* Wedlund, P. J., **73:** 422
Williams, Kenneth M. *See* Lee, Edmund J. D., **73:** 1542
Williams, N. A.; Amidon, G. L.: Excess free energy approach to the estimation of solubility in mixed solvent systems I: theory, **73:** 9
—; Amidon, G. L.: Excess free energy approach to the estimation of solubility in mixed solvent systems II: ethanol–water mixtures, **73:** 14
—; Amidon, G. L.: Excess free energy approach to the estimation of solubility in mixed solvent systems III: ethanol–propylene glycol–water mixtures, **73:** 18
Williams, W. L., Jr. *See* Hall, Iris H., **73:** 973, 1788, 1819
Wills, Robert J. *See* Pearlman, Robert S., **73:** 932
—; Yakatan, Gerald J.; Pearlman, Robert S.: Dose-dependent pharmacokinetics and hepatobiliary transport of bromophenol blue in the beagle, **73:** 928
Wilson, Carol A. *See* Davis, Michael G., **73:** 949
Wilson, W. C. *See* Garst, John E., **73:** 1616
Wilson, W. David *See* Yen, Shau-Fong, **73:** 1575
Winkel, Deborah R.; Hendrick, Sheila A.: Detection limits for a GC determination of methanol and methylene chloride residues on film-coated tablets, **73:** 115
Wislocki, P. G. *See* VandenHeuvel, W. J. A., **73:** 1731
Wittmers, L. E., Jr. *See* Alich, A. A., **73:** 1876
Wojtowicz, Edward J.: Reverse-phase high-performance liquid chromatographic determination of halogenated 8-hydroxyquinoline compounds in pharmaceuticals and bulk drugs, **73:** 1430
Wong, Lan K. *See* Lin, Li Shei, **73:** 131
Wong, Yan Yan *See* Mungall, Dennis, **73:** 1000
Wood, J. D. *See* Crider, A. Michael, **73:** 1612
Woodward, A. J. *See* Lewis, P. A., **73:** 996
—; Lewis, P. A.; Aylward, M.; Rudman, R.; Maddock, J.: Determination of nitroglycerin and its dinitrate metabolites in human plasma by high-performance liquid chromatography with thermal energy analyzer detection, **73:** 1838
Worden, Ann *See* Anik, Shabbir T., **73:** 684
Worland, Peter J.; Drummer, Olaf H.; Jarrott, Bevyn: Gastric and intestinal absorption of captopril in acutely and chronically treated rats: comparison with salicylic acid, **73:** 1755
Woronick, Charles L. *See* Maderazo, Eufronio G., **73:** 1403
Worthen, Leonard R.: review of "Antibiotics: Assessment of Antimicrobial Activity and Resistance", **73:** 1017
Wou, Lyndon L-S.; Mulley, B. A.: Microstructure of aluminum hydroxides and the formation of aluminum dye lakes, **73:** 1738
Wu, Anne T.; Massey, Ian J.; Kushinsky, Stanley: A high-performance liquid chromatographic method for the simultaneous determination of nicardipine and its pyridine metabolite II in plasma, **73:** 1444
Wu, P. L. *See* Beerbower, A., **73:** 179; Martin, A., **73:** 188
Wyrick, Steven D. *See* Chapman, James M., Jr., **73:** 1482; Hall, Iris H., **73:** 378, 1788
—; Hall, Iris H.; Dubey, Agnes: Structure–activity studies on antihyperlipidemic *N*-benzoylsulfamates, *N*-benzylsulfamates, and benzylsulfonamides, **73:** 374

Y

Yacobi, Avraham *See* Sum, Check Y., **73:** 1177
—; Baughman, Robert A.; Cosulich, Donna B.; Nicolau, Gabriela: Method for determination of first-pass metabolism in human skin, **73:** 1499
Yagi, Akira; Hamada, Kozo; Mihashi, Kunihide; Harada, Nobuo; Nishioka, Itsuo: Structure determination of polysaccharides in *Aloe saponaria* (Hill.) Haw. (Liliaceae), **73:** 62
Yakatan, Gerald J. *See* Pearlman, Robert S., **73:** 932; Wills, Robert J., **73:** 928
Yamamoto, Akira; Nakamura, Junzo; Takada, Shigeyuki; Kimura, Toshikiro; Sezaki, Hitoshi: Effect of systemic anaphylaxis on the absorption of salicylic acid from the rat small intestine, **73:** 48
Yamamoto, Jyunji; Haruno, Akihiro; Yoshimura, Yuji; Unemi, Norio; Kunimune, Yoshio; Yamashita, Kazumasa; Morita, Ken-'ichi: Effect of coadministration of uracil on the toxicity of tegafur, **73:** 212
Yamamoto, Midori *See* Nishihata, Toshiaki, **73:** 109, 1326
Yamana, Tsukinaka *See* Hamano, Shoichiro, **73:** 1422; Tsuji, Akira, **73:** 1418
Yamashita, Kazumasa *See* Yamamoto, Jyunji, **73:** 212
Yamazaki, Iwao *See* Okada, Hiroaki, **73:** 298
Yashiki, Takatsuka *See* Okada, Hiroaki, **73:** 298
Yeh, S. Y.: Metabolism of meperidine in several animal species, **73:** 1783
Yen, Shau-Fong; Wilson, W. David; Pearce, Stevens W.; Gabbay, Edmond J.: A new series of reductive amination derivatives of daunorubicin: syntheses, partition coefficients, and DNA binding, **73:** 1575
Yoshida, H. *See* Tamai, G., **73:** 1825
Yoshimura, Yuji *See* Yamamoto, Jyunji, **73:** 212
Young, R. L. *See* Holazo, A. A., **73:** 1108
Yu, Cheng Der; Jones, Richard E.; Henesian, Maida: Cascade impactor method for the droplet size characterization of a metered-dose nasal spray, **73:** 344
Yu, M. W.; Finlayson, J. S.: Quantitative determination of the stabilizers octanoic acid and *N*-acetyl-DL-tryptophan in human albumin products, **73:** 82

Z

Zacchei, Anthony G. *See* Weidner, Linda L., **73:** 268
Zaidi, Z. *See* Gibbs, V., **73:** 1248
Zampaglione, Nicola *See* Hilbert, James M., **73:** 516
Zapata, Mary I.; Feldkamp, Joseph R.; Peck, Garnet E.; White, Joe L.; Hem, Stanley L.: Mechanism of freeze–thaw instability of aluminum hydroxycarbonate and magnesium hydroxide gels, **73:** 3
Zatz, Joel L.; Knapp, Steven: Viscosity of xanthan gum solutions at low shear rates, **73:** 468
Ziemniak, M. A. *See* Gengo, Francis M., **73:** 961
Zoglio, M. A. *See* Streng, William H., **73:** 1410
Zurzola, F. J. *See* O'Connell, S. E., **73:** 1009

A

Absorption—aspirin, sodium- and potassium-containing buffered solutions, **73:** 998
—GI, dinoprost, effect on concentration, pH, buffer capacity, and hydrodynamics, rats, **73:** 1588
—GI, dinoprostone, rat jejunum, effect of buffer pH, buffer capacity, lumenal hydrodynamics, and concentration, **73:** 1594
—GI, proxicromil, lipophilicity, ion pair formation, **73:** 949
—GI dose-dependent, physicochemical model, **73:** 1274
—intestinal, salicylic acid, effect of anaphylaxis, rats, **73:** 48
—iron, effects of divalent amino acids, **73:** 1245
—iron, effects of glycine, neutron activation of iron tablets, **73:** 1529
—nasal, nafarelin acetate, [D-Nal(2)^6]-LHRH, rhesus monkeys, **73:** 684
—nasal, testosternone, rats, **73:** 1300
—naval, trandermal, bioavailability, testosterone, **73:** 283
—percutaneous, *in vitro*, hydrophobic compounds, **73:** 1255
—percutaneous, alkanoic acids *in vitro*, porcine skin, permeability coefficients, operational conditions, **73:** 534
—percutaneous, alkanoic acids *in vitro*, porcine skin, permeability coefficients, regular solution theory, **73:** 538
—percutaneous, disposition of iodochlorhydroxyquin, dogs, **73:** 1369
—percutaneous, hydrocortisone, influence of age, site, and skin sectioning on permeation rates, hairless mouse skin, **73:** 1287
—percutaneous, maximum *in vivo* penetration rates, humans, physicochemical predictive model, **73:** 461
—percutaneous, permeability of ionizable compounds through human skin, **73:** 1352
—pulmonary, excretion, theoretical pharmacokinetic and toxicokinetic analyses, **73:** 1136
—rectal, cefoxitin, rats and dogs, **73:** 1523
—salsalate, normal subjects, **73:** 1657
—*in situ* perfusion method, *in vivo* experiments using a microenema technique, **73:** 1326

Acetaminophen—cerebrospinal fluid, sulfate depletion in rats, **73:** 853
—HPLC, content uniformity, **73:** 1553
—HPLC, trace amounts, plasma, **73:** 117
—HPLC with ascorbic acid and aspirin, **73:** 1830
—relative bioavailability, pharmacokinetics, coadministration with pentazocine, **73:** 326
—renal clearance, serum protein binding, glucuronide and sulfate metabolites, **73:** 1038

Acetazolamide—biological fluids, reverse-phase HPLC, pharmacokinetics, **73:** 985

3-Acetoxymethylcephalosporins—stability in aqueous solutions, HPLC, pH, primary salt, buffer, temperature effects, **73:** 611

Acetylcholine—HPLC, lyophilized preparation, **73:** 1311

***N*-Acetylcysteine**—HPLC, plasma, urine, **73:** 996

***N*-Acetyl-DL-tryptophan**—stabilizers, octanoic acid, human albumin products, **73:** 82

α_1-Acid glycoprotein—binding of disopyramide, competitive equilibrium dialysis, **73:** 824

Acrylic acid polymer—release of phenacetin from inert wax matrices, channeling agent, **73:** 910

Acyl transfer reactions—methylprednisolone 17- and 21-monoesters, carboxyl group catalysis, **73:** 604

Adenosine—deaza analogues, inhibition of ADP- and collagen-induced platelet aggregation, **73:** 366

Adhesive ointment, mucosal—tretinoin, irritation-free formulation, clinical assessment, **73:** 548

Adinazolam—*N*-demethyl metabolite, HPLC, plasma, **73:** 1173

Adjuvant action—salicylate, 5-methoxysalicylate, peptides, **73:** 1326

α- and β-Adrenergic antagonists—dopamine-induced response, heart of *Mercenaria mercenaria*, **73:** 1491

β-Adrenergic drugs—oxprenolol, propranolol, atenolol, and metoprolol, individual and simultaneous assay in formulations, HPLC, **73:** 751

Adsorption—pepsin, aluminum hydroxide, **73:** 1514
—pepsin, aluminum hydroxide, pepsin inactivation, **73:** 1517
—phosphate, aluminum hydroxycarbonate, **73:** 1355
—sulfonylureas, carbutamide, chlorpropamide, tolazamide, tolbutamide, glibenclamide, glipizide, **73:** 253

Aerosol particles—labeling with short-lived radionuclides, particle deposition, **73:** 1091

Agglutination—kinetics of enzymatically treated normal and diabetic rat hepatocytes, trypsin, neuraminidase, **73:** 628

Aging—effect on dispersions, hydrocortisone-polyethylene glycol 4000, hydrocortisone-polyvinylpyrrolidone, **73:** 1539

Alcoholism—effects on mortality kinetics, **73:** 1191

Alizapride—bioavailability, multiple dosage forms, **73:** 1450

3β-Alkanesulfonates—synthesis, screened as glucose-6-phosphate dehydrogenase inhibitors, **73:** 1643

Alkanesulfonyl chlorides, long-chain—synthesis, antitumor agents, **73:** 1643

Alkanoic acids—percutaneous absorption *in vitro*, porcine skin, permeability coefficients, operational conditions, **73:** 534
—percutaneous absorption *in vitro*, porcine skin, permeability coefficients, regular solution theory, **73:** 538

Alkoxyquinoline derivatives—potential CNS stimulants, synthesis, **73:** 1652

***n*-2-Alkyn-1-ols**—*in vitro* antifungal activity, effect of chain length, pH, adsorbents, **73:** 1840

Alloxan—analogues, potential tumor-imaging agents, pancreatic insulinomas, effect on blood glucose levels, rats, **73:** 394

Aloe saponaria—isolation of neutral polysaccharides, As mannan 1, As mannan 2, structural determinations, **73:** 62

Aluminum hydroxide—adsorption, pepsin, **73:** 1514
—adsorption of pepsin, pepsin inactivation, **73:** 1517
—carbonate containing, precipitation at constant pH, **73:** 967
—dye lake formation, **73:** 1738
—effect on ethambutol absorption in rabbits, **73:** 1053

Aluminum hydroxycarbonate—adsorption of phosphate, **73:** 1355
—desorption of carbonate, nitrogen purging, **73:** 209
—freeze–thaw instability, mechanism, added polymers, surface-active agents, **73:** 3
—removal of sodium by magnesium, **73:** 1007

Amines—biologically active, interaction energy of the lone electron pair and a proton, angular dependency, **73:** 389

Amino acids—divalent, effects on iron absorption, **73:** 1245
—L-valine, L-histidine monohydrochloride monohydrate, effect on fat emulsions, long-term stability of admixtures, **73:** 91

5′-Amino-5′-deoxythymidine—3′-*O*-acyl derivatives, synthesis, antiviral activity, **73:** 1568

Aminoglycosides—2,4-dinitrofluorobenzene, colorimetric determination, **73:** 1301

Aminophylline—preparation from spherically agglomerated crystals of theophylline and ethylenediamine, **73:** 1407

***N*-Aminosuccinimides**—physicochemical and analytical characteristics, HPLC and IR, UV, and MS, **73:** 829
—synthesis, anticonvulsant and neurotoxic potential, mice, **73:** 405

Amiodarone—serum and myocardial kinetics, rabbits, **73:** 1208

Amoxapine—isocratic HPLC method, determination of metabolites, **73:** 696

Amphetamine—(+)- and (−)-enantiomers, HPLC, trace amounts, **73:** 1162
—rat brain metabolism, norephedrine, phenolic metabolites, GC, **73:** 808

Amphotericin B—quantitation with amphotericin A, reverse-phase HPLC, **73:** 835

Ampicillin—renal handling in dogs, renal insufficiency, **73:** 892

Analgesics—conformationally restrained leucine enkephalin derivatives, synthesis, **73:** 457
—6,14-*endo*-ethanotetrahydrooripavine series, buprenorphine, stability, acid-catalyzed structural rearrangement, **73:** 243

Anaphylaxis—effect on intestinal absorption of salicyclic acid, rats, **73:** 48

Ancitabine—bioconversion to cytarabine, mechanism, *in vivo* and *in vitro* pharmacokinetics, **73:** 728
—conversion to cytarabine, kinetics, aqueous solutions, **73:** 896

Angiotensin-converting enzyme—enalapril maleate, bioavailability, influence of food, **73:** 1655

Angiotensin-converting enzyme inhibitors—captopril, spectrofluorometric analysis, plasma, **73:** 1427

Antacid formulations—liquid, simultaneous determination of 4-hydroxybenzoic acid and its methyl, ethyl, propyl, and butyl esters, GC, **73:** 128

Antagonists—α-normetazocine, alkylation, antinociception, psychotomimetic, mice, morphine-dependent rhesus monkeys, **73:** 1864

Anthracyclines—new derivatives, antineoplastic agents, **73:** 1575

Antiarrhythmic agents—amiodarone, physicochemical and analytical characteristics, HPLC and IR, UV, and MS, **73:** 829
—flecainide acetate, quantitation in biological fluids, GC–ECD, **73:** 1469

Antibacterial agents—1-(2,4-dichlorophenyl)-4-dimethylaminomethyl-1-nonen-3-one hydrochloride against *Escherichia coli*, effects of concentration, temperature, medium pH, **73:** 803
—dose-dependent pharmacokinetics of pefloxacin, **73:** 1379
—norfloxacin, human plasma and urine, ion-pair reverse-phase HPLC, **73:** 99

—potential, 2-(α-hydroxyacetyl)pyridine thiosemicarbazones, **73:** 1763
Antibiotics—cefotaxime, stability, degradation profile, kinetics, **73:** 611
—interaction with phenothiazine tranquilizers and antihistaminics, *Staphylococcus aureus*, **73:** 841
Anticancer agents—*Lactobacillus casei*, **73:** 264
—potential, *N*-alkanoyl-*S*-benzyl-L-cysteinylglutamic acid esters, activity in P388 leukemia screen, glyoxalase I inhibition, synthesis, **73:** 559
—potential, *N*,*N*′-disubstituted *N*″-2-(2-quinolinylmethylthio)ethylguanidines, H_2-receptor antagonist activity, **73:** 1168
Anticoagulants—heparin, EDTA, plasma protein binding, *in vitro* and *in vivo* comparisons, pregnant and nonpregnant rats, **73:** 1121
—heparin, pregnancy, anticoagulant action, rats, **73:** 72
Anticonvulsant agents—α,β-diphenylsuccinimide, hydrophobic properties, overt neurotoxicity, maximal electroshock screen, mice, **73:** 310
—phenytoin, phosphate prodrug, parenteral administration, rats, **73:** 1087
—phenytoin, water-soluble prodrugs, stability, pH profiles, **73:** 1074
—phenytoin prodrugs, water-soluble, hydroxymethylation, **73:** 1068
—potential, 1,5-diaryl-Δ^2-1,2,3-triazolines, synthesis, screening in mice, **73:** 850
—potential, 2-aminoethanesulfonic acid (taurine) derivatives, synthesis, **73:** 106
—potential, *N*-aminosuccinimides, synthesis, neurotoxicity, mice, **73:** 405
—potential, nipecotic acid esters, synthesis, **73:** 1612
—*in vitro*, rats, excitatory amino acids, **73:** 1550
Antidepressants—bupropion and its metabolites, HPLC, dual-wavelength UV detection, **73:** 1104
—potential, propanamide derivative, GC, **73:** 317
Antifungal activity—*n*-alkynols, *in vitro*, effect of chain length, pH adsorbents, **73:** 1840
Antihistamines—buffered aqueous–organic-liquid chromatographic mobile phases, **73:** 1480
Antihyperlipidemic agents—binuclear copper(II) complex, rodents, lipid metabolism, **73:** 973
—N^2-*n*-butylindazolone, activity in rodents, cholesterol and triglycerides reduction, **73:** 1788
—3-*N*-(1′,8′-naphthalimido)propionic acid, rodents, cholesterol and triglycerides reduction, **73:** 956
—phthalimide derivatives, cyclic imides, reduced and hydrolytic products, **73:** 1482
—potential, *o*-chlorobenzylsulfonamide, activity in rodents, cholesterol, triglycerides, **73:** 378
—potential, 4-phenyl-5,5-dicarbethoxy-2-pyrrolidinone, rodent screen, **73:** 812
—4-pyrimidinecarboxylic acids, activity in mice, **73:** 1819
Antihypertensive agents—cadralazine, degradation kinetics, identification of oxidative, hydrolytic, and thermal degradation products, **73:** 1812
—captopril, new synthetic method, **73:** 1843
—GC, (±)-[[6,7-dichloro-2-(4-fluorophenyl)-2-methyl-1-oxo-5-indanyl]-oxy]acetic acid, biological fluids, **73:** 268
—(2*R*,4*R*)-2-(2-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinecarboxylic acid, human blood, HPLC, electrochemical detection, **73:** 119
Anti-inflammatory agents—ibuprofen, HPLC, capillary and venous plasma, saliva, humans, **73:** 1487
—ibuprofen, inhibition of polymorphonuclear leukocytes, **73:** 1403
—literature survey, **73:** 579
Antileukemic agents—potential, 9-(β-D-arabinofuranosyl)adenine–corticosteroid conjugates, synthesis, L1210 screen, **73:** 278
—potential, Mannich bases derived from acetophenones, P388 screen, toxicological assessment in rats, **73:** 471
Antimalarial agents—potential, 2-(α-hydroxyacetyl)pyridine thiosemicarbazones, **73:** 1763
Antimicrobial agents—2,3-dihydrothiazole derivatives, antihypertensive and anticonvulsant properties, **73:** 1166
—potential, 5-nitro-3-phenyliminoindol-2(3*H*)-ones and their *N*-Mannich bases, synthesis, **73:** 407
—potential, 4-oxoquinazoline analogues, synthesis, **73:** 982
—potential, 4-substituted aminoquinoline-3-carboxylates, **73:** 1141
—*N*-substituted *N*′-cyano-*O*-(triphenylstannyl)isourea–triethylammonium chloride complexes, bacterial, fungal screens, **73:** 1012
Antimicrobial screening—preservatives, parenteral formulations, efficacy, preformulation, **73:** 903
Antineoplastic agents—potential, copper(II)–trimethylamine carboxyborane complex, Ehrlich ascites carcinoma screen, **73:** 222
—potential, podocarpic acid derivatives, synthesis, *n vitro* human epidermoid carcinoma (nasopharynx) screen, L1210 and P388 screens in mice, **73:** 694
Antinociceptive activity—9α- and 9β-hydroxyphenylmorphans, potency, withdrawal symptoms, substitution for morphine, antagonism, **73:** 1867
Antipyrine—disposition, pharmacokinetics, effect of bis(2-ethylhexyl) phthalate pretreatment and renal failure, rats, **73:** 29
Antiradiation protection—thioureas, metal-ion complexes, stability constants, **73:** 1284
Antirheumatics—proquazone and its *m*-hydroxy metabolites, oral and intravenous pharmacokinetics in humans, **73:** 332
Antischistosomal agents—synthesis of 8-(5-substituted amino-1,3,4-oxadiazol-2-yl) and 8-(5-substituted amino-1,3,4-thiadiazol-2-yl) methoxyquinolines, **73:** 403
Antisickling agents—cetiedil, GC analysis in human plasma, nitrogen-phosphorus detector, **73:** 1748
—potential, bissalicylic esters of methylenecitric acid, synthesis, hemoglobin-modifying ability, **73:** 418
Antitumor agents—combination chemotherapy, 2-dimethylaminoethanol and mechlorethamine, differential antitumor activity, **73:** 34
—potential, nitrogen mustard derivatives, Ehrlich ascites carcinoma screen, **73:** 1175
Antitussive agents—dextromethorphan hydrobromide, HPLC, GC, **73:** 1248
Antiviral agents—potential, *N*-substituted bicyclo[3.2.1]octane-3-spiro-3′-pyrrolidine hydrochlorides, influenza A, **73:** 1307
9-(β-D-Arabinofuranosyl)adenine—conjugates with corticosteroids, synthesis, antileukemic activity, **73:** 278
Aromatic halides—effect of *para*-substitution on *in vitro* dehalogenation, **73:** 1101
Ascorbic acid—HPLC with acetominophen and aspirin, **73:** 1830
Aspartame—phosphonate analogues, sweetness, **73:** 1844
Aspirin—absorption kinetics, after sodium- and potassium-containing buffered solutions, **73:** 998
—HPLC with acetominophen and ascorbic acid, **73:** 1830
—pharmacokinetics, oral administration, sodium bicarbonate–citric acid buffer, humans, **73:** 1258
—stabilized normal-phase HPLC, solid pharmaceutical dosage forms, salicyclic acid, **73:** 195
ATP—behavior toward phenothiazine drugs, binding, micellar solubilization, **73:** 662
Azobenzene—HPLC determination, **73:** 1706
Azo dyes—relationship between structure and rat hepatic azoreductase activity, amaranth, azosulfamide, orange G, 1,2-dimethyl-4-*p*-(carboxyphenylazo)-5-hydroxybenzene, brilliant crystal scarlet, sulfachrysoidine, Sudan I, **73:** 161
Azoreductase—rat hepatic activity, relationship to azo dye structure, amaranth, azosulfamide, orange G, 1,2-dimethyl-4-*p*-(carboxyphenylazo)-5-hydroxybenzene, brilliant crystal scarlet, sulfachrysoidine, Sudan I, **73:** 161

B

Bacampicillin hydrochloride—encapsulated oral suspensions, *in vivo* bioavailability correlations with *in vitro* dissolution, taste evaluation, **73:** 141
Barbiturates—equilibrium dialysis, high concentrations of aqueous sodium alkylsulfonate solutions, solubility, **73:** 256
—lipophilicity, determination by the HPLC parameter R_Q, **73:** 625
Bare silica—reverse-phase stationary phase, HPLC, **73:** 1480
Bendroflumethiazide—HPLC, nadolol, combination tablet formulations, **73:** 259
Benzalkonium chloride—determination by GC, **73:** 1700
Benzenoid drugs—tablet and capsule formulations, second-derivative UV spectrometry, **73:** 413
Benzethonium chloride—electrostatic complex with methoxyethylene–maleic anhydride copolymer, **73:** 1148
Benzoic acid—model drug, solubility in individual solvents, four-parameter extended Hansen approach, UNIFAC, **73:** 179
Benzoic acid derivatives—*p*-hydroxybenzoic acid, methyl *p*-hydroxybenzoate, model drugs, solubility, individual solvents, four-parameter extended Hansen approach, **73:** 188
***N*-Benzoylsulfamates**—potential antihyperlipidemic agents, structure–activity relationships, mutagenicity, toxicity in mice, **73:** 374
Benztropine mesylate—prolactin secretion, serum haloperidol levels, rats, **73:** 1833
Benzylpenicilloic acid—epimerization, alkaline media, imine tautomer of penamaldic acid as intermediate, **73:** 125
***N*-Benzylsulfamates**—potential antihyperlipidemic agents, structure–activity relationships, mutagenicity, toxicity in mice, **73:** 374
Benzylsulfonamides—potential antihyperlipidemic agents, structure–activity relationships, mutagenicity, toxicity in mice, **73:** 374
Beta-blocker—ultra-short-acting, esmolol, GC–MS, **73:** 1177
Bile acid—mesophase formation during cholesterol gallstone dissolution, **73:** 1160
Bile flow rate—nonuniform, biliary excretion of bromophenol blue, dogs, **73:** 932
Biliary excretion—bromophenol blue, dogs, nonuniform bile flow rate, **73:** 932
—pharmacokinetics, model, cimetidine, isotretinoin, **73:** 313
Binding—behavior of ATP toward phenothiazine drugs, micellar solubilization, **73:** 662
—chemotherapeutic agents and related mole-

cules to calf thymus DNA, microcalorimetry, **73:** 1279
Binding affinity, *in vitro*—selenium-substituted estrogens, correlation with *in vivo* estrogenic and antiestrogenic activity, rats, **73:** 416
Binding parameters—overlapped fluorescence quenching, monomer–polymer system, **73:** 1815
Binuclear copper(II) complex—antihyperlipidemic activity, rodents, lipid metabolism, **73:** 973
Bioassay, *in vivo*—glucagon, continuous glucose monitoring, dogs, **73:** 1298
Bioavailability—absorption of ethambutol in rabbits, coadministration with aluminum hydroxide, **73:** 1053
—alizapride, multiple dosage forms, **73:** 1450
—bacampicillin hydrochloride, microencapsulated oral suspensions, correlation with *in vitro*, dissolution, **73:** 141
—bumetanide, intravenous, intramuscular, oral administration, **73:** 1108
—caffeine, HPLC, human plasma, oral dosing, **73:** 1009
—choline magnesium trisalicylate, once-daily and twice-daily dosage schedules, humans, **73:** 977
—codeine, human plasma, HPLC, **73:** 1556
—comparative, furosemide formulations, humans, plasma, urine, **73:** 437
—corneal penetration mechanisms, low-viscosity solutions, **73:** 1021
—hydrochlorothiazide, tablets, suspensions, pharmacokinetics, **73:** 359
—hydrocortisone, commercial 20-mg tablets, dissolution, **73:** 964
—isosorbide dinitrate, oral and sublingual formulations compared, human, **73:** 699
—long-term controlled administration, navel, testosterone, **73:** 1064
—nafronyl in dogs, HPLC, red blood cell partitioning, plasma protein binding, effect of anticoagulants, pharmacokinetics, **73:** 635
—nicorandil in dogs, oral and intravenous administration, pharmacokinetics, plasma detection by HPLC, **73:** 494
—nonlinear, metoclopramide, rat, saturable first-pass metabolism, **73:** 215
—oil-in-water emulsion, tissue distribution, probucol, biliary elimination, rats, **73:** 1758
—pharmacokinetics of ranitidine, humans, **73:** 1376
—phenytoin prodrugs, dogs. **73:** 1080
—relative, coadministered pentazocine and acetaminophen, pharmacokinetics, **73:** 326
—relative, commercial trifluoperazine tablet formulation, RIA, **73:** 261
—relative, phenobarbital tablets and elixir, pharmacokinetics in humans, **73:** 485
—sarpicillin, methoxymethyl ester of hetacillin, humans, **73:** 169
—theophylline, sustained-release formulations, USP rotating-basket apparatus, **73:** 939
—topical pilocarpine, precorneal area, disposition, **73:** 219
—transdermal, naval, **73:** 283
Biodistribution—^{99m}Tc-labeled tyramine iminodiacetic acid, preparation, **73:** 1363
Biological activity—lipophilicity–topological molecular comparison, diverse molecules, **73:** 429
Biological fate—[^{14}C]normacromerine, rat hallucinogenic potential, **73:** 692
Biscarbamates—synthesis, antitumor activity, **73:** 1182
Bis(2-ethylhexyl) phthalate—pretreatment, effect on antipyrine disposition and pharmacokinetics, renal failure, rats, **73:** 29
Blocking agent—calcium entry, fostedil, pharmacokinetics, dogs, **73:** 1400
Blood fraction binding—humans, sulfadimethoxine, equilibrium dialysis, **73:** 1319

BOOKS
Advances in Chromatography. Vol. 22, **73:** 1336
The Alkaloids: Chemistry and Pharmacology. Vol. 21, **73:** 1017
Alkaloids, Volume 1: Chemical and Biological Perspectives, **73:** 573
Analytical Profiles of Drug Substances, Vol. 12, **73:** 572
Animal Models for Oral Drug Delivery in Man: In Situ and In Vivo Approaches, **73:** 1676
Annual Review of Pharmacology and Toxicology, Volume 23, **73:** 573
Antibiotics: An Introduction, **73:** 572
Antibiotics: Assessment of Antimicrobial Activity and Resistance, **73:** 1017
Applied Clinical Pharmacokinetics, **73:** 1188
Applied Statistics: A Handbook of Techniques, 5th Ed., **73:** 289
Applied Therapeutics: The Clinical Use of Drugs, 3rd Ed., **73:** 1335
Calcium Antagonism in Heart and Smooth Muscle: Experimental Facts and Therapeutic Perspectives, **73:** 1016
Cell Surface Receptors, **73:** 572
The Clinical Research Process in the Pharmaceutical Industry, **73:** 1336
Cologne Atherosclerosis Conference No. I: Inflammatory Aspects, **73:** 862
Compartmental Models and Their Application, **73:** 1018
Current Trends in Organic Synthesis. Proceedings of the Fourth International Conference on Organic Synthesis, **73:** 574
Deposition of Toxic Drugs and Chemicals in Man, 2nd Ed., **73:** 426
Dermatological Formulations: Percutaneous Absorption, **73:** 573
Diuretics: Chemistry, Pharmacology, and Medicine, **73:** 288
Drug Dosage and Administration—Modern Theory and Practice, **73:** 1336
Drug Fate and Metabolism: Methods and Techniques, Vol. 4, **73:** 862
Drugs and Therapy: A Handbook of Psychotropic Drugs, 2nd Ed., **73:** 1016
Formaldehyde: Toxicology—Epidemiology—Mechanisms, **73:** 1018
Free Radicals and Cancer, **73:** 574
Fungal Metabolites. Vol. II, **73:** 1878
A Guide to the Chemical Basis of Drug Design, **73:** 1502
Handbook of Powder Science and Technology, **73:** 1676
Host Factors in Human Carcinogenesis. (IARC Scientific Publications, No. 30.), **73:** 288
Information Theoretic Indices for Characterization of Chemical Structures, **73:** 1336
Instrumental Data for Drug Analysis. Vol. 2, **73:** 1335
Manufacturing Processes for New Pharmaceuticals, **73:** 572
MARTINDALE: The Extra Pharmacopeia, 28th Ed., **73:** 862
The Merck Index, 10th Ed., **73:** 862
Methods in Industrial Microbiology, **73:** 1018
Molecular Aspects of Anti-Cancer Drug Action, **73:** 1502
Natural Product Chemistry—A Mechanistic and Biosynthetic Approach to Secondary Metabolism, **73:** 287
New Calcium Antagonists: Recent Developments and Prospects, **73:** 290
Nicotinic Acid: Nutrient–Cofactor–Drug (Clinical Pharmacology Series, Vol. 1), **73:** 1016
Nucleosides, Nucleotides, and Their Biological Applications, **73:** 1676
Nutrition and Drugs, **73:** 863
Pain, Analgesia, and Addiction: The Pharmacologic Treatment of Pain, **73:** 1017
Pattern Recognition Approaches To Data Interpretation, **73:** 1878
Pharmaceutical Quality Control, **73:** 864
Polyether Antibiotics, Volume 2: Naturally Occurring Acid Ionophores, **73:** 289
Progress in Drug Metabolism, Vol. 7, **73:** 863
Recent Advances in Clinical Therapeutics, Vol. II: Psychopharmacology, Neuropharmacology, and Gastrointestinal Therapeutics, **73:** 426
Review of Organic Functional Groups: Introduction to Medicinal Organic Chemistry, **73:** 1188
Solid-State Chemistry of Drugs, **73:** 573
Structure–Activity Correlation as a Predictive Tool in Toxicology: Fundamentals, Methods, and Applications, **73:** 289
Techniques of Solubilization of Drugs. (Drugs and the Pharmaceutical Sciences Series, Vol 12.), **73:** 288
A Textbook of Pharmaceutical Analysis, 3rd Ed., **73:** 1015
Total Synthesis of Natural Products: The 'Chiron' Approach, **73:** 1502
The Total Synthesis of Natural Products, Vol. 5, **73:** 426
USAN and the USP Dictionary of Drug Names, 1984 Ed., **73:** 862
X-ray Crystallography and Drug Action, **73:** 1878
Brattleboro rat—vasopressin, controlled delivery, microporous polymers, **73:** 1713
Breaking strength—tablets, computerized *versus* unaltered hardness values, **73:** 1324
Bromine substitution—^{13}C-NMR chemical shifts, bromoaminoquinoline isomerization, **73:** 1854
Bromoaminoquinolines—^{13}C-NMR chemical shifts, isomerization, bromine substitution, **73:** 1854
Bromophenol blue—biliary excretion, nonuniform bile flow rate, dogs, **73:** 932
—pharmacokinetics, hepatobiliary transport, dogs, **73:** 928
Bromperidol—polymorphism, comparison of IR spectra, X-ray diffraction patterns, crystal structures, **73:** 512
—RIA, human plasma levels, haloperidol–bovine serum albumin conjugate, **73:** 546
Brompton's cocktails—circular dichroism, spectropolarimetry, UV absorption, **73:** 1827
Bumetanide—pharmacokinetics, intravenous, intramuscular, oral administration, **73:** 1108
Buprenorphine—6,14-*endo*-ethanotetrahydrooripavine analgesics, stability, acid-catalyzed structural rearrangement, **73:** 243
Bupropion—metabolites, HPLC, dual-wavelength UV detection, **73:** 1104
***N*^{2}-*n*-Butylindazolone**—hypolipidemic activity in rodents, cholesterol and triglycerides reduction, **73:** 1788

C

Cadralazine—degradation kinetics, antihypertensive agent, identification of oxidative, hydrolytic, and thermal degradation products, **73:** 1812
Caffeine—HPLC, human plasma, bioavailability, **73:** 1009
Calcitonin—enhanced rectal absorption using polyacrylic acid aqueous gel base, rats, bioavailability, **73:** 1366
Calcium antagonists—isolation of nootkatol from *Alpinia oxyphylla* Miquel, **73:** 843
Calcium gluceptate—precipitation in aqueous solutions, identification of α- and β-epimers, GC, **73:** 78
Calcium gluconate—determination by selective oxidation with periodate, quantitation, Malaprade reaction, **73:** 681
—hypercalcemia, etidronate disodium, dogs, **73:** 1097

Captopril—HPLC, combination with hydrochlorothiazide, tablet formulations, **73:** 686
—*S*-methyl metabolite, human plasma, GC–MS, selected-ion monitoring, **73:** 1493
—new synthetic method, antihypertensive, inhibitor of angiotensin-converting enzyme, **73:** 1843
—plasma, disulfide metabolites, GC, **73:** 340
—reduction of disulfides, GC–MS, selected-ion monitoring, **73:** 1113
—*in situ* absorption, comparison with salicylic acid, rats, **73:** 1755
—spectrofluorometric analysis, plasma, **73:** 1427
Carbamazepine—carbamazepine 10,11-epoxide, HPLC, **73:** 1874
Carbamazepine 10,11-epoxide—HPLC with carbamazepine, **73:** 1874
3-Carboxylate derivatives—synthesis, antimicrobial activity, **73:** 1141
Carboxylic acid dimerization—influence on molecular complexation, griseofulvin and straight-chain fatty acids, isooctane solution, **73:** 1195
Cardiotonic agents—milrinone, pharmacokinetics, bioavailability, **73:** 1438
Carprofen—dosage forms and drug substances, HPLC, **73:** 1211
Cascade impactor method—droplet-size characterization, metered-dose nasal spray, **73:** 344
Catalysis—general base, detection in the presence of specific-base catalysis, theoretical basis, effect of buffer composition, acid concentration, and ionic strength, **73:** 724
Catechol–homocysteine derivatives—bridged, synthesis, inhibition of catechol *O*-methyltransferase, **73:** 1241
Catechol *O*-methyltransferase—potential inhibitors, bridged catechol–homocysteine derivatives, **73:** 1241
Cefazolin sodium—surfactants, stability, bioavailability, **73:** 1602
Cefmetazole—rectal absorption, rats, epinephrine metabolites as adjuvants, HPLC, plasma, **73:** 109
Cefotaxime—kinetics and mechanism of degradation, pH–rate profile, **73:** 611
—sodium salt, stability determined by HPLC, **73:** 565
Cefoxitin—rectal absorption, rats, epinephrine metabolites as adjuvants, HPLC, plasma, **73:** 109
Cellulose acetate phthalate—preparation of enteric-coated microspheres, encapsulation, **73:** 39
Cellulose propionate—dynamics of clomethiazole edisylate interaction with plastic infusion systems, polyvinyl chloride, **73:** 43
Cephalexin—renal handling in dogs, renal insufficiency, **73:** 892
Cephalosporin—nonaqueous suspension, stability, bioavailability, **73:** 1602
Cetiedil—antisickling agent, GC analysis in human plasma, nitrogen-phosphorus detector, **73:** 1748
Charge transfer complexes—iodine and disulfiram, clomethiazole, tolnaftate, **73:** 1687
Chemotherapeutic agents—coadministration of tegafur and uracil, toxicity, species comparison, **73:** 212
Chenodeoxycholic acid—HPLC, human serum, ^{13}C-NMR elucidation of structure, methyl ester, **73:** 847
Chiral stationary phases—HPLC, determination of trace amounts of (+)- and (−)-amphetamine, **73:** 1162
Chlorambucil—isocyanate derivative, alkylating activity, fluorescence assay, **73:** 1157
Chlordiazepoxide—assay with demoxepam in formulations, difference spectrophotometry, **73:** 55
Chloride determination—rat urine, 4-chloro- and 4,4′-dichlorobiphenyl, **73:** 1171
***o*-Chlorobenzylsulfonamide**—antihyperlipidemic activity, rodents, cholesterol, triglycerides, **73:** 378
Chloroprocaine hydrochloride—bulk drug, injection formulations, HPLC, **73:** 251
Chlorothiazide—physicochemical model, dose-dependent GI absorption, **73:** 1274
Chlorpheniramine—demethylated metabolites, urinary excretion in children, pharmacokinetics, **73:** 595
—maleate salts, HPLC, content uniformity, **73:** 1553
—subnanogram quantitation in plasma, RIA, comparison with HPLC–UV, **73:** 1144
Cholesterol—antihyperlipidemic effect of binuclear copper(II) complex, **73:** 973
—gallstone dissolution in human bile, effect of bile acid composition, **73:** 1160
Choline acetyltransferase—inhibition, α-phenyl-β-(3,4-dimethoxy)phenethylamines, **73:** 1548
Choline magnesium trisalicylate—pharmacokinetic comparison of once-daily and twice-daily dosages, humans, **73:** 977
Cimetidine—HPLC analysis in plasma and urine, **73:** 1015
—noninteraction with temazepam, pharmacokinetics, **73:** 399
—possible nitroreduction, nitrazepam, **73:** 1187
Cinchonine—comparative disposition kinetics in dogs, effects of stereochemistry and 6′-methoxy group substitution, **73:** 452
Cinoxacin—time-dependent elimination, effect of fasting, urinary pH, rats, **73:** 1697
Cinromide—anticonvulsant, fraction metabolized, **73:** 285
Circular dichroism—spectropolarimetry, UV absorption, Brompton's solutions, *R*-(−)-cocaine hydrochloride, morphine sulfate, (±)-methadone, (−)-fructose, β-cyclodextrin, **73:** 1827
Clastic binding hypothesis—electron-transfer mechanism, opiate–receptor interactions, *in vitro* model system, **73:** 715
—proton-transfer mechanism, opiate–receptor interactions, *ab initio* molecular oribital calculations, **73:** 719
Clofilium tosylate—nasal drug delivery, **73:** 1251
Clomethiazole—charge transfer complexes, iodine, **73:** 1687
Clomethiazole edisylate—dynamics of interaction with plastic infusion systems, polyvinyl chloride, cellulose propionate, **73:** 43
Cloud point relations—effect of inorganic additives on nonionic surfactants, octoxynol 9, **73:** 793
Coacervation—gelatin–acacia, polyethylene glycol, polyethylene oxide, phase separation, microencapsulation, **73:** 879
—pectin–gelatin, sulfamerazine, microglobules, recovery, size, **73:** 1799
Coadjuvants—phytate, tripolyphosphate, adjuvant action in the presence of α-glycerophosphate, **73:** 1523
Codeine—bioavailability, HPLC, **73:** 1556
Colorimetry—aminoglycosides, 2,4-dinitrofluorobenzene, **73:** 1301
—assay of prednisolone, application to dissolution, octoxynol 9, **73:** 157
—bias in USP XX assay for diazotizable substances, free amine, hydrochlorothiazide, **73:** 1545
—procainamide, injectable preparations, cupric ion complexing, **73:** 1184
Competitive indicator methods—α-cyclodextrin, methyl orange, nitrazine yellow complexes, **73:** 1779
Complexation—metabolic intermediate, orphenadrine analogues with cytochrome P_{450}, **73:** 953
Composite profiling—pharmacokinetics, ceftriaxone, diazepam, **73:** 1667
Compressional force—effect on tablets containing cellulosic disintegrators, dimensionless disintegration values, **73:** 781
Conductivity—docusate sodium coacervate, caffeine, theobromine, theophylline, glucose, sucrose, concentration effects, **73:** 1729
Connectivity indices—relationship with steric contributions to rate constants, **73:** 1472
Content uniformity—single-tablet, sodium levothyroxine, HPLC, **73:** 75
Contraceptives, male—gossypolacetic acid, analysis, HPLC, **73:** 396
Controlled administration, navel—long-term, testosterone, rhesus monkeys, bioavailability, **73:** 1064
Controlled drug delivery—vasopressin, microporous polymers, Brattleboro rat, **73:** 1713
Copolymers—ethylene–vinyl acetate, controlled release of macromolecules, **73:** 1034
Copper(II) complexes—with trimethylamine carboxyborane, antineoplastic activity, Ehrlich ascites carcinoma screen, **73:** 222
Corneal penetration—ocular bioavailability, low-viscosity solutions, **73:** 1021
Corticoids—solutions dispersed on silicas, dissolution rates, prednisone, prednisolone, hydrocortisone, free-flowing powders, **73:** 401
Corticosteroids—conjugates with 9-(β-D-arabinofuranosyl)adenine, synthesis, antileukemic activity, **73:** 278
Cough suppressants—dextromethorphan, dextrorphan, and metabolites, human urine, HPLC, **73:** 24
Counterions—removal of sodium by magnesium in aluminum hydroxycarbonate gel, **73:** 1007
Cream formulations—meclocycline, tetracycline analogue, HPLC, **73:** 1650
Cucurbitacins—cytotoxic principles from *Ipomopsis aggregata*, **73:** 411
α-Cyclodextrin—competitive indicator methods, methyl orange, nitrazine yellow, **73:** 1779
γ-Cyclodextrin—inclusion complex with prostaglandin $F_{2\alpha}$, solution and solid phases, solubility, dissolution behavior, **73:** 382
Cytarabine—conversion of ancitabine, aqueous solutions, kinetics, **73:** 896
—*Eleutherococcus senticosus*, N^6-(Δ^2-isopentenyl)adenosine, L1210 leukemia, **73:** 270
Cytochrome P_{450}—complexation with metabolic intermediates, orphenadrine analogues, **73:** 953

D

Daunorubicin—self-association, 4-demethoxy analogues, effect of buffer concentration and ionic strength, **73:** 766
Deacetyldiltiazem—human plasma, GC–ECD concurrent assay with diltiazem, **73:** 207
Dechlorination—chloride in rat urine, 4-chloro- and 4,4′-dichlorobiphenyl, **73:** 1171
Decontamination, shower—percutaneous absorption, pig skin, **73:** 1388
Degradation—cadralazine, antihypertensive agent, **73:** 1812
—fenprostalene in polyethylene glycol 400, **73:** 1414
—LHRH aqueous solutions, *in vitro* bioassay, HPLC, **73:** 819
—moxalactam in aqueous solutions, kinetics, epimerization, **73:** 369
—polymers, hydrolysis of poly(*ortho*-ester)s, homogeneous solutions, **73:** 1563
Dehalogenation—rat liver *in vitro* studies, microsomal, cytosolic, **73:** 1101
Dehydration—β-hydroxycyclopentanone analogue of prostaglandin E_1, mechanism, kinetics, **73:** 306
Delivery systems—enteric-coated microspheres, cellulose acetate phthalate, rapid preparation, **73:** 39

—oxprenolol hydrochloride, glassy hydrogels, **73:** 1344
—phospholipid liposomes, structural characteristics, external lipid layers and aqueous volume, **73:** 122
—redox chemical, brain-specific sustained delivery of testosterone, rats, **73:** 385
Demineralization—dental enamel, simultaneous remineralization, quantitative study using microradiography, **73:** 650
—dental enamel, simultaneous remineralization, solution ion activity product, quantitative microradiography, **73:** 653
Demoxepam—assay with chlordiazepoxide in chlordiazepoxide formulations, difference spectrophotometry, **73:** 55
Dental enamel—demineralization/remineralization, quantiative study using microradiography, **73:** 650
—demineralization/remineralization, solution ion activity product, quantitative microradiography, **73:** 653
Dentifrices—simultaneous determination of nitrte and nitrite, HPLC, **73:** 1004
Derivatization—trifluoroacetic anhydride, capillary GC, human plasma, **73:** 1313
Desacetyldiltiazem—quantitation with diltiazem, dog plasma, HPLC, **73:** 688
Desorption—carbonate from aluminum hydroxycarbonate gel, nitrogen purging, **73:** 209
Detection limits—GC, methanol and methylene chloride residues, film-coated tablets, **73:** 115
Dexamethasone—quantitative determination in human plasma, stable isotope dilution MS, **73:** 446
Dextromethorphan—HPLC determination, semi-microbore column, dog plasma, urine, **73:** 1821
—hydrobromide salt, HPLC, content uniformity, **73:** 1553
—hydrobromide salt, HPLC, GC, **73:** 1248
—with metabolites, HPLC, human urine, **73:** 24
Dextrorphan—human urine, HPLC, **73:** 24
Diacyl esters—aspirin derivatives, acylation of hemoglobin, **73:** 1013
Dialysis—plasma protein binding, experimental time, **73:** 708
Diaspirin—hemoglobin, sickle cell anemia, carboxylate substituents, **73:** 1851
Diazepam—metabolism, hepatic and extrahepatic, *in vitro* assessment, comparison with *in vivo* parameters in the rat, **73:** 826
—pharmacokinetics, cat, nordiazepam, **73:** 348
Dichlorophen—HPLC, major impurity, **73:** 822
Diclofenac sodium—release from topical ointment bases, oil-in-water emulsions, physicopharmaceutical characteristics, **73:** 676
Diethyl malonate—percutaneous absorption, pig skin, **73:** 1388
Difference absorption spectrophotometry—assay of 1,2-diphenolic substances, **73:** 1582
Difference spectrophotometry—chlordiazepoxide and demoxepan, chlordiazepoxide formulations, **73:** 55
Differential titration—curve-fitting technique, pK_a, octanol–water partition coefficients, programmable calculator/microcomputer, **73:** 226
Diffusion—physicochemical model, predictive, stratum corneum-limited percutaneous absorption, maximum *in vivo* penetration rates in humans, **73:** 461
—transport of alkyl amines across a silicone rubber membrane, **73:** 1028
Diflorasone diacetate—HPLC, cream, ointment, bulk drug, **73:** 1606
Digitonin—derivatives, solubilizers, lipophilic drugs, comparative toxicity, **73:** 240
Digoxin—bioavailability, coadministered fluid volume, **73:** 1397
—kinetics of red blood cell partitioning, plasma protein binding, analogues, **73:** 1042
Dihydrocurvularin—intravenous injection, hyperpyrexia, rabbits, effect of lipopolysaccharide, **73:** 1846
2,3-Dihydrothiazole derivatives—synthesis, antimicrobial, antihypertensive, and anticonvulsant properties, **73:** 1166
Diltiazem—HPLC determination, six metabolites, human urine, **73:** 771
—human plasma, GC–ECD, concurrent assay with deacetyldiltiazem, **73:** 207
—quantitation with desacetyldiltiazem, dog plasma, HPLC, **73:** 688
Dimerization—doxorubicin, daunorubicin, and their 4-demethoxy, 4′-epi, and 4′-deoxy analogues, effect of buffer concentration and ionic strength, **73:** 766
2-Dimethylaminoethanol—analogues, protection against mechlorethamine cytotoxicity, inhibition of choline uptake, combination chemotherapy with mechlorethamine, **73:** 34
Dinoprost—GI absorption, effect of concentration, pH, buffer capacity, and hydrodynamics, rats, **73:** 1588
Dinoprostone—GI absorption, effect of buffer pH, buffer capacity, lumenal hydrodynamics, and concentration, **73:** 1594
7,8-Dioxygenated-3,4-dihydroisoquinoline—secondary amine, oxidation with potassium permanganate, **73:** 1639
1,2-Diphenolic drugs—difference UV assay in formulations, **73:** 1582
α,α-Diphenylsuccinimide—anticonvulsant potency, hydrophobic properties, overt neurotoxicity, maximal electroshock screen, mice, **73:** 310
Dipole moments—aliphatic group, correlation with Taft polar substituent constants, quantitative structure–activity relationships, **73:** 553
—substituted phenylfluorohalogenoethanes as solutes, **73:** 1164
Disintegrating force—new formulation parameter, Weibull distribution, coated aspirin tablets, **73:** 701
Disintegration—dimensionless values, effect of compressional forces on tablets containing cellulosic disintegrators, **73:** 781
Disintegrators, cellulosic—effect of compressional force on tablets, dimensionless disintegration values, **73:** 781
Disopyramide—binding to α_1-acid glycoprotein, competitive equilibrium dialysis, **73:** 824
Disposition—ibuprofen, nephrectomized dogs, pharmacokinetics, **73:** 705
—multilamellar liposomes, *in vivo*, lung, mice, phosphatidylserine, **73:** 203
—precorneal, topical pilocarpine, bioavailability, **73:** 219
Dissociation constants—verapamil, determination using liquid–liquid partition coefficients, effects of ionic strength and temperature, **73:** 442
Dissolution—bioavailability, hydrocortisone, commercial 20-mg tablets, **73:** 964
—capsule, rate decrease, formation of formaldehyde, polysorbate 80 autoxidation, **73:** 1186
—corticoid solutions dispersed on silicas, prednisone, prednisolone, hydrocortisone, free-flowing powders, **73:** 401
—griseofulvin–dimyristoylphosphatidylcholine coprecipitates, comparison with physical mixtures, physical properties, **73:** 757
—multicomponent product, rapid HPLC, metoprolol, hydrochlorothiazide, **73:** 799
—phenytoin and phenytoin sodium *in vitro*, comparison with *in vivo* bioavailability in dogs, **73:** 733
—pore effects, theophylline, **73:** 1771
—powder suspension method, two-site model for hydroxyapatite kinetics, **73:** 146
—prednisolone, colorimetric assay, octoxynol 9, **73:** 157
—prostaglandin $F_{2\alpha}$–γ-cyclodextrin complex, solubility, **73:** 382
—systematic error associated with USP dissolution Apparatus 2, glass and plastic vessels, **73:** 1125
—tablets composed of microcapsules, sodium phenobarbital and ethylcellulose, core–wall ratio, aggregate size, **73:** 52
—tolbutamide, intra- and interlot variation, effect of humidity aging, **73:** 1629
—tolbutamide, solid dispersions, **73:** 1441
—*in vitro*, microencapsulated bacampicillin hydrochloride in oral suspensions, correlation with *in vivo* bioavailability, taste evaluation, **73:** 141
—warfarin, ionization kinetics, **73:** 946
Distribution—^{14}C-labeled polymethyl methacrylate nanoparticles, intravenous injection, rats, **73:** 1433
—doxorubicin, rat liver and kidney nuclei, binding, **73:** 524
Disulfiram—charge transfer complexes with iodine, **73:** 1687
—sustained-release implantable formulation, rats, poly(glycolic-CO-L-lactic acid), **73:** 1718
Diuretics—bumetanide, pharmacokinetics following intravenous, intramuscular, oral administration, **73:** 1108
—GC, (±)-[[6,7-dichloro-2-(4-fluorophenyl)-2-methyl-1-oxo-5-indanyl]-oxy]acetic acid, biological fluids, **73:** 268
—liquid membrane phenomenon, critical micelle concentrations, chloride, sodium, potassium ion transport, furosemide, triamterene, **73:** 1579
DNA—microcalorimetry, binding of some chemotherapeutic agents and related molecules to calf thymus DNA, **73:** 1279
Docusate sodium—coacervate system, partition coefficents, caffeine, theobromine, theophylline, glucose, sucrose, concentration effects, **73:** 1729
1-Dodecylazacycloheptan-2-one—influence on penetration kinetics of triamcinolone acetonide, concentration dependence, **73:** 1794
Dopamine—α- and β-adrenergic antagonists, effect on heart of *M. mercenaria*, **73:** 1491
Dopamine-β-hydroxylase—*in vitro* activity, effect of methyl-substituted 1,2,3,4-tetrahydrocarbazoles, **73:** 1531
Dopaminergic activity—central, apomorphine, 3-(3,4-dihydroxyphenyl)-1-*n*-propylpyrrolidine hydrobromide, **73:** 1585
Dosing—pharmacokinetics, mode of intravenous administration, blood sample collection, **73:** 1599
Doxorubicin—interaction with rat liver and kidney nuclei, binding, distribution, **73:** 524
—pharmacokinetics, mechanism of tissue distribution, tissue-to-plasma partition coefficient, **73:** 1359
—self-association, analogues, effect of buffer concentration and ionic strength, **73:** 766
Droplet-size characterization—cascade impactor method, metered-dose nasal spray, **73:** 344
Drotaverine—HPLC, plasma, **73:** 1489
Drug delivery systems—biodegradable, starch microparticles, lysosomal degradation, **73:** 1507
—clofilium tosylate, nasal administration, **73:** 1251
—controlled-release transdermal administration, prostaglandins, rhesus monkeys, **73:** 282
—polymeric gels and films, pilocarpine, sustained release to rabbit cornea, **73:** 618
Drug diffusion—*in vitro* release of salicylic acid from lanolin alcohols–ethylcellulose films, **73:** 302

Drug–receptor systems—interaction energy of the nitrogen lone electron pair of amines and a proton, angular dependency, **73:** 389
Drug release—flurogestone acetate, intravaginal, sheep, **73:** 1464
Drug stability—statistical prediction of shelf-life, nonlinear parameter estimation, Arrhenius prediction comparison, **73:** 657
Drug transport, rectal—lumen perfusion, *in situ* technique, humans, sodium benzoate, **73:** 95
Dye lakes—aluminum hydroxide, processing variables, **73:** 1738
Dynamic mechanical testing—viscoelastic properties of powder-filled semisolids, starch-anhydrous lanolin model, Kerner equation, **73:** 590

E

Edema, carrageenin-induced—inhibition in rats, neutral polysaccharides isolated from *Aloe saponaria*, As mannan 1, As mannan 2, **73:** 62
EDITORIALS
"Coming of age" for device technology, **73:** 713
A drug is a drug—or is it?, **73:** 1189
FDA commissioners—their function and operation, **73:** 1
Good public policy requires good science, **73:** 1019
Having a voice in APhA scientific policy, **73:** 291
The industry–university interface, **73:** 1677
Observations on the selection of our professional leaders, **73:** 427
Putting an end to secret formulations, **73:** 577
The sad state of current research instruments, **73:** 865
"Scientific proof"—an elusive goal, **73:** 1337
Sending unapproved drugs abroad, **73:** 1505
Universities for hire, **73:** 139
EDTA salts—protection of oxyhemoglobin during freeze-drying, prevention of methemoglobin formation, **73:** 784
Effervescent enteric-coated tablet—levodopa, intestinal absorption, lag time of dissolution and absorption, effect of size and shape, **73:** 942
Electrochemical oxidation—glassy carbon electrode, flow-injection method, determination of hydralazine hydrochloride, **73:** 989
Electron transfer—mechanism, extended clastic binding hypothesis, opiate-receptor interactions, *in vitro* model system, **73:** 715
Electrostatic complexes—reaction of benzethonium chloride and methoxyethylene–maleic anhydride copolymer, **73:** 1148
Eleutheroccus senticosus—cytarabine, N^6-(Δ^2-isopentenyl)adenosine, L1210 leukemia, **73:** 270
Elimination—^{14}C-labeled polymethyl methacrylate nanoparticles, intravenous injection, rats, **73:** 1433
Emulsions—particle size analysis, photon correlation spectroscopy, Laplace transforms, **73:** 919
—surfactant–hydrocarbon oil, self-emulsifiability, measurement by laser nephelometry, **73:** 1267
Enalaprilat—*metabolite of enalapril, bioavailability, influence of food,* **73:** 1655
Enalapril maleate—bioavailability, influence of *food,* **73:** *1655*
Enantiomers—(+)- and (−)-amphetamine, HPLC, trace amounts, **73:** 1162
Encapsulation—*radiopaque liposomes, effect of* formulation conditions, **73:** 1751
—rapid preparation of enteric-coated microspheres, cellulose acetate phthalate, **73:** 39
Endogenous inorganic sulfate—depletion in cerebrospinal fluid of rats by acetaminophen, **73:** 853
Enteric coating—*in vivo* disintegration, radiotelemetry, hydroxypropyl methylcellulose phthalate, **73:** 935
3-Epi-isocucurbitacin B—novel cytotoxic constituent of *Ipomopsis aggregata*, **73:** 411
Epimerization—benzylpenicilloic acid in alkaline media, imine tautomer of penamaldic acid as intermediate, **73:** 125
—moxalactam in aqueous solutions, kinetics, degradation, **73:** 369
Epimers—calcium gluceptate, GC, precipitation in aqueous solutions, **73:** 78
Epinephrine metabolites—4-hydroxy-3-methoxymandelic acid, 3,4-dihydroxymandelic acid, adjuvants, rectal absorption of cefmetazole and cefoxitin, rats, **73:** 109
Equilibrium dialysis—barbituric acids, high concentrations of aqueous sodium alkylsulfonate solutions, solubility, **73:** 256
—plasma protein binding of prednisolone, effects of drug stability, radiotracer purity, buffer composition, fluid shifts, **73:** 774
Equilibrium dialysis, competitive—binding of disopyramide to α_1-acid glycoprotein, **73:** 824
Ergocalciferol—crystal degradation products, HPLC, identification of a Windaus ketone, **73:** 1322
Erythema—inhibition by indomethacin derivatives in humans, inflammation inhibition in rats, delivery vehicle, **73:** 1734
Erythrityl tetranitrate—HPLC, tablet forms, **73:** 1303
Esmolol—GC–MS, ultra-short-acting β-blocker, **73:** 1177
—HPLC, **73:** 1660
Estrogens—selenium substituted, estrogenic and antiestrogenic activity in immature rats, comparison with *in vitro* binding affinity, **73:** 416
Estrone 2- and 4-thiourea derivatives—free phenolic group, synthesis, binding to the estrogen receptor, cytotoxic activity, **73:** 1871
Estrus cycle—vaginal absorption, leuprolide, rats, gonadotropin responses, RIA, **73:** 298
Ethambutol—disposition, pharmacokinetics in dogs, effect of nephrectomy, interspecies comparison, **73:** 787
—pharmacokinetics in rabbits, coadministration with aluminum hydroxide, **73:** 1053
Ethoxzolamide—iris/ciliary body, rabbits, HPLC, GC, **73:** 1261
Ethylcellulose—films with lanolin alcohols, *in vitro* release of salicylic acid, drug diffusion, **73:** 302
Ethylenediamine—use as a bridging unit in syntheses of peptide derivatives, *N*-phosphonoacetyl-L-aspartic acid, **73:** 275
Ethylene oxide residues—GC, determination of three components in one analysis, **73:** 1305
Ethylene–vinyl acetate copolymer microspheres—drug delivery, release kinetics, **73:** 1859
Etidronate disodium—hypercalcemia, intravenous toxicity, dogs, **73:** 1097
Etoposide—analysis with metabolites, HPLC–ECD, human urine, plasma, and CSF, **73:** 164
Excess free energy—solubility, mixed solvent systems, binary and ternary mixtures of ethanol, propylene glycol, and water, **73:** 18
—*solubility, mixed solvent systems,* ethanol–water, **73:** 14
—use solubility, mixed solvent systems, theory, **73:** *9*
Excitatory amino acid receptors—*N*-methyl-D-aspartate, glutamate, kainate, **73:** 1550
Extended Hansen approach—solubility of *p*-hydroxybenzoic acid and methyl *p*-hydroxybenzoate in individual solvents, four-parameter system, **73:** 188
—solubility of naphthalene and benzoic acid in individual solvents, four-parameter system, UNIFAC, **73:** 179

F

Fat emulsions—stability, effect of L-valine and L-histidine monohydrochloride monohydrate additions, buffers, **73:** 91
Fenprostalene—autoxidation, degradation, kinetics, **73:** 1414
Film-coating—detection limits, GC, methanol and methylene chloride residues, **73:** 115
—tack behavior, viscosity, concentrated polymer solutions, **73:** 477
Film irregularities—sunscreen efficacy, opacity, **73:** 888
Flecainide acetate—quantitation in biological fluids, GC–ECD, **73:** 1469
Flow-injection method—amperometric determination, hydralazine hydrochloride, glassy carbon electrode, **73:** 989
Fluid volume—bioavailability of digoxin, **73:** 1397
Fluorescence, HPLC—stereospecific analysis of warfarin and its metabolites, **73:** 1392
Fluorescence probe—1-anilino-8-naphthalenesulfonate, differences in plasma protein binding, acidic drugs, rats, **73:** 519
Fluorescence quenching—binding parameters, monomer–polymer systems, **73:** 1815
Fluoride, sustained release—topical application, concentration in whole saliva, **73:** 135
Fluphenazine—hapten synthesis, conjugation with bovine serum albumin, antisera production, rabbits, RIA, **73:** 247
—synthesis, deuterium-labeled analogues, propylpiperazine side chain, **73:** 87
Flurbiprofen—HPLC detection compared with fluorescence detection, human serum, **73:** 1823
Flurogestone acetate—intravaginal release and permeation measurement *in vitro*, **73:** 1464
—stability-indicating HPLC, stability kinetics, **73:** 1461
Folic acid—effect on acutely administered phenytoin, pregnant and nonpregnant rats, **73:** 1180
Formulations—benzenoid drugs, second-derivative UV spectrometry, tablets and capsules, **73:** 413
—disintegrating force as a new parameter, Weibull distribution, coated aspirin tablets, **73:** 701
—penicillamine, development, evaluation of enteric-coated tablets, **73:** 1215
—radiopaque liposomes, effect on encapsulation efficiency, **73:** 1751
—tablets, neutron activation to evaluate the effects of glycine on iron absorption, **73:** 1529
Formulations, veterinary—HPLC, neomycin, petrolatum-based ointments, **73:** 69
Fostedil—pharmacokinetics, dogs, **73:** 1400
Freeze-drying—vial heat transfer coefficients, measurement of resistance to mass transfer, **73:** 1224
Freeze–thaw cycles—stability, aluminum hydroxycarbonate and magnesium hydroxide gels, added polymers, surface-active agents, mechanisms, **73:** 3
Furaltadone—*in vitro* and *in vivo* metabolism, fate in cattle and goats, pharmacokinetics, **73:** *293*
2-Furoic acid—ester derivatives, synthesis, antitumor potential, Ehrlich ascites screen, **73:** *266*
Furosemide—comparative bioavailability, brand-name, generic formulations, humans, plasma, urine, **73:** 437
—liquid membrane phenomenon, anion/cation transport, **73:** 1579
2-Furylacrylic acid—ester derivatives, synthesis, antitumor potential, Ehrlich ascites screen, **73:** 266

G

Gallstone dissolution—human bile, effect of bile acid composition, **73:** 1160

GC—captopril, quantitative determination in blood and plasma, disulfide metabolites, **73:** 340

—cetiedil, human plasma, nitrogen-phosphorus detector, **73:** 1748

—determination of benzalkonium chloride, **73:** 1700

—determination of three components in one analysis, ethylene oxide residues, **73:** 1305

—isosorbide 5-mononitrate, human plasma, **73:** 1317

—nitroglycerin, picogram quantitation, **73:** 923

—quantitation of flecainide acetate in biological fluids, **73:** 1469

—quazepam, two metabolites, human plasma, **73:** 516

—solvent residues in drug raw materials, comparison with MS, **73:** 1664

—tris(2-butoxyethyl) phosphate, plasticizer, GC, serum, variable recovery, **73:** 1791

GC–EC—*N*-(*trans*-2-dimethylaminocyclopentyl)-*N*-(3′,4′-dichlorophenyl)propanamide, *N*-demethyl metabolite, dog serum, **73:** 317

GC–MS—selected-ion monitoring, *S*-methyl metabolite, captopril, human plasma, oral administration, **73:** 1493

—selected-ion monitoring, nadolol, human serum and urine, nadolol-d_9, **73:** 1571

—selected-ion monitoring, total captopril, human plasma, reduction of disulfides, **73:** 1113

Gelatin capsules—drug release, GI-tract resistance, laser-drilled design, **73:** 1806

Gentamicin—component separation serum protein binding, radiolabels, HPLC, **73:** 1836

Ginseng—stability kinetics of ginsenosides in aqueous solutions of varying pH, **73:** 409

Ginsenosides—stability kinetics, aqueous solutions of varying pH, **73:** 409

Glassy hydrogels—oxprenolol hydrochloride, nonuniform distribution, **73:** 1344

Gliclazide—protein binding in healthy and diabetic human serum, **73:** 1684

Glucagon—*in vivo* bioassay, continuous glucose monitoring, dogs, **73:** 1298

Glucocorticoids—prednisolone levels in plasma and leukemia cells, therapy of chronic lymphocytic leukemia, **73:** 66

Glucocorticosteroids—partition coefficients, determination by two HPLC methods, **73:** 1703

Glucose monitoring—glucagon, *in vivo* bioassay, dogs, **73:** 1298

Glutathione—role in *in vitro* dehalogenation, *N*-ethylmaleimide inhibition, **73:** 1101

Gonadotropin response—leuprolide, rats, vaginal absorption, estrus cycle, RIA, **73:** 298

Gossypol—analysis, gossypol–acetic acid, HPLC, **73:** 396

Granulation—computer-interfaced capacitive sensor, high-intensity mixer, moisture measurement, instrumentation, process control, **73:** 420

Griseofulvin—coprecipitates with dimyristoylphosphatidylcholine, physical properties, dissolution behavior, **73:** 757

—solubility in isooctane solution, straight-chain fatty acids, **73:** 1195

Guaifenesin—synthetic impurity, HPLC with phenylephrine hydrochloride, phenylpropanolamine hydrochloride, and sodium benzoate, **73:** 1856

H

Hallucinogens—normacromerine, biological fate in the rat, **73:** 692

Haloperidol—polymorphism, comparison of IR spectra, X-ray diffraction patterns, crystal structures, **73:** 512

—prolactin secretion, benztropine mesylate, serum levels, rats, **73:** 1833

Heat transfer coefficients—freeze-drying, experimental measurement, mechanisms, **73:** 1224

Hemoglobin—acylation by aspirin-like diacyl esters, sickle cell anemia, **73:** 1013

—carboxylate-substituted diaspirins, acylation, sickle cell anemia, **73:** 1851

Heparin—activity, laser nephelometry, USP method, recalcification clotting time, **73:** 1640

—anticoagulant action, effect of pregnancy, rats, **73:** 72

Hepatic clearance—propranolol, venous equilibrium model, **73:** 1498

Hepatic tissue binding—effect on oral availability of lidocaine, healthy subjects and epileptic patients compared, **73:** 422

Hepatobiliary radiopharmaceuticals—^{99m}Tc-labeled compounds compared, sulfobromophthalein-treated and normal rats, **73:** 1861

Hepatobiliary transport—bromophenol blue, dogs, pharmacokinetics, **73:** 928

Hetacillin—methoxymethyl ester, bioavailability of sarpicillin, humans, **73:** 169

Hexylamine—transport across a silicone rubber membrane, octylamine, two-chamber diffusion cell, **73:** 1028

HPLC—acetazolamide, biological fluids, pharmacokinetics, **73:** 985

—*N*-acetylcysteine, plasma, urine, **73:** 996

—adinazolam and *N*-demethyl metabolite in plasma, **73:** 1173

—analysis, propranolol and its 4-hydroxy metabolite, plasma, **73:** 1825

—analysis of dichlorophen, major impurity, **73:** 822

—carprofen dosage forms and drug substance, **73:** 1211

—cimetidine in plasma and urine, **73:** 1015

—crystal degradation products of ergocalciferol, **73:** 1322

—determination of esmolol hydrochloride, **73:** 1660

—diflorasone diacetate, cream, ointment, bulk drug, **73:** 1606

—diltiazem and six metabolites, human urine, **73:** 771

—electrochemical detection, trimipramine and its metabolites, **73:** 1745

—halogenated 8-hydroxyquinoline compounds, **73:** 1430

—(2*R*,4*R*)-2-(2-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinecarboxylic acid, human blood, electrochemical detection, **73:** 119

—improved assay for pirmenol, plasma, urine, cyclohexane extraction, **73:** 754

—minoxidil, compressed tablets, topical solution, and bulk drug, **73:** 1290

—norfloxacin, human plasma and urine, ion pairing, **73:** 99

—octanol/water partition coefficient, equilibrium, **73:** 1623

—octanol/water partition coefficients, **73:** 1616

—pantothenic acid, multivitamins, **73:** 113

—partition coefficients of glucocorticosteroids determination with and without 1-octanol, **73:** 1703

—pharmaceutical dosage forms of metronidazole, **73:** 1331

—plasma, drotaverine, **73:** 1489

—primaquine, human plasma, urine, pharmacokinetics, **73:** 1329

—reverse-phase simultaneous determination, nicardipine and its pyridine metabolite II, human plasma, **73:** 1444

—ritodrine, serum, electrochemical detection, **73:** 131

—sodium levothyroxine, determination of bulk, tablet, injection formulations, **73:** 1315

—stability-indicating, fluorgestone acetate, **73:** 1461

—sulindac and its metabolites, human plasma, urine, bile and gastric fluid, **73:** 1270

—tiflamizole, human plasma, **73:** 1829

—tracazolate and its free carboxylic acid metabolite, individual and simultaneous assay in plasma, **73:** 667

—trace amounts, acetaminophen, plasma, **73:** 117

—use of the parameter R_Q to determine lipophilicity, homologous series of barbiturates, **73:** 625

Human albumin products—stabilizers, octanoic acid, *N*-acetyl-DL-tryptophan, **73:** 82

Human carbonic anhydrase C—structure–activity relationships with sulfonamides, interactive computer graphic display, **73:** 352

Hydralazine hydrochloride—amperometric determination in a flowing stream, glassy carbon electrode, **73:** 989

Hydrazobenzene—HPLC determination, **73:** 1706

Hydrocarbon oils—self-emulsifiability, effect of added surfactants, measurement by laser nephelometry, **73:** 1267

Hydrochlorothiazide—bias of USP XX colorimetric assay for diazotizable substances, free amine content, **73:** 1545

—bioavailability, tablets, suspensions, pharmacokinetics, **73:** 359

—dissolution profile, multicomponent product with metoprolol, rapid HPLC, **73:** 799

—HPLC, combination with captopril, tablet formulations, **73:** 686

—physicochemical model, dose-independent GI absorption, **73:** 1274

Hydrocortisone—bioavailability, commercial 20-mg tablets, dissolution, **73:** 964

—dispersions with polyethylene glycol 4000 and polyvinylpyrrolidone, effect of aging, **73:** 1539

—lecithin–water liquid crystals as potential ointment vehicle, **73:** 1484

—percutaneous absorption, influences of age, site, and skin sectioning on permeation rates, hairless mouse skin, **73:** 1287

Hydrolysis—maleimide, effect of temperature, **73:** 1767

—poly(*ortho*-ester)s, homogeneous solutions, **73:** 1563

Hydrophilic–lipophilic character—effects of solvent medium, ethanol–water, ethanol–cyclohexane, solubility, **73:** 1869

—effects of solvent medium, solubility, ethanol–water, **73:** 1094

—polyoxyethylated nonionic surfactants, comparison with solubility parameter, **73:** 790

Hydrophobic compounds—*in vitro* percutaneous absorption, **73:** 1255

Hydrophobicity—α,α-diphenylsuccinimide, anticonvulsant potency, overt neurotoxicity, maximal electroshock screen, mice, **73:** 310

Hydroxide catalysis—detection of coexisting general-base catalysis, theoretical basis, effect of buffer composition, acid concentration, and ionic strength, **73:** 724

Hydroxyapatite—dissolution kinetics, powder suspension method, two-site model, **73:** 146

4-Hydroxybenzoic acid—simultaneous determination with its methyl, ethyl, propyl, and butyl esters, liquid antacid formulations, GC, **73:** 128

Hydroxylation—conjugation, *cis*-3a,4,5,6,7,7a-hexahydro-3-(1-methyl-5-nitro-1*H*-imidazol-2-yl)-1,2-benzisoxazole, NMR, MS, **73:** 1731

α-Hydroxymetoprolol—HPLC, metoprolol, human serum, urine, cerebrospinal fluid, **73:** 961

9α- and 9β-Hydroxyphenylmorphans—hydrogenation, diastereoisomer spectral data, synthesis, **73:** 1867
Hydroxypropyl methylcellulose phthalate—*in vivo* disintegration, tablet coating, radiotelemetry, **73:** 935
8-Hydroxyquinoline—halogenated, HPLC, **73:** 1430
Hydroxytriamterene sulfate—HPLC, major metabolite of triamterene, blood, plasma, urine, **73:** 831
Hypercalcemia—etidronate disodium and calcium gluconate, toxicity, dogs, **73:** 1097

I

Ibuprofen—disposition in nephrectomized dogs, pharmacokinetics, **73:** 705
—HPLC, small volumes, human plasma and saliva, **73:** 1487
—inhibition of polymorphonuclear leukocyte cell responses, **73:** 1403
—LC, plasma concentration profile, optical isomers, humans, **73:** 1542
Imides, cyclic—phthalimide derivatives, reduced and hydrolytic products, hypolipidemic activity, **73:** 1482
Indanyl oxyacetic acid derivatives—diuretic, antihypertensive agent, **73:** 268
Indomethacin—derivatives, erythema inhibition in humans, inflammation inhibition in rats, delivery vehicle comparison, **73:** 1734
Infusion, constant-rate—volume of distribution, initial slope technique, metronidazole pharmacokinetics, **73:** 58
Infusion systems, plastic—dynamics of clomethiazole edisylate interaction, polyvinyl chloride, cellulose propionate, **73:** 43
Inhibitors—disodium 4,4′-diisothiocyano-2,2′-disulfonate stilbene and calcium chloride, **73:** 1523
Initial slope technique—apparent volume of distribution, constant-rate infusion, metronidazole pharmacokinetics, **73:** 58
Interaction energy—nitrogen lone electron pair of amines and a proton, angular dependency, drug–receptor systems, **73:** 389
Intravaginal administration—flurogestone acetate, sheep, **73:** 1464
Iodochlorhydroxyquin—partition coefficients, acid dissociation constants, **73:** 1647
—percutaneous absorption and disposition, dogs, **73:** 1369
Iohexol—pharmacokinetics, intravenous administration, humans, **73:** 993
Ionization constants—determination, compounds which precipitate during potentiometric titration, **73:** 1410
Ionization kinetics—warfarin dissolution, **73:** 946
***Ipomopsis aggregata* (Polemoniaceae)**—isolation and identification of cytotoxic constituents, **73:** 411
Iron—absorption, effects of divalent amino acids, **73:** 1245
Isomers—potassium guaiacolsulfonate, chemical constituents and spectral properties, commercial and NF reference standard, **73:** 1238
—stereospecific fluorescence HPLC, warfarin and its metabolites, **73:** 1392
Isosorbide dinitrate—bioavailability from oral formulations, oral and sublingual formulations compared, humans, **73:** 699
—HPLC, tablet forms, **73:** 1303
Isosorbide 5-mononitrate—GC, human plasma, **73:** 1317
Isotonic agents—boric acid, EDTA, propylene glycol, glycerol, mannitol, effect on the stability of thimerosal, ophthalmic formulations, **73:** 840
Isotope methodology—labeled metabolites, **73:** 285

J

Jejunum—everted, effect of pH on theophylline transfer, rats, **73:** 320

K

Kerner equation—dynamic mechanical testing, application to viscoelasticity of powder-filled semisolids, starch-anhydrous lanolin model, **73:** 590
Kinetics—agglutination of enzymatically treated normal and diabetic rat hepatocytes, trypsin, neuraminidase, **73:** 628
—ancitabine conversion to cytarabine, aqueous solutions, **73:** 896
—dehydration, β-hydroxycyclopentanone analogue of prostaglandin E_1, mechanism, **73:** 306
—digoxin and analogues in blood, plasma protein binding, red blood cell partitioning, **73:** 1042
—enzymatic, pivampicillin, surface monolayers, Michaelis–Menten, **73:** 1694
—fenprostalene in polyethylene glycol 400, **73:** 1414
—fluorgestone acetate, **73:** 1461
—microbial, analysis and characterization of bacterial regrowth after treatment of *Escherichia coli* with β-lactam antibiotics, **73:** 1422
—microbial, β-lactam antibiotics against *Escherichia coli*, **73:** 1418
—moxalactam degradation and epimerization in aqueous solutions, HPLC, **73:** 369
—powder suspension method, two-site model, hydroxyapatite dissolution, **73:** 146
—serum and myocardial, amiodarone and its metabolite, rabbits, **73:** 1208
Kinetics, mortality—effects of alcoholism, **73:** 1191
Kinetic steric factors—relationship with connectivity indices to rate constants, **73:** 1472

L

β-Lactam antibiotics—kinetic analysis and characterization of bacterial regrowth after treatment of *Escherichia coli*, **73:** 1422
—microbial kinetics against *Escherichia coli*, **73:** 1418
Lactobacillus casei—anticancer agents, **73:** 264
α-Lactose—alterations, differential scanning calorimetry, **73:** 856
—mechanical and thermal treatment, transition, **73:** 857
Lactulose—determination of dry substance, refractive index–dry-substance content, **73:** 1478
Lanolin alcohols—films with ethylcellulose, *in vitro* release of salicylic acid, drug diffusion, **73:** 302
Laser-drilled capsules—drug release, GI-tract resistance, X-ray studies, **73:** 1806
Laser nephelometry—heparin activity, USP method, recalcification clotting time, **73:** 1640
—self-emulsifiability, surfactant–hydrocarbon oil mixtures, **73:** 1267
Lecithin—liquid crystals as potential ointment vehicle, **73:** 1484
Leucine enkephalin—conformationally restrained analogues, synthesis, analgesic activity, **73:** 457
Leuprolide—vaginal absorption, rats, gonadotropin responses, estrus cycle, RIA, **73:** 298
Levodopa—effervescent enteric-coated tablet, intestinal absorption, dissolution, **73:** 942
Lichen ruber planus—treatment with tretinoin, irritation-free formulation, mucosal adhesive ointment, **73:** 548
Lidocaine—binary system with prilocaine, phase diagram, aqueous solubility, **73:** 481
—oral availability in healthy subjects and epileptic patients compared, **73:** 422
—pharmacokinetics, thermally injured rats, **73:** 1117
—*precursor–metabolite interaction, metabolism*, **73:** 136
Lipolysis—*in vitro* and *in vivo* comparisons, plasma protein binding, pregnant and nonpregnant rats, **73:** 1121
Lipophilic drugs—digitonin derivatives as solubilizers, comparative toxicity, **73:** 240
Lipophilicity—homologous series of barbiturates, determination by the HPLC parameter R_Q, **73:** 625
—topological molecular descriptors, biological activity assessment, **73:** 429
Lipophilic molecules—transport systems, increased skin permeability, **73:** 1153
Liposomes—encapsulation of triamcinolone acetonide-21-palmitate, synthesis, **73:** 834
—multilamellar, phosphatidylserine, disposition *in vivo*, lung, mice, **73:** 203
—phosphatidylcholine–cholesterol, ionic strength, lipid composition, physical stability, **73:** 1559
—phospholipid, multilamellar, structural characteristics, external lipid layer and aqueous volume, **73:** 122
—radiopaque, effect of formulation conditions on encapsulation efficiency, **73:** 1751
Literature survey—anti-inflammatory agents, **73:** 579
Luteinizing hormone-releasing hormone—analogue, nafarelin acetate, nasal absorption, rhesus monkeys, **73:** 684
—stability, aqueous solutions, *in vitro* bioassay, HPLC, **73:** 819
Lymphocytic leukemia—prednisolone levels in plasma and leukemia cells, therapy, chronic, glucocorticoid, **73:** 66
Lyophilization—acetylcholine, HPLC, **73:** 1311

M

Macrophages, peritoneal—mice, phagocytosis, microparticles, ultrastructural cellular alterations, **73:** 153
Magnesium hydroxide gel—freeze–thaw instability, mechanism, added polymers, surface-active agents, **73:** 3
Malaprade reaction—determination of calcium gluconate with selective oxidation by periodate, quantitation, **73:** 681
Maleimide—kinetics,mechanism of hydrolysis, **73:** 1767
As mannans—isolation from *Aloe saponaria*, structural determinations, inhibition of carrageenin-induced edema in rats, **73:** 62
Mannich bases—derived from acetophenones, antileukemic activity in P388 screen, toxicological assessment in rats, **73:** 471
—5-nitro-3-phenyliminoindol-2(3*H*)-ones, synthesis, antimicrobial and antifungal activity, **73:** 407
Mass transport—non-steady-state, physical model for taste perception, drugs, and pharmaceutical formulations, **73:** 600
Mathematical models—biliary recycling in pharmacokinetics, cimetidine, isotretinoin, **73:** 313
Matrix, shellac-based—sustained-release dosage forms, solubility–dissolution rate ratios, internal self-buffering effect, **73:** 1203
Mechanisms of enhancement—reservoir effect, diffusion constant, partition coefficient, promotion of skin hydration, **73:** 1794
Meclocycline—tetracycline analogue, cream formulations, HPLC, **73:** 1650
Meperidine—TLC, GC–MS, identification of metabolites, interaction with monoamine oxidase inhibitors, **73:** 1783
Mercury porosimetry—particle size and surface area distributions, pharmaceutical powders, **73:** 197

Mesterolone—17α-propyl analogue, determination *in plasma, GC–MS, single-ion detection*, **73:** 563
Metabolism—diazepam in the rat, hepatic and extrahepatic, *in vitro* assessment compared with *in vivo* parameters, **73:** 826
—first-pass, transdermal formulations, human skin, **73:** 1499
—furaltadone, *in vitro* and *in vivo*, fate in cattle and goats, pharmacokinetics, **73:** 293
—lidocaine in liver, **73:** 136
—primaquine in rats, excretion and distribution, **73:** 502
—saturable, first-pass, nonlinear bioavailability, metoclopramide, rat, **73:** 215
Metabolites—disulfide, captopril, plasma, GC, **73:** 340
—interaction with precursor in metabolism of lidocaine, **73:** 136
—phenolic, amphetamine and norephedrine, rat brain metabolism, GC, **73:** 808
Methanol—detection limits, GC, methylene chloride, residues, film-coated tablets, **73:** 115
Methicillin—pharmacokinetics, rabbit, capacity-limited distribution, single-dose, steady state, **73:** 867
Methylene chloride—detection limits, GC, methanol, residues, film-coated tablets, **73:** 115
Methylenecitric acid—bissalicylic esters, synthesis, hemoglobin-modifying potential, **73:** 418
Methylprednisolone 17- and 21-monoesters—acyl transfer reactions, carboxyl group catalysis, **73:** 604
4-Methylpyrazole—urine and plasma analysis, GC with nitrogen-selective detection, **73:** 690
Metoclopramide—nonlinear bioavailability, saturable first-pass metabolism, rat, **73:** 215
Metoprolol—dissolution profile, multicomponent product with hydrochlorothiazide, rapid HPLC, **73:** 799
—HPLC, α-hydroxymetoprolol, human serum, urine, cerebrospinal fluid, **73:** 961
Metronidazole—HPLC, pharmaceutical dosage forms, **73:** 1331
Micellar solubilization—behavior of ATP toward phenothiazine drugs, binding, **73:** 662
Microcalorimetry—binding of chemotherapeutic agents and related molecules to calf thymus DNA, **73:** 1279
Microcapsules—sodium phenobarbital and ethylcellulose, tablets, core–wall ratio, aggregate size, dissolution, **73:** 52
Microemulsions—particle size analysis, photon correlation spectroscopy, latex suspensions, **73:** 915
Microencapsulation—ethylene–vinyl acetate copolymer microscpheres, release kinetics, sustained release systems, **73:** 1859
—gelatin–base coacervation systems, water-soluble nonionic polymer, **73:** 879
—nafarelin acetate in poly(*d,l*-lactide–co-glycolide), **73:** 1294
—pectin–gelatin coacervates, sulfamerazine, **73:** 1799
Microenvironments—2-(4′-hydroxyphenylazo)-benzoic acid bound to bovine serum albumin, solvent effects, characterization, **73:** 507
Microradiography—quantitative study of dental enamel demineralization/remineralization, **73:** 650
—quantitative study of dental enamel demineralization/remineralization, solution ion activity product, **73:** 653
Microspheres—drug carrier system, lysosomal degradation, polyacryl starch, **73:** 1507
—enteric-coated, rapid preparation, encapsulation, cellulose acetate phthalate, **73:** 39
—polyacrylamide, phagocytosis, mouse peritoneal macrophages, ultrastructural cellular alterations, **73:** 153
—poly(*d,l*-lactide), progesterone, effect of emulsifier concentration, stability, **73:** 1721
Milrinone—blood plasma levels, human volunteers, oral and intravenous administration, bioavailability, **73:** 1438
Minoxidil—compressed tablets, topical solution and bulk drug, HPLC, **73:** 1290
Miosis—morphine-induced, relationship to plasma concentration, **73:** 1496
Mitomycin C—pharmacokinetics, dogs, HPLC, **73:** 1220
Mixed solvent systems—estimation of solubility, excess free energy approach, binary and ternary mixtures of ethanol, propylene glycol, and water, **73:** 18
—solubility, excess free energy approach, ethanol–water, **73:** 14
—solubility, excess free energy approach, theory, **73:** 9
Molecular complexes—griseofulvin and straight-chain alkanoic acids, isooctane solution, solubility, **73:** 1195
Molecular connectivity—Chi indices, quantitative structure–pharmacokinetic relationships, substituted 2-sulfaypridines, **73:** 237
Monoamine oxidase inhibitors—metabolites of meperidine, TLC, GC–MS, **73:** 1783
Monomer–polymer systems—binding parameters, overlapped fluorescence quenching, **73:** 1815
Moperone—polymorphism, comparison of IR spectra, X-ray diffraction patterns, crystal structures, **73:** 512
Morphine—relationship of morphine-induced miosis and plasma concentration, normal subjects, **73:** 1496
Moxalactam—degradation and epimerization in aqueous solutions, kinetics, HPLC, **73:** 369
Multilaminates—oil–water, diffusion model, optimal biological response, partition coefficient, **73:** 102

N

Nadolol—HPLC, bendroflumethiazide, combination tablet formulations, **73:** 259
—human serum and urine, GC–MS, selected-ion monitoring, nadolol-d_9, **73:** 1571
Nafarelin acetate—microencapsulation in poly(*d,l*-lactide–co-glycolide), **73:** 1294
—nasal absorption, [D-Nal(2)^6]LHRH, rhesus monkeys, **73:** 684
Nafronyl—pharmacokinetics in dogs, HPLC, red blood cell partitioning, plasma protein binding, effect of anticoagulants, bioavailability, **73:** 635
Nalmefene—human plasma, RIA, compared with HPLC, **73:** 1645
Naloxone—HPLC with electrochemical detection, plasma and urine, applications to protein binding and red blood cell partitioning, **73:** 621
Naltrexone—HPLC with electrochemical detection, plasma and urine, applications to protein binding and red blood cell partitioning, **73:** 621
***Nandina domestica* Thunberg**—nantenine, extraction, serotonergic receptor antagonist, isolated rabbit aorta, **73:** 568
Nanoparticles—polyisobutyl cyanoacrylate, *in vivo* uptake, rat liver Kupffer, endothelial, parenchymal cells, **73:** 980
Nantenine—serotonergic receptor antagonist from *Nandina domestica* Thunberg, isolated rabbit aorta, **73:** 568
3-*N*-(1′,8′-Naphthalimido)propionic acid—hypolipidemic activity in rodents, cholesterol and triglycerides reduction, **73:** 956
Nasal spray—metered-dose, cascade impactor method, droplet-size characterization, **73:** 344
Neomycin—HPLC, petrolatum-based ointments, veterinary formulations, **73:** 69
Neuraminidase—agglutination kinetics of enzymatically treated normal and diabetic rat hepatocytes, trypsin, **73:** 628
Neuroleptics—*in vitro* interaction with coffee, tea, gallotannic acid, gallic acid, **73:** 1056
Neurotoxicity—percutaneous absorption and disposition of iodochlorhydroxyquin, dogs, **73:** 1369
Neutron activation—iron tablets, effects of glycine on iron absorption, **73:** 1529
Nicardipine—simultaneous determination with its pyridine metabolite II, reverse-phase HPLC, **73:** 1444
Nicorandil—metabolism in dogs, pharmacokinetics, detection in plasma by HPLC, **73:** 494
Nipecotic acid esters—synthesis, anticonvulsant activity, **73:** 1612
Nitrate—simultaneous determination with nitrite, toothpastes, HPLC, **73:** 1004
Nitrazepam—nitroreduction, possible interference by cimetidine, **73:** 1187
Nitrite—simultaneous determination with nitrate, toothpastes, HPLC, **73:** 1004
Nitrofurantoin—renal metabolism, isolated perfused rat kidney, **73:** 1669
Nitrofurazone—renal metabolism, isolated perfused rat kidney, **73:** 1669
Nitrogen mustard derivatives—antitumor agents, potential, Ehrlich ascites carcinoma screen, **73:** 1175
—chlorambucil and its isocyanate derivatives, alkylating activity, fluorescence assay, **73:** 1157
Nitrogen purging—desorption of carbonate from aluminum hydroxycarbonate gel, **73:** 209
Nitroglycerin—GC, picogram quantitation, **73:** 923
—HPLC, parent drug, dinitrate metabolites, human plasma, **73:** 1838
—pharmacokinetics, parenteral and oral dosing, rats, **73:** 873
—vapor pressure in sublingual molded tablets, intertablet migration, effect of additives, **73:** 1608
1-(4-Nitrophenyl)-3-methyltriazene—kinetic study of the hydrolysis, effects of sodium lauryl sulfate and hexadecyltrimethylammonium bromide, **73:** 1691
NMR—phenylbutazone, comparative analyses, **73:** 1653
Nonlinear parameter estimation—drug stability, statistical prediction of shelf-life, Arrhenius prediction comparison, **73:** 657
Nootkatol—isolation from *Alpinia oxyphylla* Miquel, calcium-antagonistic activity, **73:** 843
Nordiazepam—pharmacokinetics, cat, diazepam, **73:** 348
Norephedrine—rat brain metabolites, amphetamine, phenolic metabolites, GC, **73:** 808
Norfloxacin—human plasma and urine, ion-pair reverse-phase HPLC, **73:** 99
Normacromerine—biological fate in the rat, hallucinogenic potential, **73:** 692
α-Normetazocine—alkylation, optical pairs, antagonism, antinociception, psychotomimetic, mice, morphine-dependent rhesus monkeys, **73:** 1864
Nuclei, liver and kidney—doxorubicin, rats, binding, distribution, **73:** 524
Nucleoside analogues—deazaadenosines, inhibition of ADP- and collagen-induced platelet aggregation, **73:** 366

O

Octanoic acid—stabilizers, *N*-acetyl-DL-tryptophan, human albumin products, **73:** 82
Octoxynol 9—effect of inorganic additives on nonionic surfactants, cloud point relations, **73:** 793

Octylamine—transport across a silicone rubber membrane, hexylamine, two-chamber diffusion cell, **73:** 1028
Ointments—oil-in-water emulsions, topical release of diclofenac sodium, physicopharmaceutical characteristics, **73:** 676
—petrolatum-based, HPLC, neomycin, veterinary formulations, **73:** 69
—vehicles, liquid crystals, lecithin–water, **73:** 1484
Open forum—, **73:** 425, 861, 1501, 1501, 1501, 1675, 1675, 1875, 1876, 1877
Ophthalmic solutions—thimerosal stability with isotonic agents, boric acid, EDTA, propylene glycol, glycerol, mannitol, **73:** 840
Opiate–receptor interactions—electron-transfer mechanism, extended clastic binding hypothesis, *in vitro* model system, **73:** 715
—proton-transfer mechanism, clastic binding hypothesis, *ab initio* molecular orbital calculations, **73:** 719
Optical isomers—LC, plasma concentration profiles, ibuprofen, humans, **73:** 1542
Optimal biological response—diffusion model, oil–water multilaminates, partition coefficient, **73:** 102
Organ perfusion—pharmacokinetics, sampling, **73:** 854
Orphenadrine—analogues, metabolic intermediate complexation with cytochrome P_{450}, **73:** 953
4-Oxoquinazoline analogues—synthesis, antimicrobial activity, *in vitro* screen, **73:** 982
Oxprenolol—hydrochloride salt, glassy hydrogels, nonuniform distribution, **73:** 1344
—tablet and dry ampule formulations, assay alone or simultaneously with other β-adrenergic drugs, HPLC, **73:** 751
Oxyhemoglobin—oxidation to methemoglobin during freeze-drying, protection by EDTA salts, sulfonic acid buffers, pantothenic acid derivatives, **73:** 784
Oxytocic agents—dinoprostone, GI absorption, effect of buffer pH, buffer capacity, lumenal hydrodynamics, and concentration, rat jejunum, **73:** 1594

P

Pantothenic acid—multivitamin preparations, HPLC, **73:** 113
Pantothenic acid derivatives—protection of oxyhemoglobin during freeze-drying, prevention of methemoglobin formation, **73:** 784
Papaverine hydrochloride—pH–solubility profile, supersaturation effect, common-ion effect, solubility–dissolution rate ratio, self-buffering effect, **73:** 1203
Parenteral formulations—efficacy of preservatives, preformulation, **73:** 903
Particle size analysis—microemulsions, photon correlation spectroscopy, latex suspensions, Laplace transforms, **73:** 919
—pharmaceutical powders, mercury porosimetry, **73:** 197
—photon correlation spectroscopy, latex suspensions, microemulsions, **73:** 915
Partition coefficients—liquid–liquid, determining pK_a, verapamil, effects of ionic strength and temperature, **73:** 442
—1-octanol-water, glucocorticosteroids, **73:** 1703
—octanol/water, HPLC, **73:** 1616
—octanol/water, HPLC, equilibrium, biological correlation, **73:** 1623
—octanol–water, multiparametric curve-fitting technique, programmable calculator/microcomputer, **73:** 226
—oil–water multilaminates, diffusion model, optimal biological response, **73:** 102
—photometric determination, two-solvent systems, aniline in chloroform–ammonia, **73:** 231
—tissue to plasma, mechanism of distribution of doxorubicin, **73:** 1359
Partition method—partition coefficients, dissociation constants, iodochlorhydroxyquin, **73:** 1647
Pefloxacin—dose-dependent pharmacokinetics, **73:** 1379
Penamaldic acid—imine tautomer, intermediate in the epimerization of benzylpenicilloic acid, **73:** 125
Penetration—maximun rates, *in vivo* percutaneous absorption in humans, physicochemical predictive model, **73:** 461
—triamcinolone acetonide, influence of 1-dodecylazacycloheptan-2-one, concentration dependence, **73:** 1794
Penicillamine—development, evaluation of enteric-coated tablets, **73:** 1215
Pentaerythritol tetranitrate—HPLC, tablet forms, **73:** 1303
Pentazocine—relative bioavailability, pharmacokinetics, coadministration with acetaminophen, **73:** 326
Pentobarbital—pharmacokinetics, thermally injured rats, **73:** 1117
Pepsin—adsorption by aluminum hydroxide, **73:** 1514
—adsorption by aluminum hydroxide, inactivation, **73:** 1517
Peptide derivatives—*N*-phosphonoacetyl-L-aspartic acid, synthesis, ethylenediamine bridging unit, potential prodrugs and lysosomal carriers, **73:** 275
Percutaneous absorption—pharmacokinetics, skin penetration, plasma concentration prediction, **73:** 883
—trolamine salicylate, pigs, local tissue penetration, **73:** 1002
Perfusion—lumen of the rectum, *in situ* technique, humans, sodium benzoate, **73:** 95
Perillartine derivatives—taste, discriminative structural analyses using pattern recognition techniques, **73:** 737
Periodate—selective oxidation, determination of calcium gluconate, quantitation, Malaprade reaction, **73:** 681
Permeability coefficients—alkanoic acids through porcine skin, *in vitro* percutaneous absorption, operational conditions, **73:** 534
—alkanoic acids through porcine skin, *in vitro* percutaneous absorption, regular solution theory, **73:** 538
Permeation—permeability of ionizable compounds through human skin, 4-oxo-4*H*-1-benzopyran-2-carboxylic acids, **73:** 1352
Peroral administration—polymethyl methacrylate, elimination and distribution, rats, **73:** 1309
Peroxides—sorbitan monooleate and monostearate, spectrophotometry, **73:** 1663
pH—effect on the theophylline transfer across the everted jejunum, rats, **73:** 320
—precipitation, carbonate-containing aluminum hydroxide, **73:** 967
—profiles *versus* solubility, weak acids, weak bases, **73:** 1679
Phagocytosis—microparticles, mouse peritoneal macrophages, ultrastructural cellular alterations, **73:** 153
Pharmacokinetics—acutely administered phenytoin, folic acid, pregnant and nonpregnant rats, **73:** 1180
—alizapride, multiple dosage forms, **73:** 1450
—apparent volume of distribution, constant-rate infusion, initial slope technique, metronidazole, **73:** 58
—aspirin, sodium bicarbonate–citric acid buffer, oral administration, humans, **73:** 1258
—biliary recycling of drugs, theoretical model, cimetidine, isotetinoin, **73:** 313
—bioavailability, ranitidine, humans, **73:** 1376
—bromophenol blue, dogs, hepatobiliary transport, **73:** 928
—bumetanide, intravenous, intramuscular, and oral administration, **73:** 1108
—choline magnesium trisalicylate bioavailability after once-daily and twice-daily dosages, humans, **73:** 977
—coadministered pentazocine and acetaminophen, relative bioavailability, **73:** 326
—comparison of [^{65}Zn]zinc sulfate and [^{65}Zn]zinc pantothenate injected intravenously, rabbits, **73:** 1642
—composite profiling, ceftriaxone, diazepam, **73:** 1667
—diazepam, nordiazepam, cat, **73:** 348
—dose-dependent, pefloxacin, **73:** 1379
—doxorubicin, mechanism of distribution, tissue-to-plasma partition coefficients, **73:** 1359
—ethambutol disposition in dogs, effect of nephrectomy, interspecies comparison, **73:** 787
—fostedil, dogs, **73:** 1400
—furaltadone, *in vitro* and *in vivo* metabolism, fate in cattle and goats, **73:** 293
—hydrochlorothiazide, bioavailability from tablets and suspensions, **73:** 359
—hydroxylated analogues of quinidine in the dog, HPLC, **73:** 844
—influence of mode of intravenous administration and blood sample collection, rat, **73:** 1599
—intramuscular sulpiride, humans, HPLC, **73:** 1128
—iohexol, intravenous administration, humans, **73:** 993
—methicillin, rabbit, capacity-limited distribution, single-dose, steady state, **73:** 867
—milrinone, an open two-compartment body model, **73:** 1438
—mitomycin C, dogs, HPLC, **73:** 1220
—model independent, multiple dosing, **73:** 570
—multiple dosing, mean residence time, **73:** 854
—nafronyl in dogs, HPLC, red blood cell partitioning, plasma protein binding, effect of anticoagulants, bioavailability, **73:** 635
—nitroglycerin, parenteral and oral dosing, rats, **73:** 873
—noncompartmental determination of the steady-state volume of distribution, multiple dosing, **73:** 281
—noninteraction of temazepam and cimetidine, **73:** 399
—nonlinear, model-independent, steady-state plasma drug-level predictions, theory and mathematical models, **73:** 761
—one-compartment open model, concentration ratio method to determine rate constant, **73:** 859
—organ perfusion, sampling effect, **73:** 854
—percutaneous absorption, plasma concentration prediction, topical administration, **73:** 883
—phenobarbital tablets and elixir in humans, relative bioavailability, **73:** 485
—prodrug modeling, ancitabine bioconversion to cytarabine *in vivo* and *in vitro*, mechanism, **73:** 728
—proquazone and its *m*-hydroxy metabolites, humans, oral and intravenous administration, **73:** 332
—pulmonary absorption and excretion, toxicokinetics, **73:** 1136
—quantitative relationship to structure, molecular connectivity Chi indices, substituted 2-sulfapyridines, **73:** 237
—serum gliclazide level after administration in healthy and diabetic subjects, **73:** 1684
—sulfaquinoxaline, rabbits, HPLC, **73:** 1635
—trifluoperazine and its sulfoxide metabolite, RIA, **73:** 1383
—urinary excretion of chlorpheniramine and demethylated metabolites, children, **73:** 595
—valproic acid, hexadeuterated, analogue, single- and multiple-dose regimens, GC–MS, **73:** 489

Phase separation—coacervation induced by water-soluble nonionic polymer, **73:** 879
Phenacetin—release from inert wax matrices, acrylic acid polymer, **73:** 910
Phenethylamines—substituted, synthesis, inhibition of choline acetyltransferase, **73:** 1548
—*in vitro* adsorption–desorption by a bentonite and a resin, **73:** 1372
Phenobarbital—quantitation with phenobarbital sodium in pharmaceutical dosage forms, **73:** 1158
—relative bioavailability, tablets and elixir, pharmacokinetics in humans, **73:** 485
Phenobarbital sodium—quantitation with phenobarbital in pharmaceutical dosage forms, **73:** 1158
—stability, effects of ethanol, glycerol, and propylene glycol, **73:** 1661
Phenothiazine antihistaminics—effects on bacterial cells, interaction with antibiotics, *Staphylococcus aureus*, **73:** 841
Phenothiazine drugs—behavior of ATP, binding, micellar solubilization, **73:** 662
Phenothiazine tranquilizers—effects on bacterial cells, interaction with antibiotics, *Staphylococcus aureus*, **73:** 841
Phenylbutazone—autoxidation, hydrolysis, degradation, degradation products, effects of light and pH, **73:** 1709
—HPLC, stability-indicating assay, degradation products, **73:** 1706
—NMR, comparative analyses, **73:** 1653
—polymorphic transformation, physicochemical stability under different storage conditions, **73:** 1453
—recrystallized polymorphs, spray-drying technique, physiocochemical characterization, **73:** 173
Phenylfluorohalogenoethanes—substituted, dipole moments, conformations as solutes, **73:** 1164
Phenylimidazoles—*in vitro* adsorption–desorption by a bentonite and a resin, **73:** 1372
Phenylpropanolamine—capillary GC, human plasma, trifluoroacetic anhydride derivatization, **73:** 1313
—HPLC, content uniformity, **73:** 1553
Phenytoin—acutely administered, effect of folic acid on, pregnant and nonpregnant rats, **73:** 1180
—antiseizure activity, effect of pregnancy, maximal electroshock seizure test, **73:** 1348
—bioavailability of the acid and sodium salt in dogs, comparison with *in vitro* dissolution data, **73:** 733
—hydroxymethyl esters, prodrugs, bioavailability, dogs, **73:** 1080
—phosphate prodrug, parenteral administration, rats, **73:** 1087
—plasma protein binding, lipolysis, pregnant and nonpregnant rats, **73:** 1121
—water-soluble prodrug, hydroxymethylation, **73:** 1068
—water-soluble prodrugs, stability, pH profiles, **73:** 1074
Phosphate derivatives—adjuvant or coadjuvant action, **73:** 1523
Phosphatidylserine—liposomes with phosphatidylcholine and cholesterol, physical stability, **73:** 1559
—multilamellar liposome disposition *in vivo*, lung, mice, **73:** 203
Phosphinic acids—excitatory amino acid receptors, anticonvulsant activity, **73:** 1550
***N*-Phosphonoacetyl-L-aspartic acid**—peptide derivatives, synthesis, ethylenediamine bridging unit, potential prodrugs and lysosomal carriers, **73:** 275
Photometry—partition coefficients, two-solvent systems, aniline in chloroform–ammonia, **73:** 231
Photon correlation spectroscopy—particle size analysis, latex suspensions, microemulsions, **73:** 915
Phthalic anhydride—solid–solid reaction with sulfacetamide, **73:** 1059
Phthalimide derivatives—cyclic imides, hypolipidemic activity, reduced and hydrolytic products, **73:** 1482
Physical model—taste perception, pharmaceutical formulations, nonsteady-state mass transport, **73:** 600
Physicochemical stability—phenylbutazone, different storage conditions, polymorphic transformation, **73:** 1453
Physiological flow model—sulfathiazole, swine, distribution, **73:** 1525
Pilocarpine—sustained release, polymeric delivery systems, *in vitro* release studies, *in vivo* miosis in rabbits, **73:** 618
—topical, precorneal area, bioavailability, disposition, **73:** 219
Piperacillin—isolation of amide impurity by column chromatography, identification using soft-ionization MS, high-field NMR, IR, antibiotic activity, **73:** 498
Piperacillin amide—impurity in piperacillin, isolation, identification using soft-ionization MS, high-field NMR, IR, **73:** 498
Pirmenol—improved HPLC, plasma, urine, cyclohexane extraction, **73:** 754
Pivampicillin—enzymatic kinetics, surface monolayers, penicillinase, esterases, **73:** 1694
Plasma concentration prediction—pharmacokinetics, percutaneous absorption, topical administration, **73:** 883
Plasma drug levels—prediction at steady state, model-independent nonlinear pharmacokinetics, theory and mathematical models, **73:** 761
Plasticizer—tris(2-butoxyethyl) phosphate, GC, serum, recovery variability, **73:** 1791
Platelet aggregation—induction by ADP and collagen, inhibition by deaza analogues of adenosine, **73:** 366
Podocarpic acid derivatives—synthesis, antitumor activity, *in vitro* human epidermoid carcinoma (nasopharynx) screen, L1210 and P388 screens in mice, **73:** 694
Polarography—proguanil hydrochloride, effect of pH, **73:** 1804
Poloxamer 188—number-average molecular weight, vapor-phase osmometry, **73:** 392
Polyanions—complex formation with long-chain quaternary ammonium ion, **73:** 1148
Poly(*ortho*-ester)s—hydrolysis, homogeneous solutions, **73:** 1563
Polyisobutyl cyanoacrylate—*in vivo* uptake of nanoparticles, rat liver Kupffer, endothelial, parenchymal cells, **73:** 980
Poly(*d,l*-lactide) microspheres—loaded with lomustine, progesterone, effect of emulsifier concentrations, agitation rates on formation, stability, **73:** 1721
Polymeric matrices—sustained release of pilocarpine to the cornea, *in vivo* miosis in rabbits, *in vitro* release studies, **73:** 618
Polymers—concentrated solutions, viscosity, tack behavior, tablet film-coating, **73:** 477
—hydrolysis of poly(*ortho*-ester)s, homogeneous solutions, **73:** 1563
Polymethyl methacrylate—^{14}C-labeled nanoparticles, distribution, elimination in rats, intravenous injection, **73:** 1433
—peroral administration, distribution, elimination, rats, **73:** 1309
Polymorphic transformation—phenylbutazone, physicochemical stability under different storage conditions, **73:** 1453
Polymorphism—disubstituted butyrophenones, comparison of IR spectra, X-ray diffraction patterns, crystal structures, **73:** 512
—*N*-(4-hydroxyphenyl)retinamide, X-ray powder diffraction, **73:** 1448
Polymorphonuclear leukocytes—inhibition of response, ibuprofen, **73:** 1403
Polyoxyethylene(23) lauryl ether—number-average molecular weight, vapor-phase osmometry, **73:** 392
Polysorbate 80—autoxidation, formation of formaldehyde, decreased dissolution rate, capsules, **73:** 1186
Polyvinyl chloride—dynamics of clomethiazole edisylate interaction with plastic infusion systems, cellulose propionate, **73:** 43
Pore effects—influence on dissolution rate, theophylline, **73:** 1771
Potassium guaiacolsulfonate—chemical constituents, spectral properties, commercial and NF reference standard, **73:** 1238
Potentiometric titration—ionization constants, **73:** 1410
Povidone—conjugate with sulfathiazole, laser Raman spectroscopy, **73:** 1849
—interaction with aromatic compounds, pseudo-two-phase and monophase systems, salicylic acid, complex formation, **73:** 1774
Powders, free-flowing—corticoid solutions dispersed on silicas, dissolution rates, prednisone, prednisolone, hydrocortisone, **73:** 401
Powder suspension method—re-two-site model for hydroxyapatite dissolution kinetics, **73:** 146
Precipitation—calcium gluceptate, aqueous solutions, role of epimers, GC, **73:** 78
Prednisolone—colorimetric assay, application to dissolution, octoxynol 9, **73:** 157
—levels in plasma and leukemia cells, therapy of chronic lymphocytic leukemia, glucocorticoid, **73:** 66
—pharmacokinetics, tissue distribution, tissue binding, rabbits, **73:** 362
—plasma protein binding, equilibrium dialysis, effects of drug stability, radiotracer purity, buffer composition, fluid shifts, **73:** 774
Prednisone—tablets, dissolution of 5 lots with USP Apparatus 2, collaborative study, **73:** 670
Pregnancy—anticoagulant action, heparin, rats, **73:** 72
—effect on antiseizure activity, phenytoin, maximal electroshock seizure test, **73:** 1348
Preservatives—parenteral formulations, efficacy, preformulation, **73:** 903
Prilocaine—binary system with lidocaine, phase diagram, aqueous solubility, **73:** 481
Primaquine—excretion, distribution, metabolism in rats, **73:** 502
—HPLC, human plasma, urine, pharmacokinetics, **73:** 1329
Probucol—bioavailability, oil-in-water emulsion, tissue distribution, biliary elimination, **73:** 1758
Procainamide—colorimetric determination, injectable preparations, cupric ion complexing, **73:** 1184
Prodrug modeling—pharmacokinetics of ancitabine bioconversion to cytarabine *in vivo* and *in vitro*, mechanism, **73:** 728
Prodrugs—phenytoin, bioavailability, dogs, **73:** 1080
—phenytoin, phosphate ester, parenteral administration, rats, **73:** 1087
—phenytoin, water-soluble, hydroxymethylation, anticonvulsants, **73:** 1068
—potential, topical application, 3′-*O*-acyl derivatives of 5′-amino-5′-deoxythymidine, **73:** 1568
—water-soluble, phenytoin stability, pH profiles, **73:** 1074
Proguanil hydrochloride—DC polarographic reduction, **73:** 1804
Propranolol—hepatic clearance, venous equilibrium model, **73:** 1498
Proquazone—*m*-hydroxy metabolites, peroral and intravenous pharmacokinetics, humans, **73:** 332
Prostaglandins—dinoprost, GI absorption, ef-

fect of concentration, pH, buffer capacity, and hydrodynamics, rats, **73:** 1588
—dinoprostone, GI absorption, effect of buffer pH, buffer capacity, lumenal hydrodynamics, and concentration, rat jejunum, **73:** 1594
—Prostaglandin E_1, β-hydroxycyclopentanone analogue, dehydration kinetics, mechanism, **73:** 306
—Prostaglandin $F_{2\alpha}$, inclusion complex with γ-cyclodextrin, solution and solid phases, solubility, dissolution behavior, **73:** 382
—transdermal delivery system, controlled release, **73:** 282
Protein binding—accumulation and depletion of drug from skin, **73:** 710
—acetaminophen, ligand and albumin concentration, **73:** 1038
—1-anilino-8-naphthalenesulfonate, prediction of interindividual differences, acidic drugs, rats, **73:** 519
—dialysis, experimental time, **73:** 708
—digoxin and analogues, kinetics of red blood cell partitioning, **73:** 1042
—methodological considerations, warfarin, radiochemical impurities, **73:** 1000
—microenvironments of 2-(4′-hydroxyphenylazo)benzoic acid bound to bovine serum albumin, solvent effects, **73:** 507
—naltrexone and naloxone in the presence of morphine, HPLC with electrochemical detection, red blood cell partitioning, **73:** 621
—prednisolone, equilibrium dialysis, effects of drug stability, radiotracer purity, buffer composition, fluid shifts, **73:** 774
—quinidine, humans, **73:** 1264
—radiolabeled gentamicin, component separation, HPLC, **73:** 1836
Protein-coated ODS column—reverse-phase, direct injection analysis of plasma sample, **73:** 1825
Proton transfer—mechanism, clastic binding hypothesis, opiate–receptor interactions, *ab initio* molecular orbital calculations, **73:** 719
Proxicromil—GI absorption, lipophilicity, ion pair formation, **73:** 949
Pseudo-two-phase model—compared with monophase, complex formation aromatic compounds with macromolecules, **73:** 1774
Psychotropic drugs—trifluoperazine, fluphenazine, hapten synthesis, conjugation with bovine serum albumin, antisera production, rabbits, RIA, **73:** 247
4-Pyrimidinecarboxylic acids—antihypolipidemic activity, mice, **73:** 1819

Q

Quantitative structure–activity relationships—perturbation theory, serotonin receptor binding affinity, quantum chemistry, **73:** 1725
Quantitative structure–pharmacokinetic relationships—molecular connectivity Chi indices, substituted 2-sulfapyridines, **73:** 237
Quazepam—GC, two metabolites, human plasma, **73:** 516
Quinidine—comparative disposition kinetics in dogs, effects of stereochemistry and 6′-methoxy group substitution, **73:** 452
—pharmacokinetics, thermally injured rats, **73:** 1117
—protein binding, humans, **73:** 1264
Quinidine analogues—hydroxylated, HPLC, pharmacokinetics, dog, **73:** 844
Quinine—comparative disposition kinetics in dogs, effects of stereochemistry and 6′-methoxy group substitution, **73:** 452

R

Radiochemical impurities—methodological considerations, plasma protein binding of warfarin, **73:** 1000
Radiocontrast agents—iohexol, plasma, urine levels, intravenous administration, pharmacokinetics, humans, **73:** 993
Radioimmunoassay—bromperidol, human plasma levels, haloperidol–bovine serum albumin conjugate, **73:** 546
—chlorpheniramine, plasma, comparison with HPLC–UV, **73:** 1144
—relative bioavailability, commercial trifluoperazine tablet formulation, **73:** 261
Radioligand binding—3-quinuclidinyl benzilate analogues to muscarinic acetylcholine receptor, gamma-camera imaging, **73:** 529
—simple assay, urinary scopolamine, **73:** 561
Radionuclides—short-lived particle deposition, **73:** 1091
Radiopharmaceuticals—^{99m}Tc-labeled hepatobiliary compounds compared, sulfobromophthalein-treated and normal rats, **73:** 1861
—preparation and biodistribution of ^{99m}Tc-labeled tyramine iminodiacetic acid, **73:** 1363
Radiotelemetry—*in vivo* disintegration, hydroxypropyl methylcellulose phthalate tablet coating, **73:** 935
Radiotracers—3-quinuclidinyl benzilate analogues for gamma-camera imaging, binding to α- and β-adrenoceptors, muscarinic acetylcholine receptor, **73:** 529
Ranitidine—pharmacokinetics, bioavailability, humans, **73:** 1376
Recalcification clotting time—heparin activity, laser nephelometry, USP method, **73:** 1640
Recrystallization—polymorphs of phenylbutazone, spray-drying technique, physicochemical characterization, **73:** 173
Rectal absorption—calcitonin, polyacrylic acid aqueous gel base, bioavailability, rats, **73:** 1366
—phenylalanine and peptide analogues, **73:** 1326
Red blood cell partitioning—digoxin and analogues, kinetics, plasma protein binding, **73:** 1042
—naltrexone and naloxone in the presence of morphine, HPLC with electrochemical detection, protein binding, **73:** 621
Refractive index–dry-substance content—lactulose syrups, **73:** 1478
Release rate—theophylline in propylene glycol 400–water, *in situ* rat gut model, membrane solubility parameter, **73:** 742
Renal clearance—acetaminophen, serum protein binding glucuronide and sulfate conjugates, **73:** 1038
Renal failure—effect on antipyrine disposition and pharmacokinetics, rats, bis(2-ethylhexyl) phthalate pretreatment, **73:** 29
Renal insufficiency—effect on renal handling of drugs, dogs, sulfamethizole, cephalexin, ampicillin, **73:** 892
Retinamide—X-ray powder diffraction, polymorphic forms, **73:** 1448
RIA—compared with HPLC, nalmefene, human plasma, **73:** 1645
—trifluoperazine and its sulfoxide metabolite, humans, **73:** 1383
—triprolidine in animals and humans, comparisons with GC and TLC, **73:** 1339
Ritodrine—analysis in serum, HPLC with electrochemical detection, **73:** 131

S

Salicylic acid—absorption kinetics, of sodium- and potassium-containing buffered solutions, **73:** 998
—crystallization of spherically agglomerated crystals, **73:** 1535
—intestinal absorption, effect of anaphylaxis, rats, **73:** 48
—*in situ* absorption, comparison with captopril, rats, **73:** 1755
—stabilized normal-phase HPLC, solid pharmaceutical dosage forms, aspirin, **73:** 195
—*in vitro* release from lanolin alcohols–ethylcellulose films, drug diffusion, **73:** 302
Salsalate—metabolism, normal subjects, **73:** 1657
Sarpicillin—bioavailability, humans, methoxymethyl ester of hetacillin, **73:** 169
Scopolamine—urinary determination, radioligand binding assay, **73:** 561
Selenoestrogens—estrogenic and antiestrogenic activity in immature rats, comparison with *in vitro* binding affinity, **73:** 416
Serotonergic receptor antagonist—nantenine, from *Nandina domestica* Thunberg, isolated rabbit aorta, **73:** 568
Serotonin—receptor binding affinity, perturbation theory, quantitative structure–activity relationship (QSAR) quantum chemistry, **73:** 1725
Shear rate—low range, viscosity of xanthan gum in aqueous solutions, effect of added salts, **73:** 468
Shelf-life—statistical prediction of drug stability, nonlinear parameter estimation, Arrhenius prediction comparison, **73:** 657
Silver sulfanilamides—structure–activity relationships, correlation between activity and pK_a, log K, and solubility, **73:** 133
Sintering technique—preparation of ethylene–vinyl acetate copolymer, controlled release of macromolecules, **73:** 1034
Sodium alkylsulfonate—aqueous solutions, equilibrium dialysis, barbituric acids, high concentrations, solubility, **73:** 256
Sodium benzoate—*in situ* lumen perfusion, rectum, humans, **73:** 95
Sodium levothyroxine—HPLC, determination of bulk, tablet, injection formulations, **73:** 1315
—tablet formulations, content uniformity, HPLC, **73:** 75
Sodium nitroprusside—*in vitro* stability, solutions, intravenous administration, HPLC, **73:** 838
Solid dispersions—melt method of preparation, cooling rates, physicochemical properties, **73:** 1441
Solid dosage forms—stabilized normal-phase HPLC of aspirin and salicylic acid, **73:** 195
Solubility—effects of solvent medium, hydrophilic–lipophilic character, ethanol–water, **73:** 1094
—effects of solvent medium, hydrophilic–lipophilic character, ethanol–water, ethanol–cyclohexane, **73:** 1869
—equilibrium dialysis, barbituric acids, high concentrations of aqueous sodium alkylsulfonate solutions, **73:** 256
—mixed solvent systems, excess free energy approach, binary and ternary mixtures of ethanol, propylene glycol, and water, **73:** 18
—mixed solvent systems, excess free energy approach, ethanol–water, **73:** 14
—mixed solvent systems, excess from energy approach, theory, **73:** 9
—profiles *versus* pH, weak acids, weak bases, **73:** 1679
—prostaglandin $F_{2\alpha}$–γ-cyclodextrin inclusion complex, dissolution behavior, **73:** 382
Solubility parameters—individual solvents, four-parameter extended Hansen approach, UNIFAC, naphthalene, benzoic acid, **73:** 179
—individual solvents, four-parameter extended Hansen approach, *p*-hydroxybenzoic acid, methyl *p*-hydroxybenzoate, **73:** 188
—polyoxyethylated nonionic surfactants, comparison with hydrophilic–lipophilic balance, **73:** 790
—theophylline in propylene glycol 400–water, *in situ* release in rat gut, membrane solubility parameter, **73:** 742

Solubilizers—digitonin derivatives, lipophilic drugs, **73:** 240
Solvent medium—effects on solubility, hydrophilic–lipophilic character, ethanol–water, **73:** 1094
Solvent residues—drug raw materials, GC, comparison with MS, **73:** 1664
Soman—percutaneous absorption, pig skin, **73:** 1388
Sorbitan monooleate—spectrophotometric quantitation of peroxides, **73:** 1663
Sorbitan monostearate—spectrophotometric quantitation of peroxides, **73:** 1663
Spherical crystallization—aminophylline, theophylline, ethylenediamine, **73:** 1407
Spray-drying—recrystallized polymorphs of phenylbutazone, physicochemical characterization, **73:** 173
Stability—buprenorphine, 6,14-*endo*-ethanotetrahydrooripavine analgesics, acid-catalyzed structural rearrangement, **73:** 243
—cefotaxime sodium, determined by HPLC, **73:** 565
—ginsenosides in aqueous solutions of varying pH, kinetics, **73:** 409
—long-term, fat emulsions admixed with L-valine and L-histidine monohydrochloride monohydrate and buffers, **73:** 91
—phenobarbital, effect of solvents, **73:** 1661
—*in vitro*, sodium nitroprusside solutions, intravenous administration, HPLC, **73:** 838
Stability constants—thioureas, metal-ion complexes, antiradiation protection, **73:** 1284
Stearylamine—liposomes with phosphatidylcholine and cholesterol, physical stability, **73:** 1559
Steroidal thiourea derivatives—2- or 4-position of estrone, synthesis binding to the estrogen receptor, cytotoxic activity, **73:** 1871
Stimulants—CNS, alkoxyquinoline derivatives, synthesis, **73:** 1652
Structure–activity relationships—*n*-alkynols, antifungal activity, *in vitro*, **73:** 1840
—2-dimethylaminoethanol and its analogues, protection against mechlorethamine cytotoxicity, inhibition of choline uptake, **73:** 34
—enzyme–inhibitor complexes, modeling by interactive computer graphic display, sulfonamides with human carbonic anhydrase C, **73:** 352
—silver sulfanilamides, correlation between activity and pK_a, log *K*, and solubility, **73:** 133
Structure–taste relationships—discriminative structural analyses using pattern recognition techniques, perillartine derivatives, **73:** 737
Sulfacetamide—solid–solid reaction with phthalic anhydride, **73:** 1059
Sulfadimethoxine—blood fraction binding, equilibrium dialysis, humans, **73:** 1319
Sulfamethizole—renal handling in dogs, renal insufficiency, **73:** 892
Sulfaphenazole—effect on tissue distribution of tolbutamide, rabbits, interspecies comparison, **73:** 631
Sulfaquinoxaline—HPLC, pharmacokinetics, rabbits, **73:** 1635
Sulfathiazole—conjugate with povidone, laser Raman spectroscopy, **73:** 1849
—physiological flow model, distribution, swine, **73:** 1525
Sulfinpyrazone—plasma-protein binding, stereoselective displacement, drug–drug interaction with warfarin, **73:** 1671
Sulfobromophthalein—affect on hepatobiliary radiopharmaceuticals, rats, **73:** 1861
Sulfonamides—structure–activity relationships with human carbonic anhydrase C, interactive computer graphic display, **73:** 352
Sulfonic acid buffers—protection of oxyhemoglobin during freeze-drying, prevention of methemoglobin formation, **73:** 784
Sulfonylureas—adsorption to activated charcoal, **73:** 253
Sulindac—metabolites, HPLC-UV, human plasma, urine, bile, and gastric fluid, **73:** 1270
Sulpiride—intramuscular administration, pharmacokinetics, humans, **73:** 1128
Sunscreens—film irregularities, opacity, **73:** 888
Surface area—particles in pharmaceutical powders, distribution, mercury porosimetry, **73:** 197
Surfactants—nonionic, octoxynol 9, effect of inorganic additives, cloud point relations, **73:** 793
—nonionic, polyoxyethylated, solubility parameters compared with hydrophilic–lipophilic balance values, **73:** 790
Sustained-release formulations—dissolution, USP rotating-basket apparatus, theophylline, **73:** 939
—implantable disulfiram, poly(glycolic–CO-L-lactic acid), rats, **73:** 1718
—macromolecules, ethylene–vinyl acetate copolymer, **73:** 1034
—tableted microcapsules, sodium phenobarbital and ethylcellulose, core–wall ratio, aggregate size, dissolution, **73:** 52
Synergism—2-undecyn-1-ol and ketoconazole, *in vitro*, *Candida albicans* and *Candida tropicalis*, **73:** 1840
Synthesis—2-aminoethanesulfonic acid (taurine) derivatives, anticonvulsant activity, mice, **73:** 106
—13-*cis*- and all-*trans*-retinamides, chemical properties, **73:** 745
—deuterium-labeled fluphenazine, propylpiperazine side chain, **73:** 87

T

Tablet-hardness tester—computerized *versus* unaltered models, **73:** 1324
Tablet stability—nitroglycerin sublingual molded tablets, vapor pressure, intertablet migration, effect of additives, **73:** 1608
Taft polar substituent constants—correlation with aliphatic group dipole moment, quantitative structure–activity relationships, **73:** 553
Taste perception—drugs and pharmaceutical formulations, physical model approach, non-steady-state mass transport, **73:** 600
Taurine—synthesis of derivatives, anticonvulsant activity, mice, **73:** 106
Tegafur—coadministration with uracil, toxicity, species comparison, **73:** 212
Temazepam—noninteraction with cimetidine, pharmacokinetics, **73:** 399
Teniposide—analysis with metabolites, HPLC-ECD, human urine, plasma, and CSF, **73:** 164
Testosterone—brain-specific delivery, redox chemical delivery system, rats, **73:** 385
—long-term controlled administration, navel, rhesus monkeys, bioavailability, **73:** 1064
—nasal absorption, rats, **73:** 1300
—transdermal absorption *via* naval, bioavailability, **73:** 283
Theophylline—dissolution, sustained-release formulations, USP rotating-basket apparatus, **73:** 939
—pharmacokinetics, thermally injured rats, **73:** 1117
—transfer across the everted jejunum, rats, effect of pH, **73:** 320
Thermal energy analyzer—HPLC, nitroglycerin, dinitrate metabolites, human plasma, **73:** 1838
Thimerosal—stablity in ophthalmic formulations, influence of isotonic agents, boric acid, EDTA, propylene glycol, glycerol, mannitol, **73:** 840
Thiosemicarbazone derivatives—2-(α-hydroxyacetyl)pyridine thiosemicarbazones, antimalarial and antibacterial activity, **73:** 1763
Thioureas—metal-ion complexes, stability constants, antiradiation protection, **73:** 1284
Thyroid hormones—single-tablet content uniformity, HPLC, sodium levothyroxine, **73:** 75
Tiflamizole—HPLC, human plasma, **73:** 1829
Tissue binding—prednisolone in the rabbit liver, muscle, kidney, lung, albumin, effective protein fractions, **73:** 362
Tissue distribution—tolbutamide in rabbits, effect of sulfaphenazole, interspecies comparison, **73:** 631
Tissue penetration—local, percutaneous absorption of trolamine salicylate, pigs, **73:** 1002
Tolbutamide—crystalline polymorphs, solubility as a function of temperature, polymorphic conversion, **73:** 1673
—dissolution, intra- and interlot variation, effect of humidity aging, **73:** 1629
—solid dispersions with urea and polyethylene glycol 6000, **73:** 1441
—tissue distribution in rabbits, effect of sulfaphenazole, interspecies comparison, **73:** 631
Tolnaftate—charge transfer complexes, iodine, **73:** 1687
Topology—apparent volume of distribution, drug in the body, steady state, moment functions, theorem, **73:** 273
—molecular descriptors, comparison with lipophilicity, assessment, biological activity, diverse molecules, **73:** 429
—structure–taste relationships, perillartine derivatives, pattern recognition techniques, **73:** 737
Toxicity—reduced cardiotoxicity, anthracyclines, **73:** 1575
Toxicokinetics—pulmonary absorption and excretion, pharmacokinetics, **73:** 1136
Tracazolate—free carboxylic acid metabolite, individual and simultaneous assay in plasma, HPLC, **73:** 667
Transdermal formulations—percutaneous first-pass metabolism, human skin, **73:** 1499
Transport systems—increased skin permeability, lipophilic molecules, **73:** 1153
Tretinoin—mucosal adhesive ointment, irritation-free formulation, clinical testing for lichen ruber planus, **73:** 548
Triamcinolone acetonide—synthesis of the 21-palmitate ester, liposomal encapsulation, **73:** 834
Triamterene—HPLC, hydroxytriamterene sulfate, blood, plasma, urine, **73:** 831
—liquid membrane phenomenon, anion/cation transport, **73:** 1579
Triangular metabolic pathway—fraction metabolized, cinromide, rhesus monkey, **73:** 285
Tricyclic antidepressants—*in vitro* interaction with coffee, tea, gallotannic acid, gallic acid, **73:** 1056
Triethylammonium complexes—*N*-substituted *N'*-cyano-*O*-(triphenylstannyl)isoureas, antimicrobial activity, **73:** 1012
Trifluoperazine—hapten synthesis, conjugation with bovine serum albumin, antisera production, rabbits, RIA, **73:** 247
—pharmacokinetics, RIA, sulfoxide metabolite, **73:** 1383
—relative bioavailability, commercial tablet formulation, RIA, **73:** 261
Trimethobenzamide hydrochloride—analysis by ion-pair column chromatography, semiquantitative analysis of 3,4,5-trimethoxybenzoic acid, **73:** 542
Trimethylamine carboxyborane—complex with copper(II), antineoplastic activity, Ehrlich ascites carcinoma screen, **73:** 222
Trimipramine—metabolite detection, HPLC, electrochemical detection, human plasma, **73:** 1745

Triprolidine—bovine serum albumin conjugate, pharmacokinetics, animal–human comparisons, RIA compared with TLC and GC, **73:** 1339
Trolamine salicylate—percutaneous absorption, local tissue penetration, pigs, **73:** 1002
Trypanocide—benzisonazole derivative, metabolism, **73:** 1731
Trypsin—agglutination kinetics of enzymatically treated normal and diabetic rat hepatocytes, neuraminidase, **73:** 628
Tumor-imaging agents—alloxan analogues, pancreatic insulinomas, effect on blood glucose levels, rats, **73:** 394
Tyramine iminodiacetic acid—biodistribution and preparation, **73:** 1363
Tyrosine hydroxylase—*in vitro* activity, effect of methyl-substituted 1,2,3,4-tetrahydrocarbazoles, **73:** 1531

U

Ultrafiltration—protein binding of gliclazide in healthy and diabetic human serum, **73:** 1684
Uracil—coadministration with tegafur, toxicity, species comparison, **73:** 212
Urinary pH—effect of fasting on cinoxacin elimination, diurnal alteration, rats, **73:** 1697
Urine collection—quantitative, rats, reusable device, comparison with metabolism cages, **73:** 816
Ursodeoxycholic acid—HPLC, human serum, ^{13}C-NMR elucidation of structure, methyl ester, **73:** 847
USP Dissolution Apparatus 2—Apparatus 2, 5 lots of prednisone tablets, collaborative study, **73:** 670
—dissolution of 5 lots of prednisone tablets, collaborative study, **73:** 670
—error associated with glass and plastic vessels, **73:** 1125
UV spectrometry, second-derivative—benzenoid drugs, tablet and capsule formulations, **73:** 413

V

Valproic acid—GC, plasma, valpromide, **73:** 991
—hexadeuterated analogue, GC–MS, pharmacokinetics single- and multiple-dose regimens, **73:** 489
Valpromide—GC, plasma, valproic acid, **73:** 991
Vapor-phase osmometry—determination of number-average molecular weights. poloxamer 188, polyoxyethylene(23) lauryl ether, **73:** 392
Vasodilators—coronary, nicorandil, metabolism in dogs, pharmacokinetics, plasma detection by HPLC, **73:** 494
—isosorbide dinitrate, oral and sublingual formulations compared, humans, **73:** 699
Vasopressin—controlled drug delivery, microporous polymers, Brattleboro rat, **73:** 1713
Verapamil—pK_a determination, liquid–liquid partition coefficients, effects of ionic strength, temperature, **73:** 442
Vesicles—multilamellar phospholipid liposomes, structural characteristics, external lipid layers and aqueous volume, **73:** 122
Viprostol—transdermal formulations, first-pass metabolism, **73:** 1499
Viscoelasticity—powder-filled semisolids, starch-anhydrous lanolin model, dynamic mechanical testing, Kerner equation, **73:** 590
Viscosity—film-coating solvents for tablets, tack behavior, concentrated polymer solutions, **73:** 477
—xanthan gum in aqueous solutions, low shear rates, effect of added salts, **73:** 468
Vitamins—pantothenic acid, HPLC, **73:** 113
Volume of distribution—apparent, theorem, drug in the body, steady state, topology, moment functions, **73:** 273
—steady-state, noncompartmental determination, multiple dosing, **73:** 281

W

Warfarin—dissolution, ionization kinetics, **73:** 946
—methodological considerations, plasma protein binding, **73:** 1000
—plasma–protein binding, stereoselective displacement, drug–drug interaction with sulfinpyrazone, **73:** 1671
—stereospecific fluorescence HPLC, metabolites, **73:** 1392
Wax matrices, inert—phenacetin release, acrylic acid polymer, **73:** 910
Weibull distribution—disintegrating force as a new formulation parameter, coated aspirin tablets, **73:** 701

X

Xanthan gum—aqueous solutions, viscosity at low shear rates, effect of added salts, **73:** 468
X-ray powder diffraction—polymorphic forms, *N*-(4-hydroxyphenyl)retinamide, **73:** 1448
—tolbutamide, solid dispersions, carriers, **73:** 1441

Z

Zinc salts—zinc sulfate and zinc pantothenate, comparative pharmacokinetics, intravenous administration to rabbits, **73:** 1642